var title_f14_32_14848="Fetal pleural effusion unilater";
var content_f14_32_14848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal view of a unilateral pleural effusion in a fetus with hydrops",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 251px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD7AWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5ylkfzX+dvvHvTfMf++3513t78K/EaRXstpFHfSW+pNp3k2+5ncgE7xkY29q5q/8ACniDT9K/tO+0a+t7AOUM8kRChg20gntyMU7CujuvghrXhTw9PqWp+LbiJrmQLaWcUlqbjyiwJaZgeNo4Hc+1bnxg1zwv4p0KVtM17SYrzTLhzDFBYvE14hjQYG1QB824815tq3g6607wfpviP7fYXNneyeTshZ98T7d21sqATjrgmuYpLTUc/e0fT+v69R3mPn77fnR5j/32/Omd6KAH+Y/99vzo8x/77fnTKKAHmR/77fnR5j/32/Om0UAO8x/77fnR5snPztz70yloAd5j/wB9vzq3pqiS4D3Dt5KcsMnn2qlTixxjPHpQM7ywvIiVaO4c9l39AK67Rrq8gKyAGSEY+dH5WvGoJ3hcbSQc9R6V0vhrxPdaZOWCRyxknKy8jB9KBo930rxXIWW3lLDAxnb82PrW3ZeKEnn8uWcbk4yVwfzFeO2HjLTpwY723ELEj5k54robS+tLyKaW2vU8sEKqPgHpQI9WTU7O5uGSXy2Yjb8uRn3xT1t9Pm3lJJYk+7hjxXmtnbTySwyxsGiJxu3Ywasx6idPZzKjnqyMQTj6UAd/c6WyEOrQFfTeCf8AGmS6SC0hOyRADhkUNn2PeuQstdnaXeN7RyZZS4GOnrVu18UKJcSJJGSMk5BWmFjQvdJzHmGILz8+3Iz9KzbqyufmjRDtA5JGNvtirf8AwlCCVMyxBSONyH+lTp4ljuY5AELoAd5d859KBGA9nJGRvjyox8znufanTWckx8syEKRgBG2/ia2G1aFozFcQFcIGXy1GcfWo0vIFLZQiMMMD0B780hmTb6Y8UpgjUu57g5B5xyT2q0LC+gLfaLmBQBtKxjcQPrV/+2YmLIRhQNv15q7Y3GmmJZA3luBjcuCM57560AZtjpJezzO7x4OcMwBYe1JrMa2ETwadEDJjJ5+Zu/FaWq3dkwZYJQGUbVYjk89awLmVVkjmtCGl3ZY9enpTFe55R8UdFmuLj+1bSKRZhGv2mMEk5/vV5n5jn+NsfWvpq4+ziO7neSGWUjCRMnDDvkd68O8f+Hl0fUTPZgtYzklflwEbuv0o3JWmhy/mP/fb86PMfH32/OmUUix/mP8A32/OjzH/AL7fnTKKBD/Mf++350eY/wDfb86bSUAaWmabf6nDeS2exktIvNl33CRkL7BmBY+wzVDzH/vt+dMIB6iigY/zH/vt+dHmP/fb86ZRQA/zH/vt+dHmP/fb86ZRQIekj/abf52/1g7/AEopif8AHzbf9dBRWVXc9HBfCz6Hi8U/EO0vdTWbQ/D80+kOJbmGa4XzEYAkOE8zcc+YoyB1wKy/Hl74suLDSPCx8PLa6prMDLcy7lfeWn8worByqgEjO7BBrK+IPjO80/V9Zkk8L6homo6vNaTsdQblooCCVA2LlWZVJrTtPjhC2qwraeG5kikl+0FIL4iZ7h5AzANs/wBWx424/GtjzbXt/X9dfuOf1zR/F9x4L0bR10TS7Ww86J2Fpco0s0shMaSSL5hKgnIzgAmuZ1P4f+JdN0q61C709Ut7U/vgJ42kVdxXfsDbtuQRuxivR4fi3JCkNk3hzU5JdNSP7VBJdBo4vIdmDhRGCrbmXJJxxXM6zq9x4m8GzapceD9TuL2OzSwbV0kkNqiIxJfaqjLc4OWI9qF0Q5PeS/pf1/Whw82g6lD4eg12S2ZdLnuGtopiR8zqMnA64x3rLFemeMfE+sah8NtN0LUvDJsIdNnh2XaJIibTF8oIYkbmBznv6V5nS6Dekmlt/wABB2ooooELSUUUDCiir1rbyrG0nl5BGOR0oEUqPTjirTWFwF3CJivbHNR/Zpw23yX3AZI20AQk+lSI251B4PrSCGTH+rf8qPKk/wCeb+v3TQBcjfpgneeOO5rSiE2NpYk4Awg5rCVZQwwj5HPAq1aahPbOCATj1FAzpYNe1XTotlvcyqOcq/IrYsPH+pQRRx3MccsQGDlcda5NNUe/njjS2aZuTsVST0yeBV3S0s9QmEcYkMpy2EUsSAMnigNTt4PHFhNGIZYpLYfxMhG3BrQt9U0qYEWl9GRs28nGK8tufIcERPGVxweQTWU58t1CcgZzzQI9nuZWly1tcxBcgD5slqzkmvIWKeWC7NjA5FeVxXtwoVI5GUexPFWYtav4yNtxI3qegoGem22t39vKRyhb5cscgj2q3e+JtRuIUt5nBRCQF2/rXmy6/fNgFlIUfKdualGuTSgvJs46qOM0Ad//AGvJIm6VgwChVAatJdZs1t2UCSOTAwOuMV5vBq0ZCB1KqD0BqdtWBdjv+cnZjPQH3oA7mfWGuC23mI9JO4qj9vmf92CYh0DLnH51y0d20eSCrD/abNKNQkdMZDkHO08DFMR0w1ZliFuVcyEDEmc7fXmoNVlW7g+zXUImgkQgsTkgk8EfSsUXreRENwB6lDyBU4kCzB8lA3HrjNANXPP9UsZNPu2hfJXqjEY3L61Vrvdes0vIFtX2mReUlB5J9K4SWJ4ZWjmUpIpwVIxigSGUGiikMKKKKAJYbeedZGghlkWNd7lELBB6nHQVFVqz1G9sY7iOyvbm3S4Ty5lhlZBIvowB5H1qrQAUCilXqPrQA0svTIpa+2vhN4c0G6+C2jXdzomlzXJsHZpZLSNnJ+bkkjOa+J3ADEYoWquEvdqOn2/4P+Q1P+Pm3/66CihP+Pm2/wCug/pRWVXc9HBfCz22w+KmmT61rP8Ab2gwNZJFPFp4SzM3kmR2Zi6u+dzZHIOBjgUyH4i+FHsr2Aac5HkWK2wi02EODFtMuWz90kHjH410UvjnSvM1JIPGdjbT/bbKVrpFuN15bxKwkD4iGXbPKkY6DNcf4e8V6Or+J10XVo/C91easl5b3TpJhrQFt0PyKxGc5weD0rU8+K1t/W6/zf3M1/EPxR8LXVrqMGkW1zbC+sLy2Yx2EMahpHBjyNxJPBBOce1YXh/x3pNnpOjXEyakup6Pp02mrYxW6tb3DSbsOzFuD83I2nOK6vVLrwBBptt4mks7FJL7UZ7m2Ijl85tlxGFJUHaE27yQRnpimaf4y8J6dqmsyTy6NcQXWtWt3CtqlxGBGsrEyvkD5lBBIHB9Kf8AX9fcSlqk/wCv6Umcv8TviBYeJPDUlhaJdhn1GKdTLAqLtS2WMjI77weP/wBVeWCGQsVEblhjICnjPSvo+b4jeEz5D3uqW9xAl2TbRw28g8o7pP3rxspVcblO5Dk9xXO2Pj9tLvNQju/HEuqTnQJohdwQyRK11keWNxAZ2Az8zAYo/r8QXV/1ov8AgfieH9aKfLI8srySszyOxZmY5LE8kmmUhhRRWt4Y0lNX1SOG4l8i0X5ppMZwvoPc0DSudB8P/Cf9qH+0tRBXT422oOhdux/3RXrsXh6yW3iASyd1UsYm6sPr61gR3FpBYRWsCbbWL5EwxVtnbitK0ktTDHJEs0gIw4OMqR6GgbfY0dP0bSjbTb/IEZbhET5hjmi50nTGUF4LdFxt+VQWI7GoEv8AT2td4iZ05DKAN4p0Wqaetu6+VIeRtc8Y9s0xETaboLWsqSK4kRcJiEc/l1p0uk6atgnl2sjfPtaXy+Np7GtWw1rQftccV3ayyWxj2483DBj6V0kk+jNpsoskvIypB2HaQRSB9zgzo+jRL5kbBSpCt8vP06VafQNJvLZJNsIO75iVPQ9CeK1n8m7ASS4XashyDhcjr1ArVsLSCbyEhnt0D8nzZP4ffigEYXgzw7p+leK7K+mMEMUSSqHWLGQ8bKM469ar+EPB+leHfGcM4u0ljjt5YnmSFlALxMvTr3rubqHSyrRteCS4GP3SOpT9QKxpvJjSRt/mMjcESkBT/WmI8n1b4dWiTGGxuY5xFgGZUdA/HPB5rmdS8BTxMGjL7c8vuyOa9wlvPs8qpPDlJPm4A5B9DTWFvdFlM0Sx8sxkAJx6DigEj53uvCWpW0wCoGU5IOayLqwvLRyJ4HXAzyK+mI7azlylvtkijIKqFzgH+tUZfDun3VwG3gGTOVcDPtQB83B9nTIf8sVIGZtv7w8nvXuGueAbZ4BK8ClmyxKYUqB0+tczqnw6jW3E1ncESMPljbJP8qAueepKznaVJY9KsKnlL5kjHk9CcmtS+8L6zZXW1rdmCj7y84rJl8wArMjNg/SkBYt2fGSR5XII9fepJpljSPywdwHP0qgztkxgkZ42ipQyurKQu4KAcHtQBoRSNsWRV5YfdHFaK3P7kbiD5eF+cdM1j6YjFlVjgnuewq608QEm/wDeqTtIxjFAy4ZiZM+TuZcbWQg/jWb4isUuYVmt0JuEO1yMnf8A/Xp6SRecZYR0GCFH6Va8yTbmFgjgZZTzj6UxM4j14oNausWgDG4gDFf+WoxwprKpAFFHaigAoq/puqTadDeRxQWcouovKY3FskpQeqFgSp9xVDoMUAFKOo+tJSr1FAH3P8HX/wCLB6WfTT5f/Zq+GW+8a+3vg8//ABj5Yn0sJv8A2aviA9fwoj8CCr/vE/l+oi/8fNv/ANdB/SilT/j5tv8AroP6UVlU3PRwXws9a8ZTeFtcTxdqEcUcUumtHbafBE1vbiRmmYM4EUY3qAARnJx1NdF4f/4RC6+HOlaXdR6R/aFxphaV5Wt4SGNxtLGUoXV1XkDPI7UniH4TaTqV7Pc2DSaOot9/2VInLRNlyJJo5G3RphcE5IJIIrPtvgxptzbRSxa1fu8aRPcW6WiM8hkhEgSEbvmP1xWzPNirK39dV+L1Nqbwh8N0uG0ZdQtFtxqMLvcLqEbybWhYmNX4+UuAPxqHw7pXhLSp9cs1tdIFkX+W7vdQtrmXyQrfMVPQE4GI235rN1LwDpmgaHLHbaBH4kjht7ia81cXTwLbSxv8qHDbBxgFepycGtO38GeEtU8R6faDS9O05JNJt799sszDdKpLkhpMkKQMAevNL+v6+8pa6r+tP/tWZt94H8A2YuLkalDPa+XNPbpFqkeXRbZXUEckEyEgA81w3xI0zwtpkOit4VuJZ2vLf7ZOHn8zyQ2AsR4HzAhs1F8U9D0/QvEa2+mIkStCrvEr71VvUckgEc4JrjvamQveWn9Wv/XyA0UUd+ASe1IofDG0sqxpyzHAru9IsbOK2kgTe6BdxlXGS30qtpmhxWWnB7xU+2TDIDEjaO2KveHLuG3vFhudhjYEqyDn6UFeRsWEN3DFGpMZgn6SEZx9fStddPDci4DKTs3xqdpOPWtCzuYpreWGzgaRGGArgcH2Haut8IaFdS2rGJhaeW27bLHkEY68UBucdbeHb21svt0e1YHO0Oh3cjuanu7NzHHIpX5hv2p3PuMV6XC+l6PczS3F+S3H7pQNjjHX6UX91oN/plsBYqpUktNHw4P+FMl+R5rYaTc3rRyQW+cMAApJJrW120ezFratOks0vLRqpV4yexzXoFnrdnoK6cLG1hB8s7w5/wBY3bnsareLLubXLyC4k077PdQ8MyJuyO3zUkNmFp+hahDp/wBomtLloIgXO1Mhh/vdqp6VZ3uoNizsJBGyllI4JI698V03hbxVdql1Zxgyx4O8ls49eCeKhXxFLo16q6e8d0JBgKF2qhPY0B1Ma+SzhVra7jmM20ZAQBsntmsa50uVooVgvRFE7cK5xz7mvSLlNWu5GvZtLa5l+VnaA4Cj2PeqOua5p2s+HjYwWZSSFupQFs57+hpi/M8y1KfUbOQC4Ec0QOArMDkDuKzxrEjsI2gjVed2OwNesaRo+gXMU0N4ksFzEoWNu27r3riNT8PTTanKLNZGlbjYQPn+mKA62MmyujBdM0bFhJjAHOP8a1HvJoZY3Ty2ySxC9R7EGsPUfDtxpt/Is0bRyJjcHBGw980yzvGFyjTIkiBv9bt+bj0FIadz0DT9YF9IAEnEZADIOmfp2qaC1sLi8MJDb2PyEN1PofauXt1s5r5fKndZJWDM7rgqPTHeuvtNJt4tMcw38Ml7LIE2+WRtX1DdBQHmT3Hh61eIeUcSAFTGBjntkmvPtY8GQS+b9ptvKVGwzIOh/rXoer2+o6bCWmm+0WkQUhoWDAH39TSafrq+c00586GUYYyY3KPamK1z5v8AEPhibTLtzEDMoOM+1YreYGKlVU+uMGvoTxHpmnXin7KWiEx+6y9B6+teYeJfCgtyz2h8+QZLLngCgSdtzi/NcL8xjIPGB1oWVGlKhNpIwoHKk1HdApIUKLGR1wOtAdSEO3LJ2xikMt284OE3AnoUA6mn+a0Uu9wAqgNj19veo4w7Wz+WQPm5GKdCQ0ro+OmR0yMUDLUG24TBRGidyCMGuX1O0NndMindHn5WroUZYQhG4D0yRTp7eC7s5gFO5sYOeAfWmJnI0VLcwvbzPFKMOp/OoqQBRV7TbiwghvFv9Oa8kki2wOLgxeS+fvYAO76VR7CgYUL1FFKOo+tAM+1PhBLj9nq1Gf8Alxn/APZq+Ku34CvsH4UXAX4D2aZ/5cbn+TV8fD7o+goj8KFV/jy+X5sVP+Pm3/66CikT/j5t/wDroP6UVjV3PRwXwsmmmlaeZmlkLSZVyWOWHofak+0TbgRNJkEEHeeCBgH8q+k9V8H+CbXU7n7do8Nm0ME160JR4XMdvOP4C78OhxuyM4yAOlcrP4X8Kj4paJotvZ281uulvdGFpigurh1aWKNmyPVV4I6VuedF3t5/8H/JniYZhG8YdhG5yy7jhj7jvThLIJFcSOHUbVYMcgeldV8VdM07R/HOoWejxpBbqsTNBHJ5iwyNGC6BsngMSOtdP8KLLwonhPW9X8X2tpNFb3ltDumjlkbYwbcqBGGGOBgngUPewou8eb+u36nlbMWYs5LMTkknJNJXqviL4daLp3hC01+2v71ree7tU+fy/JEU2SQGBLbkAwc96d8dvDeh6A+knRrGCwlkadPLhuDKJrdCvlTHLHBYE+lA27b97fhf9TyitTR4IPmnuJXjkTBhCjqQe9ZyIWzjn29at2srNMAATt52+tIaOxuWk1Jop2IULj7h5+uKv2ujwySMQxRzgh8H9al8LhHgEYt2KnrkZOD6Guju9EuI7ZZI2Zog3+sbgqOwNA7WG6JBcWAkmQzfJ94Hnj15rf0vxVdaVcNMJ5Cjr6/LjuCKrNfOI4yVSSV/3ayK4AJ9653XAY5GiQAyg5fBwOaBNnYXGpw+ItQCW0EEUjrgIhO0+/tWVrT6rp1pJ9jmkt548ho8cEfUVieG57q1vRdZO6M/MBnkVv8AiPWItZRY1RxcBOFbv7EjrQJqy0PNtV8XajJcqJ7hhKvcdj+NTwfETXAzD+0pSuBwDjiqfi3w0yWyahaquW4kiGSVNcpFH8y7wVIHcYpgjpB4o1CG5eeC7kXzM+ZtPUVbt/EV/qFzH5kskjqeNgOW/KuPSNCx+bJP4Yr0XwPFbx3Vv+5YnOQ6HkGkyoov2fjPxdp/mR2M2o28XTlTg/nWx4b8f+LNLhmSzha8kl/56W3mAH8q6bxfd3I0+O3tiU+QF2DAcms3QLprSJVuJGGATuySSaBJ7lfVPH2r32oWL6xY/Yp4mzL5cXl+YPXFdPpniu3mee4S5iQhQAkgO4fSuOvpxqXiVDI8gCjjec5H4iui8VWVrJo7TwxKGVckhAD+go6ivaNzYe0sPEJlmF2RJMRuMjAKfoOtX/EPhq10HUI47VbVvMhA5QsrHHJPPBrgfD1vevaQXUN+fMjBCxFCfwq3o3iCaa6l/tRLgyq5USKpwPx7UDt0RrTrbWXkzTWaBWG0bUO0DuQDya77w5dWx0wqlvZzxeW2ySd8N06YGaxtVk8PauLezsrcNdRIDJMJc8kc02LQLvRxBei6jFhIfL3M4yufUCgOjTG61bX9vZNcaUZrkffkiiBCKvpk1yL6rFHcCOaxMch4ZJG45+ldbdzXlzcLb2cc0yxZy8cjbWH0zzXGeMhbR3ds822KZuHjUEEflTF1Nq3u/KuPPZS8TDG1U5UDuDVS8/s6WzllmlAc8qpQBiPf1rHsNUtpI1tJJS7R5EbBjjH0qZrWVQ8iuJZAM8j5QKQM4HXNDjnc3FtCzH+IsMAj6VyV5A1vMY5EYjPYV606ySShJmRGJwDkn9KxPEmgFyWjbODkkkdfpTFsedWz/vXBLR5PDHoBUlxGsM42sHTqSB81al5o81tIHZX5GRms54MPJLJvdQOoPWkMS0keRgJ2cjnCAYqwcSgsF2IjdzxUMEbylCynB7g4JqSJww2RcMCVC5yPqaBlXVrQXS74RukUcEdx6Vzp4J7GutjkZE2b1A7jHOKytWtPNjN3DHsA4kUDAHvTFsY9FaugQaLPNKNe1C+sogo8trW0W4LHPIILpjj612PiK38Jr8KtLl0v7Emti5CSFpA9zcLlsuVVz5YHHBH40geiv6fiec0DqKB60o6igD6m+Gdzs+DFon/TlcD9Gr5YX7o+gr6P+Htxs+E1quf+XSf/ANmr5vX7o+goXwodT+NL+urFT/j5tv8AroKKE/4+bb/roP50VjV3PQwXws9fHwzt/EcqXOjW2q6BAN0Eh1MGcTSGUomwqqnaSPmJGB70+w+HOkN4o062ul1G4hXw+uqz29tIDLPMGKlUO04Geeh6V5xceKfED6g92+uao1z5Rt/NN3IW8s/wZz09qqQa1qkF7a3cOpXkd1axiKCZJmDxoP4VOcgcnitmeenb+vJ/q0/610PH2hw+GvGer6RazPNBa3DIjvjdjAPzY7jOPwrtPh54R8L6l4FvNZ8T3MlqFvmthL9tEIQCAuCqFD5jbuNuR1ry6WR5pZJZneSV2LO7kszE9SSepqX7Xc/YTZfaJfshk83ydx2b8Y3bemccU3uKOkbP+tj1vxH4N13+zvC2ma34oNzps2ow6f8AZ0tzGIC6Bg24gB8Kw55xXO/F/wAH6d4W1DTW0lL+CG6hkJt71g0kZjlMecgD5WxuHHesXxL431jxDpWm6bevDFZ2GDFHboUywAUMeTzgdsVk6pqV7qMyz6ld3V3dFQpkuJC7bR0AJ5xQglrt3+/T/MhgRWOQGKgAZHY1pWmlNJKhgfZKCCMng1X0raGAU8scEZ613Oj2Ja33vEBKhBA7MB/WkV5l/R/ttgJFPlLBjDKy8g16D4Z1OXUbH90BugHIK/Iw9Dmsex0651iGSIFo48KxBjIwPrVe4tP7KaWGG4kO87GMJIAHrQDfcu+ILaMyOxtYfKJyHt3+43uBXHzpfQzMA6yFurEZOK6FBdzIm14VZOrSEKZPx9aILiUSut1b5YjBJX+tMlKw3TrYPbSSzO0RTg8YzkVi2tvJ/aTyQsySxnO7HX8+Ks3DzhpYmjm8snIK5YfWtjTrNIrb7RL5zTt95QmVxSH5hY6xHaxzLewxt5q7WAwMH1IIrybxQqyaizWyKhYnPGP/AK1eoanAFtSvlks+Snt+VcfeWay2E32tA+QN+AvmABuPLz39c9qZL79jz3BSULIeQa67wZqklvdLkM2D0JxiuRfiQ7ScZPB5OPer+iHGoxF5VhUH7+GIH4Cky47nuMjy6lCjqu5NvLEmti0hktrBZlS3YgFduTuPvXMeHmkZo4m8yONwDhpC2OOG59etdrHdGxtyxhik52Yb731oEzirWQS64JX8tpCduDxiuq126vBZtAZGKMAFSPkVUnsWvrgzGSK3IO4A8Zp2q2rwrEPN4fkmM9Pxp9RdLF7R4bi105JJbhyrDkFensMCuVk8Sx6FLdCYF8sdozzzXSW2rfYNJmjgWaaZUIChtwya8g1Hw/q+p3spngaOU5bcc8D6UdAbvLQ1YPEgt7lr3CZJyYXOcivQPCvxJF8/2W+jgaxbgIynap7YrzaDwpdoBbSxozEZEm4g/SpVig0mZLKaPEwbIYZINIpdj6F0LUfIjd7K1M8W7HUqCfw7Vka1a/2pfyXeq2ixO33A2AAfYVR8P+MW8P6AiNcBBP8AL8qZ2j15qtf67puovHHcAjnLMRukYUIUlrocDGj22u3AeWLZkkHO0EenFdP9uQ6dut5AhYYIBABArH8R2sEN2ggtLgLjKmRfmI96gtLl96xsiEIMKFXkfWmJbWLMYYz+cxds/wARUkZ9qvWTq8zylf3eNu5xn8h61T86aa7iCrIF7q7/AC0+OG7Vt6ojxqxITJ4pDND+yopbKR5MPP1G7jj0rlPEnh1QIxsEbMuWG37tdhYztOjM2S6EcL2FRaq1usEmS4nlOCzMG4PamJo8vu9MEEYZoxJGOBsByap+SFceQilFHKL1r0RrINPsaESDbwgbt71zt3aBHaSJJERn2hI1wPzoA594nWINHEm7vxnHtToYPtFowZQiA4YnqRVq88yGVC0ZXbztHPHrTTmeFSqLChPAzyfr6UgOO1ixFncsYtxgb7pPb2rPr0lNH/tGzvIZ7myhWGLzMTS7TIfRODk157fWslnctDMORyD6imG2hBQOoooHUUgPePA9xt+Gdsmcf6LN/wCzV4Mv3R9BXsvhC42/D+Bd3/LvKMfnXjSfdH0prYJ/xH/Xccn/AB9W3/XQf0opE/4+bb/roKKxqbno4L4WPl/1r/U0yny/6x/qaZWp5wGiipYYw7csq+m7PNAxAAqnOSSOMdK2tLtkvoxFu8o/wueefQ1QMTLGJIijL/EvWtLRY/36uhIJ+baKARfs9EnEjPIsYOOHXkN7H0rqtG064Q5RXSNgNwZgcH2q3odo15ECWaLt1GT/AI1013btpkNtcP8AMjcFwMFfqKB7EUE9xp+GkvDHuGwnsR9RVazu7lLojzbeZMlPn5OPXIpNZkF60qp5cgKja6cfnjisqJI/3cqxm3liHJJxvoEampvb28u1EZ1xzvAIB9u+KswXNtJBsSbZMOiOdyH6GqaE6ndGObYrYBIAxuqytnFJtTyQpHBEmOaAHurf2lDMfKjkHAwvyNj1FdNPdQ2k8TF4YmYAmSMnYM9tuDXJOttHG0sMgjcMBsPKt+FXrHVoIixuYwyHp8okQ/UdRQBq382mybpPLJkj5EsT7cE98dMVzF8k6wShRlXOcmMDr706C8spbtl8uUA9BHnH9a2FSC8uAbSRnBTaYpmAGfwpiseAavAba+nE6bSWO3H/ANamWkeJFDkBG5yT+ldX45sBFJIxhZdrEEhcge2RXIRSqrLgHHuaGKLPZfhzYCdGyyBAuckc/hXoUkFulos0UzCQYJAjzivLfAGrmOxbY4j7FgMY+ldBda/bQPtWeXLcMwGf0pIuR01s1hLdLJfxEoOjh9gz+Aqjqi6bcXBS2WaQk/KrPnH48VkJrdpcptTBAP3sf0q0t/DFARHFmQnIDL+owaZJqCB4BsSIrK64VW5P6UljYpDdO96JFkYDhh1PpVu1urrUvs0TyrbSA5EnQAf596r3NzJb6g8NxctdN/CwH3vxpD6j9W00m9imbyoAejJJz9MDNcH8U8B1miu2dxwAp6fU112ozxR3LSRbomIyTnnNed+OZ5r4LBDs3scH6fWmS+ljFGr3d5ZQJLdStGhAA2HA/HvXp/hrSze28dwb3AUgkZ+YgelcDB4Ve1so57qWLJ/hV8kV6r4AbSII1/tG/CnYQsUSb2P68UjRdTM8QwkyM0UrLCCCWMgLGsXUYICUu1mYHgBQuCT6811Wuwo6TfY1k3luZHx09K5i+tJnsdywsshO3czj5vwNMzRZ0yN8h2lO0DgnGKtapeSLbCCJgVA9c81XsNN82NFkmxMB91fuj61WvbWWIMpYFQdzHdtBpIbIY5CVG9Nh6ZBPP1q00xjCosYdx/eHH1rNguFRsI4jQZJI6k+2afb3jSEkKHJ67zjNMZpLLJHZhkUK+7ndwCahmupHXbCqO+Dl+oT+lR3V0txAkaSIrA/6sAmoruRdqRyOeB9xeAfrQJmY0BeV9+ZAeCSRlqr3dgS6rGVBJyR6YrasLVpI5JjIkYH8ROM+wqnqEiWtpvtj8wHLAZ/WgHoc9eRMoJPmZU5OTgYrN1Oy+3WbM5SORDlMnp7V0lhZ3moQXk8VpczxW0XnTyKpIVfXFcxcykQK7xEsxyFI60A+x0Pwu8AaZ4o8J+LtQ1TU7W0u7C3/ANESS4VNjjnzHGeEPC5Pc15jyDz19ua9n+HWv+HtG8IeM4fEOkwTX15YjySGdftIz/qSAezANnjjNeMd+gHsKS2CXxadl+p6j4Ym2+C4V/6Yyf1ry1fuj6CvQdAm2+FYl/6ZOP5158v3R9KFsOXxv+u4qf8AH1b/APXQUUJ/x823/XQfzFFY1d0ehgvhY+X/AFr/AFNMp8v+sf6mmVsecKoz16U4Ek8Y+hpoBPAp4wwO4MPTAoAsWC75VCZWQcg9q6izs3eJWiUeZuDblHI+lc7p5aKUoYmdG5PHNdXYyNG8UbSgRDknGDigo7/SLK7ksIZjIky4xu24YNWnPqYuLUW8zos0fy7jlT9GH9a56yuFRY9shktuzKcEH3FRalff2jcsuYmZVx5uef8AGhClqRzkwXQZZI0bkHyjw4PqK1nslazMsysECYVlbr9ay4oFEIF1MGYA4dQMg+9RXGo3Ai8ohEQD78YxmmLpYda6g9rJGvmKSB8vPzCr0GqSReYXDsznjrj8qbo2nLfQxlohP/E2eoH4Vb1rTUgeNrdMIRwqnI/PqKQ3oYuoXpn/ANbtjw2QQAAau2Lqu1ppAY88AnkisTUngYeSWcuePlO4VRtrpoW8iNSW6DHBpiR0f2mCxu5TE0kbk5GBxj8K0dN1WcRtLAltIG4PnwhiPcHiuOuZ3MqbzIsgHzEVoWRm/wCe4Me3gL60hoXx19oNoGVwqyDLrGOD715eFUOVkAYE4J5yK9c1SwnutPESTl229AQOPpXP6H4dhS+JuJ4oGByfOUgn6UxJajfCNoRbvKJMQZ5U5B/lW5ZrbCcmJI1U53M3U/nVosqWr4ETqnA2ggH8ayDexsoUMIZAfu/eApDvdmvNaQJZKYwiyo2QVI5FTWWpsyj7XscA4UsuSD9a5+4lm8jzBcEKDjcqYB/GpYrqUwDCh2HAy2c0AdhdztI3LquAMttJAq3bTJAu+S4VjnoBwR+PSuLk1K4to1EsKc/eJJ4+magl8QztGFdWMaDgnA/lQI6bXfFEHlSRrFGjqMAnBJ/DNcnYF72+8yZFCE5y3b6Cqcf2rVbks/CZ644xXX2ejNbSRyRSRgIoY7ep/CmNK2rKWv3ciWAghuGMYHK+WeTUnhCe8jjIiYB5Rhii/NimeIRJds7GUToccFtuBVLw9cSCd0guDBk7VUHt9aTCPU764tbr7DnbMqL1WZ9n5cZrnWkxMLeKSNieSAc/mxq/q8klnp6B7y4LN1TG7P41hpCm8SkEIOcucH8qYupr2STPISzrGB0VTjP86tX9zBHaqrERyv0AGSaxZb24LrHbiUg9dvBI+tTfbRFMojKQ8fMW+Y/nQBRS3V5y11/qxz0xTp3Qy/6IUWMDsOf1pZBHeO+65cDux4U0iyR71E0abEH3l4zQBNaQyecipnzDyAe1WrmwjeVhdsrFATlQOT6cVmy3dwTmyKojckjsPrUMr+dEQku0D7xz1oAuxI7koHAKr/dGAKzo5PMuWi89F29WlXIUew9aZFdBJWWH5NvVsHiq9ncAyOSnBziRuM+9AFO7Ie4YrvbcdpYjAYf4VBfuPJ/e4wOFweTU95KvmvGrIY1X5pG4xWTfzB4iEUMucKc0AZd3dlP3a9T3zmsq4RVO6P7p7Z6GrkwHnYyJWHJx0Wq7SE28owqgkfU0AdLpE23QUXj/AFbD+dcgBwD7VuWU23TVX/ZNYfbml0G92Cf8fVt/10FFCf8AH1bf9dBRWVXc9DBfCx8v+tf6mmU+X/Wv9TTK1POHKM5OcYrY06E3myO3GJjxg9G9qpWNr9pjfnADAZrSS0eCRGU7gvdeo96Bl2K2niuFRoPKcHA3HHNdFYNbGIGePlDh1YYK1WsGOoWjJPiRh0EowT+NVL2CZSFjyjL1BbnH170Btobl5cpp5XyGVoHHyFuQPaslby5Uy+UNgPzDA3YqvHNKALW5Qv8A3TkEVJdXZtoIo5VUMmeVB5FMRKNTmadGWfJK7WBG3NEd9LI5jAZHJweeCPpWE1xEGAEnU5B6gVetZEaRWl2qy/MHU4zSGjtbKPUdJhFzatHKQu7YM5xTptfneEFYZYGIO7nNc7/bFyhXy2Drj5WDYOPSqcUzXM5lZ5QueSOcUBuXGumk4Mau5bqODUdzIwmC7JYiDkHvUctx5cu54VnjxjO3B/MVAl+7qojlPB4V+cUxGjaQPIdzDco77uasu0tmoZmyrHjeOR+NZM10jPi7jBJxhoW2nP0qfcvlkgy4PTzBkGkBoN55QXBHynpskzn8KdKZZlR5ImXn5WORVW0jETAqcE9AoxW62pW8lskZZcr/AAOOKBlS7v5YNOKJCx3H6j61zD3Dxb2e33ufVSMfjW8blInbzEDQs3ABwF/WtBYbKdEMc4Vm/wBqmLzOevtWtJLKOBonQAdFbjP0p+j3UZ2hQA45BHJH1p2tWsQuAzMjFRggnA/PFZbyoJNsSFVH3mRutIEzsZ7vMDsku5gNzLIuR+Fcwl1JeXJhRFVGPLr3qo8DXUyCJpkQ8fWuz8N+GzHJEUuYmyQcP2oGlqaHhrRo5XUyS7ox94heQK6+a98MaVYO3nRvcuChQx7tvvnNQXOkxWkMk0rxyTEcRI5GR+Fec6pC0+oeY0KRLnIB5oE3fQs6zqFtFGzQwo0bH13ZrmINY+yXivaW0Kn25NdLfwuttuCxsuMlmx+gFcNfsvnMYFYIOuRTBaM6KHxDLeXbm8ilmHRctxV64vJXhDFIolzjagJx9TXA2M8sbMpc7M557/rXRR3MX2VAzNIf7g4VfrSH0NRb+VnEfmMEJ+6oxU8W8Esx3ke3SsCS8WR1VcsBxiNcfrVm2d1OUWQZ4xnn+dAGuFkuiCWfapzg8Z/CnBwyuJTlugwc/hjtVGySdt2WfBPQHpW1p2ktjzWdYYh8xZ270AVJVPlqzpKi44GQAfwq/Zovkb4hEkx7MtEkJZZJopGlRf4nGFrPF+iuMLu554xk0BcNUeQ8KoZv4gvINZdxKjlFkkjUjnYO31q1dXN3fOVihMcecFl6kentWS8qWVy6rCrM3VzyfwNMRIms3lhHfx2Vy0MN1H5Uy8YdfTBFc9NE5RS0p8ofwqKdfTLI8jA4+gyRUBbbAOVGegJzn60B5leYBm2wDGB6/rUEyFB1B9TilOFOOWc+vApkr5yvYeh4pAPScLEE9qr0UUDBP+Pm3/66CihP+Pm3/wCugorKruehgvhY+X/Wv9TTKdL/AK1/qabWp5x0XhGIzySREFkJBKg89K6KC0w0w2gYOF3jHPpmuc8JwSM0s8T4MbAYB68V376hbS2ayMxS6HysD0egpnLJcrHclZUe2kHBKNlT74p93Kux2LmQHrjp+XapNRtFu1MkeBNGeVA5x9O9YcjsJA/KH7pGeDTJL9kylFaNg8inhZB2+tQXhmubsbSMjja3O2jaTCfn2k9iOKqPKxkXDL5gHB6GkBSls8yMGkAcdRngVpQObaNSk6uOhT/61Q7jNOJpGDMvUbcH8aW8hWWWMxRuAvPTIoA0oLiPar+WhUdj0/8ArVOs8IlRnZ0jJ5Qc8exrHDzK5KqADweajin23DskrMU5Cg8GgZ21iLO6u1gtL9VDdPOUDFXNV08xxNDJBBO8Zz5kYwcfWuDuLwSx/PBEH/vKvJq3Y3WY9sU0yq/HzueD7UAbT20LqwE7bAMnKhippbO3DxKIryB2J+68mCPqDWeQ7AxzDLY4ZV6/XFPEMXlbHjRZByGAzQBoT2k9rKWR42x/zyYEVSnuJ0mO0hhjlWFNIcx5VyGXqrnbUMDyPcbZkQg9Mc0xDJLsMxOxx6+lOW9YFVIPl9SF6itBCIA4aPa5GPujb+GaTyBIwkhmjV8YHy4GaQym05mlCrvdenJ5P4GmwRHzXKIF5wCzE/yqRtMvCFcTx7i3HzHGat2llfmUxm33Z5JHI/OgEE+ntKR5bfNjJGev0rT0HTNRGGVJMqeE3HmtPwymJhHICuD95TW3qWrwWrGO1uI5C/VTHuZT9aA2JdO094U36sdhkGQMf1zXP67Pbx36x2sQEfoG3Z+tOuNavLwC3mcSRr90Yzj8BWPqkw3pGrM2Oq+Tt/8Ar0xGm9++yT5IU+XAJiANcLrsTnfh+Mbtw6fpWzJqfloyJal26ZfJFYeoia4JD9P7qnC/pQhMw4eXBmPHr3rYtL6MR7TlR0GEyf1rAlHlvsIwAc8VZtbhYyvydT1x/jSKOitL5R8saPJ/vjAFW4JI5+JSI29BWYt7FGPkAORnnnmnrcSXAyg5H8MYwaANYS/Z5PLikYIed2KsSawEyGLzsOmetZen20t/cKIoWDLx8xyPxPSumtdJs7ZmOpXaGQDIjh5/WgCpZT3N+yoVkAY4C5NXLjTYLVl+0R7n64U8fiao6jq0dnKvkoSo6Bj0rGudflu5gZAXiUdFyBTFfsdDeXsMNoVJQtj5UToK4i5ujI7MSFwMZFWdTvRdxEBhEuMCOMc/nWNIzRwLFEmWJ5ySTQBdtdTsoI7qKfTEvTLFtikeZ4/Jf+/hfvfQ1lSOWIYcnoP8aa3mSdeOwA61bWLZFtjVmkbrmgBojRj+8YnsO1VrhlAZIx8oPXFBSSN2AwzHsvNJMrKg3DHtSAr0tHSigAT/AI+bb/roP50UJ/x9W3/XQUVjV3PRwXwsdL/rX+pptPl/1r/U0ytjzzpfCADCbccLuHPYcV2E0GbUmKSNh3Rx/KuM8LMiRTu7FCHGGB9u4ro/J/tGPy4nKMfQ8H6UAynJKDOobKyLwMcH6VFeRqweQSMQeShH9KvNZNAhF8HYrxvOQRVGbyySwkUsOMMMZpiMe6uC0LYLAjoAO1V4GicxmQg4Ofn4/DNXruJBKGhx9O4NNiXBKTx5U8hwuaQIkaNpl3xfd7Amqcdybe4XzJmCqeh7VZDeSpWOQMh5wRx/9as4nc7eYmP8+tMDr7QpdxjZArow+Yryfr61QuksFm2HbAe7YrMs457eRHiZlY8hlOalvY2uW3SvHvPUk80gZLHaPbsTaXMbwn+6f6GpSEK7pVTzB1KkD8apNCURAVAkH8SHrU6FUdTuU5HORQBLFNtZDHcsAT0HGa2I7O+SVZVPmxHlc4JqlGtrLGA9kruP4kbrVmGQ2iEeVMo/hKtx+VAwvJJHnD3JKP6Fcf0rR0vb5ykxKyno5GKzVnlmlAU4924rVtrTWog08ESybTkFeaAR1zR6Z5US3qHc3PsKW807Rowk1vLC8Z4w2Qc1StNR1CS2AnjV3I5IXp+YrV0+3tzAz7Y2nPfBGPxPFAGFdQx+aP3sSovKoFwT9Cazby+bzyqMfu4GOtdTeW4eFmvHy44XJDD8Kx2tYOsSFyPv+gpiM/R1njZh5MmW7gdfxq/qenzeZHJb21xHKw6llH61q6GFjLqfNC91kcYP0q7qMryOI3gWOPHy7R1pDZgaFZGNybmUb2ONu4HH4ioPFOmJCN4eJWY8srZb+dazL5UPmKuSTjaTjH6Vi67dSGDy4o0JHUg5/nTEznWWHZtDnd3O7NVL5o4124bns3/16fdTGNl835UHXaMGsLUJ4ppRsjkbHTd0oAz79j55C4GOoFFnC9xIuM46AAVHNIDJ+8QA+lOtppEl/dlsHtk0gRvw6egkAIUY7k1rLDaWYyZI0GP4RWNZ3M7rhRtBHJYgYrRg+xxoHviZT6BuKBmha3++TyrViVI4VQBmmSzSwTO0kYT1Z2HFYV/qkX2gtYxiJFGB1z+lZVxfPMQWUuc9WPFMRY1W+DzEK7OpOSTwDVZLp8bVGTjoOAKrSHzGOSN/8qeIyo2hNzEdc8CkBMjTPHnBwD2polnD8EhOlPGY4QvC981AzYwMZI5JPNAGp4fi0SW5uP7fn1K2jwPKaygSUk55zudccema9O+GyeChoMD6s+jC8W+uVT+0pGDSJ5Y8syKCQBnPANeQ2waTMjsFx0yKJXLKPmLKP4Rxmgd+hp+LY7D/AIS7Vh4bZP7La6k+zGPOzy88Yzzjrisa5UBcFy7Dqe1TkEqMLgEZ2r/WoJsrEVOBnsKe7JS5Ul2K1FBopDBP+Pq2/wCugooT/j6tv+ugorGruejgvhY+X/WP9TTKfL/rX+pplbHnGrou0rJu6ZHH4Vt2M4WdUt5Cin371y0BKKzZ289QK0Lado2BeT73fbQM66+v7pH2tKQrDHzjKtWdJdI8Zyqbx2C9apSXfmoElKYz1PFVZ8QygR4+o5piNSxjlu5C1vCpK8lehrcgtfMAQQqpPXIwR+NZumeaIFm85V984q1c3s7MDEAzDqVPX8KQ2Mv7CIDyiSs2f4uKy7rRL2BVlAZoj/EjZralvWmjX5GY9CDj5fpVzTpNkbKGLKRyp4x+FMRx7RXG0qWkjYeqdRVbdMEyCrgHBOK7WSMtuaNIs90as+50+1nmUqohkbqUzg/WgDKgdU2FEUgj5h0qm8TPclVynPAfp+ldHd6VbwQ7UnKnHIU7v0rGisBNMFEjFl6E9/wNIfUSD7RBcK8ewOPTnP4Vti/kMRa7tw4Ixuxj+VQ2mjy/at5Vdo6kjP5YrXuNLWNP3LRHd0JyM/mKAexysk8ZlOGCjOORmtvShcSqRbXBIHo5BH4VF/Z4j4cxq5PIOKvadbQJKGmUD02t1/KgEbdopFq0lzPGuOvz4NV7jW5LJj9lnOMcgPnNVfEN3aRoI/OjZWGCCuWFcZqk6RxgoY5OwxgEUxXOxTxhqFvfK9pGuccq2CP1ofXNVvLtpZLUfN12qAP0rziYTqokXdg9wM4/GiHVL6AgR3Mi47ZpDPoHwnb393bhP7OaYtztUZro9U0nUobJVfSJrXA4cgj+dfP+leL9YtpEVL+5WP8A6ZvirOo+L9Zu2KTalNMo6IXJI+tCCWux6BqivBCweVw/c79w/nXKSXMFxvRn3uO5GM1Q0k3moDM0oGPfFa8dlDBJma4jUn/az/Ki4WOeu7V7g7ba3Zvwziqs2g3ax7p9sSnszgV1d35cSO8Ujkj+6CM1x+p3VzJPhnKD/aOaYinqFisMHzyKT7LmsdH8p84bP1xWjeBmXBkJ981mOu1iKALX2qclQHA+h6CkMh3Z3jHqTmq6EDnAz9Kc+9RnJAPakBK7nPytk44NQjkbc/pSFmPAzj0p24gAlT+NADGG0g5qSN9oyWbPbFM6tx0pcA8sxGOlAC5I5IOT370oGXwCwHf1pyuB6ZPTikJweCGPpigDV0jTYLuG7ebUbK0+zReYqXDsGmP91MKcn64otI0lOM4GOT2FZ8ZzhmwPRVP86th5CP8AXAg9do6e1AySaaNHaOGElFH3m71m3EyyIQFwe9Xp1JISOIAEcsx5NUJQwRgQMD06UxEFJRRQAJ/x823/AF0FFCf8fNv/ANdB/OisKu56GC+Flm9tpbcxvKoVZhvTDA5GSO3Sq1amq6xd36LDNI21Tl/nY+a+fvtk9ccVl1seeSwuqghwSDVjT7afUL6C0sIZp7mZwkUUYyWJ7VSq9od3FYaxZXc4uDFBKsjiBwjkA5wCQcUPYqNm1fY2YPCviG516/0WDTJZNRsA7XMYIxEEGWy2cfrS6hoWuaXp+majf6ZLFBfAGDDKWYEZGVBLDI5GQK62D4jaBD8Qb7xRHpOsh71ZxNb/AGyPZmRNnGE7Ak81pRfGayUaQG0CbzrW3Fs90twizxIqbFaFwmVbGM5zQStl30/W/wCn3nncWqN5QD21wUOf+WZxx1psevRRkNCsqjtwD/WvTtI+On9n2VvZ/wBn38tvGSXWS6Vt4aSRmz8vJIdQfpXiTkM7MBtBOcelMOp1dt4jtFbdJDIXPGdo/wAa7JI1eIOuwjH8JDV5B3rWGqTfw4zjkGkPod1dspkRXjG31RsEVf060giQklyh5DA7vzrz231qZCqvsb/eGf1roNN8SGzmSS1uERz1VhkGgEdLc2Ns8e+OWMv1AY4b8KpPpyTjf5qeavRCeTVDV/E8V4g86K2L99qbSKx4vEb27j7Pu2g8E84piO106ztSAzM6SdxzipNQVPs5DSuoXoGwP5muTj8UhnJuSXYj0xVK910ybihYp6c8UAzVe6CkhGRyD/EKz7nVbmIMQGCHj7gP61jDVmL84IPQknIqne3rzjh2x0xk0AXL/UCxAWQycc7gMj8ayvMJcE8n3FR9TkA0owGB6gGgC4jybCiK2T65wKqSqyMQ3WrK31wFKxyOo9M5qKe4mnIMrbiO+KQC20mwdQBnOTUjuHTcZdrdgM81Ckh6E/TvUjhNg5O8d8UAbPh+eTnzHcD1ABrZaR3lIRCw7OW21yFnO8ZIQjcfbNaRu3VcvKIz7dTQNm1fXAWMbigZe+/dXL3V0zz/ADyyMPY4rRWaFossWc+oGTWTe+WZCVUr/vdaYhlwUJ53Yxwc1Xx8ueKfwRhQPxppBJ6DikA3NP28AZ5pvQ8YqXOSCxyw5570AK0EqKG2sAalhs5ZQGUqPcmj7S7QlN4/DimJK6rlRxjqaAJJYorc4dt798HioZNhjG3qe1Ip3HkD15pH5IyTn0FADwVKBcEN60CNActk+wOKaQW652j0pjEg5oA1tN0u91O3vG02ymnhtY/NndAMInqahjaNIhtJOfzNUtilN24DIxjuatW6kuu4HHXgdKBkjeZLhABHGOpqO4Vlt5BjagxjI5NaDRDhycL6ZzVbUFVrV3DZxjFAjIoo+lFAAn/Hzbf9dB/OihP+Pm2/66Cisau56OC+Fj5f9a/1NNp0v+tf6mm1secJRQaKBhRR+NFAgooooAKX60laD2wdch0J9B1oAo9eg/AVMLeXaCA209wOlaum6TPLjI+XswGSK2I7aeE+XIwf/dbbn8DQM5U7kBWUMQehIpLfY8wDNsHqOa6zyY3YxtCy56BhgH8elXtP0uxlVlnsg+OpA5H4igDmoPD0lyd8d5bkHuzYNMk8N6j55ihRZ27BXHNdNqWjWVvCHtDNbnPTzAw/I1lfZbuM74p1cem8g0xGc/hbWE/1lhKmPVeKig8PanMziK1L7OWAYcV0tnqVzCfnaePjG5HJNdHplxZzxj7ROxlP8Txgn+dIdjyxrG4QEvbyjHB+U8UtlHbmQidiPqOlek63oihg9neEhhyDlQP1Nc5c+GpyhJZZXHOU5FMSZUtLXQip895C2fcVnammnwz7bNW2+rHOKsXFtcWqhW2cHpgZqhczByAV6f7AoAjkWA8hyW9hxUDYGecn2rfsNXht7fy5LS1f6xgmq2o3FrcAusEUJPQRrikDKFpIqZLdfzqeS6ibG4H6LxVdWAQqIwwPc9aikUkZCEY9qYF0XMaDCyMT2HpVO5c+YcE8+tRxnD57U52Ln5QBj0pAMHHUE0cds0/5iO+B1NNIwAADk0ANzTsBm74oPHBWgHA5oACOcLnHvVrTdOvNV1C3sNPge5u7hxHFEhGWY9hmqw6fLgEdya6z4RzxwfE3w3LPJHFEt6hZ3YKoGD1JpN2Vy6cVKSi+poD4QfEDOP8AhFL/APOM/wDs1Ifg/wDEA8Dwpfj3zH/8VX1R8T20vXJtKmttRtLt7SQtHCtzatCHJHzyiQ5wBn7vNYUheXxs9+98rREE/a/7TgU+T5TKbcIH6l8EcY75qjO+n9f1/XyPnhPg/wCPl/5lfUD+Kf8AxVKPhJ4/BGfCl+fp5YH/AKFXvn20yfCmHTi9+NRt44lWz/tC2BYrNuzkS5JwOctjFdZ4e1m0h+Imq3c0/lWN1YwAXFxfQtH5i5yqgSEgjPpjikU1rY+M/EPhfWPDV+LbxDYTWVw0fnCOQjO3OM8E96ooF+bzWYD3r3L9pbxE8fjoHRNY/cXWmLBN9kmBWRd5+ViK8IlljTCjEjd/T86bREZXWv8AWpeht8qGGSD13GoNRlgELRoVMjY+72rPeeR/vMcHsKipFC0Ud6KABP8Aj5tv+ug/pRQn/H1bf9dBRWNXc9HBfCx8n+tf6mmU+X/WP9TTO1bHnBRRS0AFJRRQAUUUUAKOCK1DeWpK5WTA/wBkf41lUUDOq07xBZ2q7GWcp6BQf61cbxRppIDQTyJ/tKMj9a4ntRQB2K+JdPjmykVwYv7pA/xrXg8daVGM/YZCwGAfLHP615vS0AehX3jPS7mEhYLlWPYoCB/49WIdeswCEWfH+0gP9a5eigR0ia3a78t5+M9Ao/xq5/wkGlgZRbsMeuY1IP61x9FAHUTa9ZlwYVuE9wAP61AdeHQNMwz3ArnqKAN+XVrKRfngmLeu7/69UZ7q3eQPF5qY7Yz/ADrPFJQBoK9i7Fpmm/CMH+tT7tKyoEt0E7gQj/4qsiigDbjOhoci41DP/XBf/iqbNPpW1hHJfPn+8AP61jUYoAmZ4wx2plffrSNIuAFQAVFRQA/fz/Fj0zTmkDetRUUAKDzzSu2485/Gm0UAKpxT2ZGXkfpUdFAxw8odY1I+lTI8IUgpj6KKr0CgCzHLDGcrCCR3IFNeZSxYRoWPqOlQUUCFJJz2HtSCiloAQ0UUUDAUd6KKABP+Pm2/66CihP8Aj5tv+ug/pRWVTc9DBfCx0v8ArX+pptaDwR+Y/wAvc9z603yI8fd/U1qecUaKvmCPP3f1NHkR/wB39TQBQoq95Ef939TR5Ef939TQBRoq95Ef939TR5Ef939TQBRoq/5Ef939TSeRHx8v6mgCjRV/yI/7v6mkMEf939TQBRNFXzBH/d/U0ggjx939TQMo0Ve8iP8Au/qaXyI8fd/U0CKFFXvIj/u/qaPIj/u/qaAKNFXvIj/u/qaBBH/d/U0AUaKvGCPH3f1NBgj/ALv6mgCiaWr3kR/3f1NJ5Ef939TQBRoq8II/7v6mgwR/3f1NAFHvRV7yI/7v6mjyI/7v6mgCjRV7yI/7v6mjyI/7v6mgCjRV8QR8fL+po8iPH3f1NAFCgVe8iP8Au/qaBBH/AHf1oGUaKveRH/d/U0eRH/d/U0CKNFXvIj4+X9TQYI/7v6mgCjRV/wAiP+7+ppPIj/u/qaAKNFXzBHx8v6mk8iP+7+poAo0Ve8iPP3f1NHkR/wB39TQBRT/j5t/+ug/nRWhFBH5sfy/xr3PqKKxq7no4L4Wf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Svena Julien, MD and Charles Lockwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14848=[""].join("\n");
var outline_f14_32_14848=null;
var title_f14_32_14849="Haemophilus influenzae type b conjugate vaccine: Patient drug information";
var content_f14_32_14849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Haemophilus influenzae type b conjugate vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/14/230?source=see_link\">",
"     see \"Haemophilus influenzae type b conjugate vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/16/38149?source=see_link\">",
"     see \"Haemophilus influenzae type b conjugate vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ActHIB&reg;;",
"     </li>",
"     <li>",
"      Hiberix&reg;;",
"     </li>",
"     <li>",
"      PedvaxHIB&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ActHIB&reg;;",
"     </li>",
"     <li>",
"      PedvaxHIB&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10028703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_hib.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11752 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14849=[""].join("\n");
var outline_f14_32_14849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178251\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178252\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028703\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/14/230?source=related_link\">",
"      Haemophilus influenzae type b conjugate vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/16/38149?source=related_link\">",
"      Haemophilus influenzae type b conjugate vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_32_14850="Bartholin gland abscess";
var content_f14_32_14850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bartholin gland abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient's left labial area is swollen and erythematous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aron Schuftan, MD. Copyright &copy; Aron Schuftan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14850=[""].join("\n");
var outline_f14_32_14850=null;
var title_f14_32_14851="Ultrasonogram diagram hip";
var content_f14_32_14851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Ultrasonographic findings of the normal hip of an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Diagrammatic representation of of an ultrasonographic landmark of a normal right hip.",
"    <br>",
"     (B) Diagram demonstrating alpha and beta angles. The alpha angle is the angle formed by the ossified lateral wall of the ilium (line 1 above) and the bony roof line (line 3 above). The beta angle is the angle formed by the ossified lateral wall of the ilium (line 1 above) and the cartilaginous roof line (line 2 above).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14851=[""].join("\n");
var outline_f14_32_14851=null;
var title_f14_32_14852="Glycerin: Drug information";
var content_f14_32_14852=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glycerin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/53/38739?source=see_link\">",
"    see \"Glycerin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/10/26787?source=see_link\">",
"    see \"Glycerin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet&reg; Glycerin Suppositories [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Liquid Glycerin [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Pedia-Lax&trade; Glycerin Suppositories [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Pedia-Lax&trade; Liquid Glycerin Suppositories [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Dry Mouth [OTC];",
"     </li>",
"     <li>",
"      Sani-Supp&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Laxative, Osmotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Constipation:",
"     </b>",
"     Rectal: One adult suppository once daily as needed or as directed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dry mouth:",
"     </b>",
"     Oral: Apply a one-inch strip directly to tongue and oral cavity as needed",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F176859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/10/26787?source=see_link\">",
"      see \"Glycerin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Constipation:",
"     </b>",
"     Rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2 to &lt;6 years: One pediatric suppository once daily as needed or as directed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dry mouth:",
"     </b>",
"     Oral: Children &ge;2 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Dry Mouth: 18% (42 g) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, for prescription compounding: USP: 100% (3840 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Liquid Glycerin: 5.4 g/5.4 mL (7.5 mL) [4 units per box]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Pedia-Lax&trade; Liquid Glycerin Suppositories: 2.8 g/2.7 mL (4 mL) [6 units per box]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal [adult]: 80.7% (25s [DSC], 100s [DSC]); 82.5% (12s, 25s, 50s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Glycerin Suppositories: 2 g (12s, 50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sani-Supp&reg;: 82.5% (10s, 25s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal [pediatric]: 1.5 g (12s [DSC], 25s [DSC]); 82.5% (12s, 25s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Pedia-Lax&trade; Glycerin Suppositories: 1 g (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sani-Supp&reg;: 82.5% (10s, 25s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Suppositories",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Apply gel to tongue and around inside and outside of tooth and gum surfaces; do not rinse out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Insert suppository high in the rectum and retain ~15 minutes; suppository does not need to melt to produce response",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Constipation; relief of dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Rectal: Gastrointestinal: Cramping pain, rectal irritation, tenesmus",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13882224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glycerin suppositories are generally considered safe to use during pregnancy (Cullen, 2007; Wald, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema",
"     </b>",
"     (Fleet Liquid Glycerin Supp Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.6 g/dose (7.5 mL): $0.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Corn Huskers External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.7% (207 mL): $2.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Computer Eye Drops Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 mL): $3.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Introl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75% (120 mL): $15.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Pedia-Lax Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (12): $1.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.8 g (4 mL): $0.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Sani-Supp Adult Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (25): $3.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Sani-Supp Pediatric Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.2 g (10): $2.38",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F176843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Babylax (AT, DE, IL);",
"     </li>",
"     <li>",
"      Bebegel (FR, PT);",
"     </li>",
"     <li>",
"      Bulboid (CH);",
"     </li>",
"     <li>",
"      Cristal (CH);",
"     </li>",
"     <li>",
"      Czopki Glicerolowe (PL);",
"     </li>",
"     <li>",
"      Czopki Glicerynowe (PL);",
"     </li>",
"     <li>",
"      Farmino (AR);",
"     </li>",
"     <li>",
"      Formula Liquida Limpieza (AR);",
"     </li>",
"     <li>",
"      Gely (ES);",
"     </li>",
"     <li>",
"      Glicerina (ES, IT);",
"     </li>",
"     <li>",
"      Glicerina Cinfa (ES);",
"     </li>",
"     <li>",
"      Glicerina Quimpe (ES);",
"     </li>",
"     <li>",
"      Glicerine (BE);",
"     </li>",
"     <li>",
"      Glicerol Vilardell (ES);",
"     </li>",
"     <li>",
"      Glicerolo (IT);",
"     </li>",
"     <li>",
"      Glicerolo Dynacren (IT);",
"     </li>",
"     <li>",
"      Glicerolo Sofar (IT);",
"     </li>",
"     <li>",
"      Glicerolo supposte (IT);",
"     </li>",
"     <li>",
"      Glicerotens (ES);",
"     </li>",
"     <li>",
"      Glycerin Suppositories (AU);",
"     </li>",
"     <li>",
"      Glycerinzapfchen Sanova (AT);",
"     </li>",
"     <li>",
"      Glycerinzapfchen Sokosi (CH);",
"     </li>",
"     <li>",
"      Glycerol Suppositories BP (AU);",
"     </li>",
"     <li>",
"      Glycerol &rdquo;Oba&rdquo; (DK);",
"     </li>",
"     <li>",
"      Glycerotone (BE, FR, LU);",
"     </li>",
"     <li>",
"      Glycilax (CY, DE);",
"     </li>",
"     <li>",
"      Glyzerinzapfchen Rosch (AT);",
"     </li>",
"     <li>",
"      Jabon de glicerina (ES);",
"     </li>",
"     <li>",
"      Jabon Dermic (AR);",
"     </li>",
"     <li>",
"      Kimos (ES);",
"     </li>",
"     <li>",
"      Luxoral (IT);",
"     </li>",
"     <li>",
"      Micronema (AR);",
"     </li>",
"     <li>",
"      Milax (DE);",
"     </li>",
"     <li>",
"      Miniderm (SE);",
"     </li>",
"     <li>",
"      Nene-Lax (DE);",
"     </li>",
"     <li>",
"      Neotomic (IN);",
"     </li>",
"     <li>",
"      Neutrobar (MX);",
"     </li>",
"     <li>",
"      Obifax (ES);",
"     </li>",
"     <li>",
"      Practomil (CH);",
"     </li>",
"     <li>",
"      Q.V. Wash Soap Free Cleansing Liquid (AU);",
"     </li>",
"     <li>",
"      RubieLax (DE);",
"     </li>",
"     <li>",
"      Supo Glicerina Brota (ES);",
"     </li>",
"     <li>",
"      Supo Glicerina Cinfa (ES);",
"     </li>",
"     <li>",
"      Supo Glicerina Cuve (ES);",
"     </li>",
"     <li>",
"      Supo Glicerina Orravan (ES);",
"     </li>",
"     <li>",
"      Supo Glicerina Orto (ES);",
"     </li>",
"     <li>",
"      Supo Glicerina Rovi (ES);",
"     </li>",
"     <li>",
"      Supo Glicerina Torrent (ES);",
"     </li>",
"     <li>",
"      Supo Glicerina Vilardell (ES);",
"     </li>",
"     <li>",
"      Supo Glicerina Viviar (ES);",
"     </li>",
"     <li>",
"      Supo Gliz (ES);",
"     </li>",
"     <li>",
"      Supo Kristal (ES);",
"     </li>",
"     <li>",
"      Supos Glicerina Mandri (ES);",
"     </li>",
"     <li>",
"      Supositorios de Glicerina Fecofar (AR);",
"     </li>",
"     <li>",
"      Supositorios de Glicerina Parke-Davis (AR);",
"     </li>",
"     <li>",
"      Suppositoria Glycerini (PL);",
"     </li>",
"     <li>",
"      Supposte Glicerina Carlo Erba (IT);",
"     </li>",
"     <li>",
"      Supposte Glicerina S.Pellegrino (IT);",
"     </li>",
"     <li>",
"      Supposte Glicerolo AD-BB Sofar (IT);",
"     </li>",
"     <li>",
"      Verolax (ES, IT);",
"     </li>",
"     <li>",
"      Vitrosups (ES);",
"     </li>",
"     <li>",
"      Zetalax (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Osmotic dehydrating agent which increases osmotic pressure; draws fluid into colon and thus stimulates evacuation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Constipation: Suppository: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rectal: Poorly absorbed",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cullen G and O'Donoghue D, \"Constipation and Pregnancy,\"",
"      <i>",
"       Best Pract Res Clin Gastroenterol",
"      </i>",
"      , 2007, 21(5):807-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14852/abstract-text/17889809/pubmed\" id=\"17889809\" target=\"_blank\">",
"        17889809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wald A, \"Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy,\"",
"      <i>",
"       Gastroenterol Clin North Am",
"      </i>",
"      , 2003, 32(1):309-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14852/abstract-text/12635420/pubmed\" id=\"12635420\" target=\"_blank\">",
"        12635420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8959 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14852=[""].join("\n");
var outline_f14_32_14852=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176849\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176872\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176851\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176859\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176852\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176838\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176826\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176840\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176839\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176870\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299412\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220687\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882224\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323173\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176843\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176829\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176842\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8959\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8959|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/53/38739?source=related_link\">",
"      Glycerin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/10/26787?source=related_link\">",
"      Glycerin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_32_14853="Somatosensory evoked potentials";
var content_f14_32_14853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Somatosensory evoked potentials",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 559px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIvAgYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5298b+F7DXf7FvvEGmW2rblT7JLcqkm5gCowT1IYY9cigDoqKqWGpWt/NeRWrs72kvkzAxsu18A4BIGeCORkVFeazp9lrGnaVc3Kx6hqAla1hIOZRGAXwcYGAw6+tAGhRVY6hZjUhpxu7f+0DCbgWvmL5piB2l9mc7ckDOMZ4qzQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMkljjIEkiKT03MBT64i70XStZ+JWpJrGl2F+I9IszH9qtklKZmus43A4zx+VAHZfaYP+e8X/AH2KPtMH/PeL/vsVyv8AwjngL+0PsH9jeF/t3/Pv9lt/M/75xmrv/CDeE/8AoV9C/wDBfD/8TQBu/aYP+e8X/fYo+0wf894v++xWF/wg3hP/AKFfQv8AwXw//E0f8IN4T/6FfQv/AAXw/wDxNAG79pg/57xf99ij7TB/z3i/77FYX/CDeE/+hX0L/wAF8P8A8TR/wg3hP/oV9C/8F8P/AMTQBt3F3DBZzXTuDBCjSOy84AGT0rNsfEmn3VqLmRpLO3YKUkvUMCyBgSNpbGeBTpdDs7bw/faZotnZ2Ec8UirHBEIowzKRkhR9MnFc/qHhS7i8J2ekaTFasX8tL4z3ci5QJhhE21ypY8ZwMAkjBxQB2sUiSxpJE6vG4DKynIYHoQe4p1QafD9nsLaEQQ24jjVPJhOY48ADapwPlHQcDjsKnoAKKKKACiiigAr51+IHw48X6n4/8X6xY2P2zRLu/wBJuDppnhj/ALUjgixIA5O6NkbpkqGDHrgV9FUUAfPHj/Tta0ux1bUPEAePQrjxVFdvZT6lHB9rs/JA8sPv2rh1zsZlB2/TNDwF4Mu/GsfhC+1LT7uTw5Hea00u+7ZCkMpQQAEOHZTsIG3I454NfS1FAHz/APDr4f8AiTSfFXgvV/Eej3N1NbaM9hdy/wBoIWtZ1uC0bv8AvPnXysDC7u2Rxmrfx78IeLvE2tb/AA9pTzxRWAFpd211HFLHcCQkhjJIu1cYIKDJPBOOnutFAHjMngbXro/EbULuK+bVLu1kj0TGolULPZeW2EEmxTv4y4GOoI61yV58KvE0Njqcmm2eoC/W00m4sj/axP8ApyOv2p/mlxuChuW4/u19J0UAFFFFABRRXEeMPiDa6Bri6LZ2c+qaubZrk2tukjNjoiZSNgGfDY3lR8uSRQB29FZfhfXbHxN4esNZ0qQvZ3kQlTdjcvqrAE4ZSCpHYgitSgAooooAKKKKACiiigArLu9RlIm+wJCY4g3m3Vw+yGMr1Hq2Oc4wBggkHik1S4kuLtdJtHeOaWFpJp0BzBH93IPQOxztz/dY87cGtbQx6oIIoI1TRLUr5alWH2gqBtxngxjgg87iAeg+YAht2sbqJ3llk16UkrmOPfDnP3VH+rUjOMk7vU1nXk+r2UL32i+FLpLxDg2iXNskdwgHGTvwG9DjjuSOK7WigDO0PWtP1y3nm0y4Ewt5mtp1KlXhlXG5HUgFWGRwfUHvWjXKataNoXiV/EkEhTTp4RDqsKoWyVx5VwABnKjcrHuhBP8AqxXVKwZQykFSMgjkEUALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRUdxPDbQtLcyxwxL1eRgqj8TSxSJNEskLrJGwyrKcgj1BoAfRRRQAUUUUAcn8Utf1Pwz4MvNT0SzS6u43jT5wWWFXcKZWUEFguckAj6gZNfPXw90q38Z/FFJvHE194gkvbd4QLm4KJCVBcFVj2gLw424xl89evuPx5vxpnwq1q7kR5LdGtxcIh+Z4TcRiVR7lCw/GtbwZ4f8LwwW+veGrCONNQgSeKb58mNwGGFY/JkEcYFYzjNyTi7LqelhK+Ep4erCvTcpte6+39fO+x598R/C3w38GaPBHJ4LsLmW8YiNY8xSDbglhMPnXGR0Oeao+B/iFZ+HJ9Lh1DxLJc6FqErWot9WnWS802XBZWMoAMkDfd3OMqdvJG7HrHjLwjpni6zht9VEqmFi0csLBXTPXGQRg4HbtXGeNPDmn+HvD/hXRdHsxI1z4jscNIFeQ7ZRLI+SOojibOOwNCVT2l38ISlgfqMYxi/bX1fS39W6Xudl/wAJz4T/AOho0L/wYQ//ABVH/Cc+E/8AoaNC/wDBhD/8VW79mg/54Rf98Cj7NB/zwi/74FbHmmF/wnPhP/oaNC/8GEP/AMVR/wAJz4T/AOho0L/wYQ//ABVbv2aD/nhF/wB8Cj7NB/zwi/74FAHNeJPEUEvhkXug6payQS3lvaPfW0iSrArzIjtnlcgN34BIJ4FWZ9KeG1uLe31bUZpTtdYXu1VyQG+XftLANjJ/3eMDIO49vDJA8EkMbQOCrRsoKsD1BHQis0eGNAFo1qND0v7KziRofskewsAQG24xkAnn3oAh8DXs2oeE9OuLqd57goUlkdQCXVirdODggjI4OMjrW7TIIYreCOG3jSKGNQqIihVUDoAB0FPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKgvbu3sLSW6vZ4re2iXc8srBVUepJoAxvE19GZBpzXU9nH5LXV1cwkqY4VOMBsHDM2AMc4D4wcGo/BHh+HRra+uxDJHfatcG9uvOkaV1JUKiFmJJ2oqjqRncRgGqOmQyan4rmuLncoMMNy8LEjagaQWyFSOufNkbPIbYOi89lQBxngTSW8PeIPFelrNJLZzXaarbK758lJwQ0YHRVEkUhAHZucnJPZ1jTxpbeLba42hTeWr27vj7zRsHjX8nmP51s0AFFFFABRRRQAVW1G7WxspbhhuKgBUBwXYnCqPckgD61ZrntevFa8CeW0sGnr9rmVRxJL0hi92JO7A5BCf3hkAjt7L7Uh0/zZLmFpnl1G4DkLI+f9SOc7c4GAcBU2HrXS1T0ezax02C3kdZJgC0sijAeRiWdsdssSfxq5QAUUUUAFcvPLb+DSJJpli8PzzhWaaU7bGRzhQCeBEzFVAyAjMMfKfk6iqesaZZ6zpV3puqW6XNjdRtFNE/R1IwRxyPqORQBcoriPhxf3lpNqPhHWWmlvtD8tbe7m63tmwPky543ONpRyP4lz/Fiu3oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDl/HlpHcW+nSu93HLa3PnRPDYteoH2Mv7yJQSVwx5GMHHIq34J+0f8I9D9rsoLKTzZcRw25t1dfMYiTyiSYy4+YqSSCxzzV7X9Uh0TRL/VLpJHgs4HndYwCxVRkgZIGePWr9ABRRRQAUUUUAcP8bo7qX4U+JFsrWO7cW26SCRtoeEMplGex8sPgjnOMV2luYjbxm32eRtHl+XjbtxxjHGMUXEMdzbywToskMqlHRhwykYINeJWHjLxv8PrTw34d8Q+DIbuza8g0S21iHVkCTbm2RMYthcHYBktjJB6ZAoA9xrhvE9v9q+LXgYMVC2tpqd2ARnLBYIhj8Jmrua4P4l6T4jOp6B4l8HRW15qejmaOXTriQRLeW8wTzEWQ8I4MaFSePXP3SAd5RXCeE/ibpeuay+jahp+reHtaWMyrZ6xb+QZ0BwzRNkq6g56HJwSBgHHdg5GR0oAKKKKACiiigAoorjfFc1mvimwi8RXCwaGbSRk86UxQPcB04dsgEhSdqnr8xAJHAB2VFebeJ7jRY4dIfR9Qjku45rfyYheSNcyw+cOIQWOc/MCcEFRgnABGt4+k1RvDtxG8NvAH1KwhgaG7kzKj3sSkPhFKAqcEKW4YjPqAdnRXnuq6hLod9oujQavZ6ZfXLebNDJKJIliD8tul+cs3CKoPUk9FNehUAFFYvjHxNp3hDw/cazrDSizhZFIhjLuxZgoAUdTkiubufGf2S0S+k8Q+GZ1mVXgsIQ7SSFvuosiO7P1xlYef7ooA76ivOYvFfjfVr2JNB8J6X9gOWa/vdTliTKuVeLymgEofI+9sK+5q/pOt+Or+W6t77whYaSygCG6k1cXETE9W2JGGOOuDtz0yOoAO3orj7fSfF13cbNX8QQ21siOhfS4VRpyT8rbZUcxbRkYDvnOcjFVZ/hnpt09vHf6z4lvdNiB8zTrrVZZYLgkD/W7jvccZ2ltv+zgkUAdtcTRW8Ly3EqRRIMs7sFUfUmuf1XxdZWYaNQ8U5O1Hv43s7cseB+9kUA844Tc3PANYb/BzwA2qjUR4btkulKsvlyyIiFTkFUDBVxjsBXTWXhPw9Yzmaz0PTIJcMoaO2RdoYYYDjgHJyB1zzQBSF54qsbtjeabYanZFQFbT5fKnD85JSUhdnTkPn/ZPaU2a2skWp65I17qO7ZbwJgpE7dEhU4y2OPMbnAYkouQC18KWejyTT+F0i0mWQANBGrfZGwMcwBgqnH8SbTwMkgYNzTtLk+0R3+sNBc6mqlUeOMqkCnqsYJJGe7Zy3sAFAA/QrOWBLm6vERb29l86VV52DAVEz3wqqCe5yR1rTpgljPIdT823r39PrTIbq3maUQzxSGI4kCODsPofSgCh4jkitrS3vZlz9luYnDf3AzeWzfgkjVq1g+K1TV/BWspYSJcGaymWFomDAvsO3BH+1irvhvVYtd8PaXq9upWG/tYrpFPUK6BgD+dAGjRWdrWsW2kC0+0rO73c32eGOCJpGd9jyYwP9mNj+FUX8WaaIbS4Vbt7K5KKLpbdvLjZ5PLVXJGVbf8pGMr/FigDforKGu2w1mPTZYbqKWUusMkkJWOVlGWCn6ZOTgHBwTWrQBX1C7isLG4u7klYYI2kcjk4AycVgaPayTzW0M6qr2z/a7/AA+7dduu4R+6qGB56Yix04TxVqEkd00cUEk8dlALto1IAmuC4W2h9fmcE9sFVycHnc0mxFhZLEz+bOxLzzEYMsh+8x9MnoOgGAOABQBcooooAKKKKACiiigDA8UafdPNZavpMKzappxfbCX2faIXAEkOegJ2owzxujXJAya0dF1S31ewW6thIo3FJIpV2yROpwyOOzA8encEgg1erlPEJ1Lw/eyavoelS6tDdyJ/aFnDKqyKFXb58QYgMwVVUpkbgq4IIO4A6uioLG7t7+ziurOZJreVdySIchhU9ABRRRQAUVk+Jdaj0LTTctbXN5O7iK3tLZN0s8h6Ko6epJJAABJIANcNqmt+KJ9UXSZrTULbVLmB2httMltjAqAgGWWeTLqMtgYRTwcAnkAHSeIfHWkaVrkPh+3lF94muFDQaXCfnYHJyzY2ooALEt2HAPAOn4VsdQstLJ1q5FxqdxI09xslZ4o2b+CLdgiNQAAMD1PJNQ+FPDFl4djuWt442u7txLcTiMKXYKF69SOOrFiSSSSTW9QAUUUUAFFFFABRRRQAUVneJLq8svDuqXWlQJcahBayy20LglZJVQlFOOcEgDivP/gV8WbL4k6ERdG2tPEVtn7TZI2Ny54ljBJJTkA9cHg9QSAdV8Uf+SceJv8AsHT/APoBrp65j4o/8k48Tf8AYOn/APQDXT0AFFFFABRWZrWv6PoUaPrerafpqP8Ada8uUhB+hYiuB1v4qR6r52lfC22TxTr4XLNE220tAeBJLKcKec4RTlsHpQB13jTxv4c8E2cVz4o1aCwjlbbGrBneT12ooLEDIyQMDIzXmPjm8134uWWlR/D2LydAtL+3vJdWvY3t2nZXBBtgy7iE5ZmIGSAFJ5B7fwX8PbLTPs2seJEh1rxi6rJdarcqJWWXnIgyAIkGSFCKvGMiu6oAKKKKAMTxR4T0DxXBDF4j0iz1FICWi+0RhjGTjO09RnAzjrgZrzsaLbfCTxlosnh2OeHwj4guhp15p4leSO2vJP8AUToGyVDEGNuQPudcAD1+vPvj8qf8Kf8AEsjyvCYYUuI5IzhlkjlR0x/wJVoA9BooByMjpRQAUUUUAFFFFABRRRQAUUUUAIyhsbgDg5GfWloooAKKKKACiiigAooooAKKKKAPJLLR9TsL6xeKwumtb/xHdXNyoib9y63c5SYjsjxFRu6fJHj71TXludch8RXNjpN5YsLF7O3sjp0kBnhEgaQsWQKWfoqAkgEnqxC+q0UAcx4Li/0vxBdQW01rYXV6slvHLbtASBBErNsYBlBZSOQM4J75Od8HbOTSPB39hzS+a2k3dxZo2D/qxKxQAnqApC5/2a7iuNsdSTQ9d1VNUZYNNluNkd05wiyNiTa56KD5oAJOCVI6kAgGp4q0OXWrnQjHO0MVlfNczNHK0chU280YCEd90i+nGfocu+8PX632mWen2lg3hqx2SrbSXciSSTh9wdz5b7wpwwBbJfljwK7EMpbAYE4BwD2PQ/pS0AczNpWpXfi6w1KWKxtobNpF86Kd3luImVgsbIUCqNzBydzcoMdTXQ3VxFaWs1xcuI4IUMkjnoqgZJ/KpayNdElzd6bp8f8Aqp5TLcgNgmFFJI9wXMSkd1ZqAMzT7e5Oo6el1HGk08k+p3asdzKcBIkPbKqyjPrF+NdVWN4dZb/7RrIOVvdqwYbI8hC3lkY/vbmf6OB2rZoAKKKKACiiigAooooAKKKKAOX1Dw7eWd7LqHhK6gsbiQs9xZTxlrS6c87mCkGN89ZF65+YNgYy9P8AHV5a6oNI8VaOtjq0t0ILdLO6WaKZGQskgZ/LIBIZOV+8ABycV3lR3MEVzbyQXEaywyKVdHGQwPUEUAYtt4s0hw63lwdMnRN7waiv2Z1XJGfnwGGQRuUke9Eni/w+LXzoNXsrssD5cVrMs0kxAztRFJLHHYVQ1LwLp+rWyafrE9xqOiIVZbG7IlwysGGZSPMZcgcFjnGCSOKrJ8LvCMOpW+oWumSWt5b5EMtvdTRmJCCDGmG+WPDN8gwoycAUAU4IbjXNVKTa1G+pTohnj06U7dOtQctGkinIeRwql+GIBKgbOOu0bw/pOitM+lafbW0s3MsqJ+8k/wB5+rdT1NXLGxtNPgEFhbQW0I6RwxhFHboOKsUAFFFFABRRRQAUUUUAFcz8R/FX/CF+D73W1sJdRmhaOOGziba88kkioqg4POW7Anjoa6auY+Jfhd/GXgnUtCgvTYT3IjaK5CljE6SLIpwCD1Qcg8UAcLpHjTx/4jv0ttFsvDVlP5CTz2mpw6hFNbg7cqxMSqzAnHB569KrWXwdutR1/wAQan4lbQLaXU4kMU2h2j289pdRsWW4jkZiVc7m3Y+8cZ7585+A/jKPR/Gmu23ijxzdXumWB2w3Wqaq9vFIWBB220w3s2Qc8jb1I5Fe3v8AGb4dpJ5Z8WaduxnIZiPzAxQB4rrGr+KvGvid/C2qLrOrLYWRhUaDqNvZQalKjkPPKZBwGRk+QZAKsVGDxu/C/wAV/EXVzqml6FJoxkMpvIf7fvbi7mgiIVTGHRAHCtg5JH3u9Y1rp+hR+KLLVfD2keN/ElrYXIvbJrHSzBbtIv3VaaQgsBnnCjPuOD1XhnXrXwxq91rY+GPxAt7+7Ro3htrRbiGFWYMwQBl4JVTyOMYGBkVjH2rs3Zdz1a8cvpupGk5S0XK9tet/0/pnQr4f+Mm4SN418P5JyYhpuVHtnGal/sD4s6oWstX8V6BpunSHElzpNo5utnQqhf5UJH8XJU8jpVofFseWG/4QH4hAn+D+xDkf+P4/Wl/4WrdSQeZB8OfHh9pdPjjP5GTP6VseUXPDPwf8EaAFkTQ7fUL3d5j3upj7VNJJ/fJfIDZ5+UAZ5rvLe3hto/Lt4o4o852xqFGfoK8sh8c/ETWYpV0T4avYkgqlzrGopEqNxgtEBvYfQj61KfhhqXiWJG+JHivUdWBHzabp5+xWS5HKkJ88mOzMQcdqAOi1Tx5p9r4+8PeFbV7e8u9UFyZTFcKWtRFHvG5Bk/NyBkjoetdhXj958PfC3gbxr4B1Lw1piadI2ozafII3ZjKklpOw3FiScNGvJ55NewUAFFFFAHEeGb++tfib4s0LUb/7RBJDa6tp0UjZeOJw8Uqj/ZV4gQO3me9bPjnwtp/jTwve6DrBnFld7d5hfYwKsGUg/VR1rmvGMkWgfFLwfr0iqkOpJN4fuJT2aQrLAPxeN1/4HXodAHLfC3WG1/4c+HdTlx509lH5uOnmKNr/APjwNdTXBfAm4a8+Fei3bRpEblricIgwqh7iRgAPTBFd7QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc7408RSeHItLljtPtSXV2YZQGIaOJYZZndQAdxCxHC96pXXi+WPSrq+t7BbiOHU1sCVmAXY0iIJM45+/0FdDqOmQ393plxM0gfT7g3MQUjDMYpIiG45G2VjxjkD6Hn4/AljB4fk0ayv9RtbN7z7Z+7aJmUhw6oC6HCKVXAxnAAJNAFzxHrV7pGo6cqx2r2l1cRWwVmYSEu4Vm3Y2rtBBAJy2MDkgV0VYeo+Hv7RkhF5qmoSWqNFI9r+6EcrxsGVmITcPmVSQrAHHTBIO5QAUUUUAFZwkVdcmtpI0CXFuJFOB+8KsVfP0DR/n7Vo1S1PTo79YC0ksM1vJ5sM0RAaNsFTjIIOQxGCCOfXBoAzX8GeGWhWL+wNLWNWZgqWqJy33ugHXvTrKFND1SGwhDLpt2uLeMklYZUXJjXOcKyDIHAGxvUCobiHxDYTRwaXJDqFvKjAz38oV7Z+zYRP3in+7wcjrg5VlzZu93/ZWsXE13aXRWWyuiAksU0fzFcqAAfl3qcc4cHgDIBuanefYbJ5xFJO4wqQx43SMTgKM8ck9TwOpwBWHe2t1b2M73VxG+salss1khj2iFTnhO5CAyPknJwegwBa0LS9Rijik1/U/7QvIZJDG0cYijCnKqSo6tsPOTjJOAOKdMi3/AIqgDYaPTITMBu6TS5RTgd1QSDntKKANeCKOCGOGCNI4o1CIiKAqqBgAAdAKfRRQAUUVm6nr2kaU+zVNVsLJ9u7bc3CRnHr8xHFAGlRWNZeKNGvJDHHfJG/mCNFuFaAyk9PL3gbwexXIPY1s0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAV7ixtLmRXuLWCV16M8YYj8TRBZWsDBoLaCNgMApGAQPwqxRQAUUUUAFFFFABRRRQBwfxWBFx4HkEixhPElrksM5zHKuB7ndiu8rhfjHapceFbJw6R3tvrGnS2TMM4n+1xqvHfIZh+JPau6oAKKKKAPPvj7FA/wk8Qzz3H2aS0hW7t5wcFJ43V4tp7EuFX/AIFXT6xeX0Hgu+vXh8jUo9PeYxRtv2SiMnaD3w3ANcX4+DeJ/ib4W8IEj+zrRD4g1FM481YnCQJ7gyncQeoT2r0q4mitreWe4kWOGJS7uxwFUDJJPpigDyz9l3UDqHwT0EOzNJbGa3Yn/ZlbaP8AvkqK9Xrz34B2kNv8LtLmtrD+z4b6W4vo7fGNkcs7vEPoIygHsBXoVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV59rE2oeIY5LrRY5pruOI3Glr9oNtFCcERyy9d5kIOFKkbOu3cczeM9cm1bU38HeF5LWfWGCSamZWby7K0Y872X/AJaOOFTIYhi3AGa67SdNh0y1MUO5mdt8srnLSvgDcfwAAA4AAAAAAABg+C/EeoasTHrdrY2dxLGJoEtbkzDAAWWJiVX95HICGAGAGXqc11dcD4otItA106raQBYrnffTKC2GuYUGSqjje9t56njnYueld5FIk0SSROrxuAyupyGB6EHuKAHUUUUAFFFFABVHW7D+0tNlt1k8qbIkhlxny5FIZGx3wwHHcZHer1FAGANY1K5SNbDR5fNI2TSXD+VHDJ0I5AaQDn5lG08YPXF/RtN/s6KcvcS3Nzcy+dPNJ/E+0L8o6KoCgADpjuck6FFABRRXKz39r4svpdKsbgT6XCrDUWjyBJkYSEMCOG+ZiVzwoH8VAF7UdZlkuvsGgJbXmoDmUvKRFbL6yFQTkngL1PPQAmobibSfCumSXOu30IaeQyTXE45lc+i8nAGAAM7VA9M1HPAkNzFoXhpItMUn7Rdy2tuoEKcDaONokfgDIOFDH+7Wnp2iWVjeNehDPqLxiF7yc7pmQHO3d2XPO0YGecZoAgv9b0WawlRru0vUmUxi3hlSRpyeNijPJOcfzxXFXXxDu/CVl5fiHwt4oktLYKj38cMUyopOAZGEnzEDaS65Bz2OQPQIdF0uC/N7DptlHeEljcJAgkyep3AZ5yc1dljSWMpKiuh6qwyD+FAGE+r6uLf7TF4emlifiOIXMaz+xdWwqj6OWAP3c5At6Rqb3Uj2l/FHa6pCoaW3SQupU9HRiqlk7ZwMHIIFUY5Ljw7K8MkF1daOx3QyQRmV7X/pkUUF2XP3SoOAcEAKCdK6trDXbCFmIli3CWGWNirIw6MrDlSOR+YPcUAaFFZ3h65uLnSo2vmRruN3gmZBgM6OULAdgdufxrRoAKKKKACiiigAooooAKKranf2ul2M15qE6W9tEpZ5HPAA/mfYc1U8P3t5qEFxc3drJaQvN/oscybJfK2Ly69iW3nBwQMZAOaANSiiigAooooAKKKKACiiigAooooAKKKKACiiigDgfGsban8S/AmlSsv2GE3eryxlT+8lgVEi59mnLY9VWu+ryS88a+GpPjbdLquv6Zp8fhzTTaqLy5SHzbi5dWfaWIDBEhjB9C/bFdHqfxa8AabbtNceLtHkRe1tcC4Y/RY9zH8BQB3FYniXxTpHhtIRqdywuZzi3tII2muJz6RxIC7fUDA74rhbLxtr/wARAF+HVodO0FiyP4j1KHh8HafssB5c5/ifCgqwIyMV2fhLwhpnhj7RLatdXepXW37VqN9MZrm4wMDe57AdFUBR2AoA4z4Sam3izxt428USafe2CLJbaTbwX0BhniWJC7h1zwS0ucem2r/xz1Cf/hEovDemMBqvii4XSICV3COOT/XSMOu1Y92SOmRTvg1NJd/8JxfOuIbnxPeGBuzpGsUO4e2Ymp2ki28V/FbUdUZFltfCsZ0yzk4IF3Koa5YH1VPJj9iX9qAO502yt9M061sLKMRWtrEkEKDoqKAFH4ACrNFFABRRRQAUUVxviuazXxTYReIrhYNDNpIyedKYoHuA6cO2QCQpO1T1+YgEjgA7KivP9bs9N1JtC03RJrh5Lw7hcx3cp8q0ibLuDu5ySsann74IyBVOxuYLXxsIzc2Wr3M2ozL5kF7It5bA7jskh5BiQAL1AxtbBJyQD0yiuD8Wrq17eeG7a5t7WGaa9lDQxX0pjkQW8jDc6ojZyOmCOBz6PttWePxxa6Fa61axx2sKm7s3ZGbcY/lijLfvGJ++WOcLj+9wAdzVfULyKwsZrq43eXEpYhFLM3oFA5LE8ADkkgVn63q95p99ZW9loeoaos6yNJLbPEiwbduN5kdepbgDJ+U8cVmzXwjuIW8QiM6kW8200qymM5wv8ZGF3nPO5htUhcc/MwBcXW726CjT9DvS3Bc3hFuqj0zySfYDHXJHGZ3XXpJUlR9NgRCd1vh5fNH/AF0+XZ/3w349Koz6zPq0i6fpEOqWczsDJeTWLxLFEOWZTKm1mP3QpBPO7GBzKNE1QqEfxRqYVCdjxwWwkYH++TEVOO21V465PNADR4u01XNpO5j1lfl/svcpuGbsFXOCD2fO3HJIAOIdX1XxDD9mtrHTNON9dnaivduwgUD5pXAjG4LlflBGSQAwzmhNL8T2dy80HiCK/jZgiQXtqiLHHt+8WjALSbsknhSONqkbjsaZZXMLyXGpXMdzeONu6KIxRog6KqlmI9SSSSfQAAAGf4J8MQeFtJe2SZ7u9uZWur69kUB7q4fl5GA4HoFHAAA7V0FFFAGV4lBj0p7yNWaWxIu0CDLHZyyr7sm9P+BVB4SUWtlNYRsHtrWTFo4bcGt2AePB/uqGKD2StyuKtobnw/rDpblprSBRi2jjJb7GT8oQD7zQvvG1R/q3UYLbQQDtaK5satq9xKb3T7BbjSlkMKw4CXE3YyqXZVVQ3G0jJUFgeitQstZv9R1ye11iF9LtLZxFFPaXHmwXcpzuXzSilShAXaQMsSMsVIAB2dFYmmT3thejTtVlku1ky1remILvHJMcm3gOAOuFDDoMg1t0AFFFFABRRWZ4k1uz8O6LdapqLSfZ7dC5WJC7uccKqjqx9P6UAYXiTUZdV1KXw9pvluQFF0PMKkg4LKccqoUqWPU71UYJLLYs/DD6PM9/pFwZNTm/4+vtMjCO6GOBgZEe3ou0cDIwc5o8CeHrjRrSa61HUbu+1G/xLcGdI0EZLO+xVRRgAyN1JP4cV1FAGfomntYW8vnSebd3ErXFxJk4ZzgYGeigBVA9FFaFFFABRRRQAVh30h0XUVulTOn3kiRz4YAQyk7VkweoYlVbHfacfeNblMmjSaF4pkV4nUqysMhgeCCKAM2GRLPX57djj7cv2iPc33nQKjgDt8ojOP8AePatWucSx+0s2i66y36Kvn208kYDsoO3k9pEyvzrtzuBAHNZvl6p4Y1rRxfeJbvUdIvJfsbLfxQCRJip8ra8UaZDEEHcCc7eeTQB2tFFQX11FZWc11cuEhhQu7E9ABQBj61d393qUWlaHdQ21wiie7uHi83yYzkIoXIG52B6nhVbuVp+keIIJvDMeqanLBaeWji6+f5I3jYpKAfQOpFO8I6VNpekIdQdJtWuT599cKoHmzEDPTsowq+iqBXK6zoOiaZ4/wD7cu5m2y2hZNKVGdJrnzFPnJEDhpPujhewbIPNAG43i621CMW3h4Pdaq7CMwSwvGbUnktOrAFABztOC3AHJrD1LxPrdtqE9lp95Y61cWqr9rTTdLaV7Uk4/eA3IwT2QZbAJwBWppnh7xBLOt1rXim+aOVzNJp9vBDFHHkHESyKvmbVyOd2Ttznkiuk0zTLLSrZbfTrWG2iAA2xqBn3J6k+55oA870r4d6lc7Na1nXdTHiBJZbm2ikmWa3tnYnbujI2MwGASoUADC4+8fRNM/tDyX/tT7KJd/yfZt23bgdd3fO78MdOlXKKACiiigAooooAKKKKACiiigAooooAKKKKACue8feIv+EX8LXeoxRC4vjtgsbXvcXMhCRRgZycuRnHQZPauhrzHUGXxd8brXTWxJpnhC1W+nTPBv5xiEMp4OyIO4I6FqAK2p+A7LSPgdquka3HDq159nn1C9upFAM1226R5ixGeCcBuu1QK7W8stG8HeHNU1HStK03T47K0luCLe3SFcIhbnaBxxWvq+nW2r6Te6bfx+bZ3kD28ybiNyOpVhkcjIJ6V5H4y1bxL4J8Da/pfiPSbvxNoQsZoLXVrLa06xmMqFvIyR0Gd0yZBAyVBzQB2HwSRl+E/hd5Gd5Z7JLmR3OWd5MyMx9csxOfer3xG8S3HhnQ4H0y0W81jULqPT9PgckI08mcFyOiKFZj7KenWpPhiixfDXwnHGyui6TaKrKcggQpyDXmP7SV9aWmpeHGvtQntJIbW8utNSKdo/Mv0ktlhzt/2ZJeewLUAek/C3wtJ4K8BaToE92Lye0VzLOFIDu8jSNjPOMuRk9cZrG+AEUv/CqdHvbyRZr7UzNqN1MF2mSSaV5CT74YD8KzvF3xj8OWdvc6Vpd683iSe5utKtbSFA8qXcZZF3rnKq0gUKT13DsCR2/gTRX8OeCtB0WUxtNYWMNvK0ZJVnVAGIzzgtk0AbtFFFABRRRQAUUUUAFFFFABRRRQBUvftzSIll9mRCrb5ZtzFW424QY3Drn5hjHfPEGjaTHpqO7yvd303M95MqiWXHQHaAAB0AAAH1yTpUUAFFFZ+qa1pulSwx6jeQ28kwZo1dsFwuNxA9BuXP1FAGhRWWniHSHv0sV1K1+1vt2xGQBiWXcoA9SvIHpWpQAUUUUAFUNUsnnkt7q1dY7y2JMZbO11IwyNjnacA+xVTg4wb9FAGCs/iWdGRtO0uzLEp5v255Wj6jeE8kBvUAsM98Vp2unW1vpMWnCMS2iQiDZL8+9MYw2euR1z1q3RQBy+o+GrGysHbToLxYo8E2VtdSrGUByRHGG2ow+8uwKdygZAJqxBa319ZQXOn+I5nQhXhdreJkkGcnzAFBORkfKUx9RXQVjXIv8ATJ5Tp1m19BcuX8vzVj+zyEdecfuyQWOMsCSQGzhQDntcXxfqeo31ro2sWtjBZ26yFra0VpXuSNwgLylk27cEnaCN6H1rXsNYuk0+C9kjbUNNdCfPt4j9ojx2khUElhgq2zkMMbAM7djS7P7DZRwFzLIMtJKRgyOTlmI7ZJJx26VWtFSx1m4twWCXmbmME/KHGFkC+n8DY7ksfWgCl/wlFrqFun/CMtb6xcSY2+XKRCnc+bKqsI+OxG4ngDrjJ1OGPVNchsL67tL3VBIAYLeNttlb/K8m/wCY/M67U3HbkOMAAtnpNYupQosdPci/m2gMFDeShODKc8DADYzwWGOeat2NnBYW4htU2JksSSSzMerMTySepJ5NAFiiiigAooooAKKKKACiiigCjq1tPPAklk6LdwP5sXmZCMcEFWIyQCCRnBxkHBxis5NX0nWo57K+Wa2lWNjLbXsT27BdpDlSwAdQCQXQsvv0Nb9Vr3T7O/8AJ+3Wlvc+S/mRedGr7GxjcuRwcE8igDjfD/xJ8MXGjRSf2xHci3PkXNxbpLPFEyts3ySBSEUkZDOQCDnOOaTX/Evh+TxPHFqWs2EVloyi5nQ3igvcN/qkMY5cqoLgddxjIBIra1PwpDe38k8ep6pZW87rJc2lnMscVww4yx27xkYB2MuQBnNX9G0DSdFtbW20rTrW1itY/KhEcYBRe4B68nJPPJOTQBmS+Ir27ZLXSNGv1upGA86+t2igiXqXY9W46KOSSAdvJFrSdFmi1NtW1e5ju9VaAWwMUflwwpuLERqSzDcdu4ljnYvQACtyigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAI7iaO2t5Z53WOGJS7ux4VQMkmvN/gHBJdeEr7xPdq6XfifUZ9VaNwMxRM2yKPI6gIikf71aHxw1eTSvhpq8Vmnm6lqijSrKINtaSa4PlqFPqAxb/gNdboGl2+h6Hp+lWYItrG3jtos9dqKFGfwFAF+vOvi1NPrkmneAtMmkgudfEhvriIZNrYJjzW9i5KxLkY+c+lehyOsaM8jBUUEszHAAHc15f8JJl8WeKvFfj1GmfT72RNM0kyqRm1gHzSJn+GSVnOCAQVOaANP4MLLp3h3UfDUzSSf8I5qM2mRTSuGeWABZYWOAACI5UX/gGe9Yf7RngyTxD4WttY0axubzxTo88T6YsAD/ADPNEG3oQVZQBuOeBjJ4zWj4OvpbL40+PdEu0KC9js9Xsuc+ZH5KwSN7YeMCvSqAPnP4b/CyTwr8X9I1TxXeW+seIdVs7/UbjbGBHb3Alh/eJ0yT5zjoMHoK+jK8un8+f9pq2jYsba18JtKvHAd7vaefcIP++a9RoAKKKKACiiigAooooAKKKKACiiigAooooAK47xfp15P4p0a+t7PUri2gsruCQ2FzHDIryPbFAd7plSI36Z5Arsapa1frpekXl+8bSi3iaXy0+9IQMhR7k8D3NAHK2Xha5vNc1G41GW7g097u0u4rZmjYzPDFEVLsNzfLIgyARkr1IPPb1zPgDWbrWNHuP7SL/wBo2dy9rdI8IiaOQBWKFQzA4DgBgxDDBHWumoAKKKKACiiigAooooAKKKKACq9/ZQX9uYblWK9QyO0bqemVZSGU8nkEHmrFFAFexsbWwh8mygjgj6kIuMn1Pqfc81YoooAKKKKACiiua1jXLy3up5rNIH0zT3jW9Yozudx+faQRt8tCrscNkZAAIoA6WikRldFdGDIwyCDkEVm3Gu6bb6tFpk90qXkuAiFTgkgkLuxtDEAkKTk+lAGnRRRQAUUUUAFFFFABRRRQAUUUUAFFFVNN1Ox1SKWTTby3u44pDE7wSBwrgAlSR35HHvQBbooooAKKKKACiiigAooooAKKKKACiiigDy34htaX/wAXvh7pGtTtDp6G51K1jI+S5vYtgiUnsUVnYc8nA7ivUq8d/aK8PWuoJ4M1u+ku4LbStahS4uLWTy3t4pmVfNDYJBWRYenP44r2KgDzL4uajeaxead8PtAkZNQ1tfM1KZAN1ppgO2aQE5AZ/uLkHknocGvRNLsLXStNtbDT4Et7O1jWGGJOiIowAPwFeXfD95Lf47fEW31lDHqd3DaXNhu58yyQNHlD2AfGRx8x74r1qgDzb4ik6D8QvA3iaE4FxdHw/dqq5MkdwN0RJ7BZY1P/AAKvSa574geGk8W+E7/SfOa2uZFElrcqSGt7hCGilBHIKuAeO2R3rj/gB8TT8RvDM/2+IQ67pjJDfIowrlgdsg9N21uOxU9sUASNmx/aOEl0sqR6l4b8m0k/gd4rgtIn+8FdW+h969NrzP4uTpovir4deI281vs+sHS3RfuiO7iZC7eysiGvTKACiiigAooooAKKKKACiiigAooooAKKKKACue8bK02n2FmihmutRtEIJwCqzLI//jkbV0Nc/rkzv4p8NWcY/wCWlxduf9lIjH/OdaAKPh+1m0/4ieLEdibbUY7TUYsn+MIYJAB7CCEn/fFddWTrSC3vdP1MyFFt3MEvoY5So/DDiM57AGpdaeSRYbG3kkimumKmSM/NHGOXb24woPYutAGjWBq3iE2Md/cwWb3djpylruSJ/nUhdzKiEfOVXBPI64GTkDDuNO1KRpv+EeN08MUzRLdz6pIZflOJEVXVlK8FAWOQwz2DVtwWJ1KOKAw3FhpMGAbVgFa4YHJD9Tsz15+c5zlfvAFTSfEd1e6bZ684sR4fvI0lQo7GWFH6O5+7xkbl4288nHPV1gatp4sHl1KwUiMgte2aRqUuk53NjH+sAJOQfmxtOeCpZLe6XtS0jbVNKly8BjkXzIAeQuWIDp2U5BAwMEcgA36KyrHULw3qW+p2cVqZ0LwFJ/MyRjcjfKMMM5wMggNzxSTeI9HhnmhfUbfdCVExVtywlvuiRhwmccbiM0Aa1FR208VzBHPbSxzQSKGSSNgysD0II4IqSgAooooAKKKKACiioL27gsbSW6u5BFBEpZ3PYf1+lAFDW7mZrqz0yzmaC5u97tMqgtFCmN7LnjdlkUZzjdnBxir9jaQWNpHbWkYjhjGFUc+5JJ5JJySTyScmuckvbLR559f8RyCznuP9Ht42Jdo4VJIUKucseXbAOOASQoNWbuxufESky3Woabp42tALWUwTTcZLOfvKOQAvB4O7sAAZfiHTvEGn6Uun+F9Rs0W5m8mFLuEh4I2OWEciEABED7cqcYHJxiqq6hpsGkNozaBrmsSvN5d7A0ZuGSTghpJZWUMOEKsDkDaQAAMddYaLZWNz9phWZ7jYYxLcXEkzBSckAuxIGQOnoK0aAOF8Ma/4kEWoafqfhi6N1YyGOCZb6GQXEWAY2diVIYqcEgEFlbntXS2OuW9xOttcxXNjdsxVYbqPZvI6hG5V+OflJ4p2q6Y9zPFeWEyWupRDYkzIXVkJ5R0DLuHXHPB5HcHO1SW5S2e212ze7gklUQ3GnQO7I3VWKfMUKsAQ4JA4JK0AdJRWL4U1v+29OLz281nfwMYrq1mTY8bjvjJ+VhhlOTkEd81tUAFFFFABRXMXOvXn9pX01nHbzaPpjiG9wGacvtDMUwcYRWUkYJbLAYKgNLrGsx32kWieH7uC5n1X5LWWGYEeX/y0mVhnhFyc/wB7aO4oA6KsnUfEei6bqcGnahqtla384VoreaZUdwzbRgE85PFYmqwSeEVj1LS4tY1OFv8AR5bJr15yWdlEbL5znGGwpwejk4OKxbHwh4k1S11Ea5fWti+phVvliBunfgBjE7bREAPkUbWwMscs1AF3xr41s4I201bK8ntLuc6bcagq7be2Zsh9zZ3HaoYllBCkckc47yKNIYkjiRUjQBVRRgKB0AHYVynhvwLp/h65jWxubx9Lgt2gttOuJPOig3kFypbLHOAMMSBzjqa1fDGn3GlW11YyPI9pDcEWbSSb28kqrBSeuFYugBz8qrQBsUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBynxX0uPWfhr4mspI/MZrCV4hjOJUUvG31Dqp/CrHw58Rf8ACW+BdE10qiSX1qkkqx/dWTo4HsGDCujryr9m9DYeBNQ8PF/M/wCEe1m90rzNuN+2Uvu/HzKAIvi7D/YfxA+Hvi20LLO2ppoV0BwJILjdjd7KwJHua9arzH9oASv4b8PR27Rid/EWnrGrnlm83gL6n+gNenUAFeYfs/WtpY+GNcsbWzt4JbDXb+zmkijCtMUmYqXI+8QrBRnsoFen15h8DQiz/EVYdxj/AOEuvjlj/EViLD6ZzQBY/aHke3+Ees3sC5nspbW7jIXJUx3MTZH4A16ODkZHSvNP2jbtbf4Q63bj5rm/8qyt4x1kkkkUAD8Mn8K9LoAKKKKACiiigArn/EniaHRNSsLF4PNmu4ZplZp44lVY2jBBLkcnzVwB6Gugrn9f0G51DW9O1OzurOKS0t7i3Md1aG4VxK0LZGHTBHkj1+8aAKx8YxJqDwS2FwLeO4trWS5V42RZZwhjGA2SMyIuQD1z0ya0fEmuLoo05fsz3Et9cm1jVXVAGEUkhJLEADETfiRVXTvCtnBrl5q17HbXV7PJFJG/kbfIKRLH8mScfdJHcbsc9SXvhLS5m0lLazsrWzsr1r17aO2URzMYJYsEDAB/eA5wfuAe4ALKeI7Fbm0tbxzbXt0QscLKWDMVLBQ4G0nAJ4PY1s1zv9g3Y8Uw6ml5Z/YreEQW9m1o2YF/j2MJAAWwBnacBQB3z0VABXMeLPEH2BoLa3+1HzFleae0iErwpGBvwDxuGc4wTwRtJIBZ4p8Nad4pvo7S/s5kSDbPJdxFoWc4YJGHXBYAksRnHCgg5OLvhnQ59JjLX1+t9cbBEjJbJbxxoCT8qL0LE5Y55IHAAAABW8CajaX1nqEenamup2lvdsIrj7T57FHVZMFsk8FyoB5AAHpTmhFx8Ro5hOmbHSmQw7ju/fzKQ2OmP9GIzTWs4tG8aLe20Kx2+tJ5FzsUAfaIwzRufdk8xST12xiptEsYR4q8QaossrzXIt7Yo2NqpEHxt7/ekkz7igDW1Wxh1TS7zT7rd9nuoXgk2nB2spU4Prg1yug6lqlpYXUfiVrX+3LKNbWHDcXeeFmUYBHmttBUdCuMmu0qKW3hmliklhjeSIlo2ZQShIxkHtxQAWkAtrWKFTkRqFz6471LRRQAVk6MBZXV3pe8skOJrcHqsLk4X6KyuAB0XYK1qz9U0xb2WC4imltr23DCGePBIDY3KVPDKdq5B9ARggEAC64mnnTZpdYhgls4FMziaMOF2g84IPOM/nWLo/hptMaS90w22n312P8ASIvswaLaM+Wm1GXlASNwPzZYkHI23LPSZ72eG88RpbSXkBHkx27uYUwciTa2PmJAPOduAATgsd2gDk9NfW9I8VG01I6fPo+pAvby2sTQvDdAbnjZCzBldVZwwI+ZXyOQa6yuf8faZf6t4VvINFlWHV4tlzZSN0E8bh0B9iV2n2YiqWk3HiTXdFj1BvJ0K/ClP7PcrdxiVWKuJXAUkZUgbGGOpLZ2gA62iuM0jxsJNZuNM1SymiMW7ZqMCM1nNtdUYBjggq7hW4Kj+91A7OgAoorkPiXqFzDo9tpWmBmv9YuY7JSnWKFnUTSn0CoTz/eZfWgCVfEk15qX2XTZtMM0nMNtcOyyFCm4SEqCAT94RkBinzEjkCrqdlr+s6rBpr6tDbWdqsd3PPZWuxzOrhoojvZwUO0swADYCjIDVuw+GtFt9FGk2umWttpylWWC3TygrKQQy7cEMCAQw5BAOataRpsOl2zRQtLK7tvlmmcvJK+ANzN3OAB6AAAYAFAEdjp0kd697fXAubsp5SFYwiRJnJCDJIyQpOSc7R6AVo0UUAFFFFABRRRQBzGt6dcReKrXV9Lx9sktGtGWSRhFMFdZFRgOhx5uH5Kk9CCQXfb9WstW0z+1JbCO11GZ7cW6g74XEbOgD5wxIR88DnAHTJ09fs5ruyRrMgXltKlxAScZZTyuewZdyE9gxrLuLjQvGenGC0urG7uoGFxCpZWktLhD8rlQdyMrYB6HqD1IoA6aoru4jtLSa4mJEUKNI5AyQAMnisyXX7e30Wwv547iT7WECRW0DzOXZc4AUE4AByTgDHOK8+8Y+LLzxfNdeCPCdo1vq0weDUpr/wDd/wBnR4BLGMZModSACDtO9fm5OADrbXxFpWg6baRa1dxWuo3I+0zWyqXkiMhLszooJVFyQXbCgLkkVgaR4k8G23i+e9s11CG41CJAJWsZ/srI8u0TI+3YqyOVywID4Vj611sXhHRFhnSSxSaS5kM1xNJzJO5AUl275AAx0wAAAABSW3g7w/bWU9nDpcC2k1r9ikhOShg/554JxjmgCfVXW61jTdO2ysAxvJSn3QI8bA/pl2BHr5Z7A1sVk+H/AA5o/h2OZNE063sVmIaQQrjeQMDP0Fa1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5z8O5PsvxK+JmkxQiK3S9tNQT/aae2UO34tEfxzXo1ed6a0kPx+1yFVfybnw9aTuf4dyzzKPxwW/I0AU/HkKeJfi74I8ONMPs+lLL4ku4ehJjZYrcg+0juSO4FeoV5jpBib9orxB5u43K+H7VYSw4EfnOXA9t238c16dQAV5n8EIlhPxAjCbX/4S6/ZznO4sI2B/JlH4V6ZXmvwcgjs9W+I1sm9j/wAJPcTlm5B8yKFsA+xJ47cUAVPivcQap8Rfhp4XckvLqj6u+D90WsTsmfqx/wDHa9VrylHST9qWRcfNH4PAGR/0+ZJH5ivVqACiiigAooooAKKKKACiiigAooooAKKKKAMbxhDPNoE5tLuOznheOdbiSIyrEEkVySgIJGAcgEcdxU+h2X2SKYtOLiR3+aQLtywHzZGccvvPHTOO1aEiLIjJIoZGBDKwyCD2NQabZW+m2EFnZoY7eBAkalixAHqSSSfcnNAFmiiigAooooAKKKKACiiigArG1Dw/Defa0N1eQ214QbiCGQKsnQHnG5dygA7SPXgkk7NFAGbqOjW13Z29uirALb/UbEUqg2lSu0jBQqSpXHQ8YIBHP+H4/EOl6TGLq9n126s5Ht7mExRQtKob5Hj5ADbChIdjnnkHr2VZ8EkcOt3NsFCtPGtyDzl2HyMfTgCL86AKK+ITdP8AZtNsnl1KM/6RazSLGbUdvMI3Abv4cZDdQcAsK9rDd3viCC5vLdbaVFMjxqwfYgDLHGxxjJZ5HOOmxR7nW1R55ZYbG0kaGSYM0kygExxjGSueNxJAGRjqecYM2nWFtp1v5NohVCxZizs7Ox6szMSWPuSTQBaooooAKKKKACiiigAooooAKytY0DTtXuLe4vIpVuYMiOe3uJLeVQRyu+NlYqeu0nGQDjIFatFAHI2HhF/D8h/4Ra6MEMoCPFqEs12sIySzQ75MqWJyw6MQp4xz0GjabFpVkLeKSaZixeSadt0krk5LMe5+mAAAAAAAL1FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFQX90ljY3N3KsjxwRtKyxruYhRkgDueOBXype+LE+IkkmveL/iVH4V8JSyOltoem3P8AprRglf3ypkgnbn5g454ABFAHu/jn4jWGiSRaRoXla34svH8i00q3kDMH7vNjPlxrySWxwD6Ehnww8H67oOo6/rXi3WotV1vWWh8z7PGUhgSJWCxoD2G9uwz1PJJrzzwv8SPhr4R09tP+Fvh3VNdudn7waVp0jSNgkgzSSAORknH3sdgBXQ6V8VPGGpBWh+E3iCNM4Pn3CwEfhIq0AaniIf2T8ffCN+kZca3pV5pMjc4TySLhT+OHH516ZXmkcPifxl4o8P3WseG/+Ed0vRbpr7dcXsc1xcuYZI1RVjyFUF8tuPPAArp/HnjHTvBvh3UdVvhJcmyhWd7S2KtMyFwgYKSPl3MMt0ABoA3ry6t7G0mur2eK3tYUMks0rhEjUDJZmPAAHc15v8BUW60bxNr8U3n2uu+IL2+tJSpXdb7/AC4+D7Rk9OhFU/Dmky/Ea6tfEni7U9PutHXZJY+H7G4E9rE5AKvcPwJpeeFI2r2zmuo8cfETQvBtxbWF0Ly/1e4Xdb6VpkBuLqRf7wQYwODySM4OM4NAHM6pf6dD+0toS21/BLqNxodzY3VshBeEK6TR7vTcCxA9BnuK9YrxTwZ4Tm1/4m2/jh/C8/hy0iea6D6jLuv72aWLysOmT5MSruwhOc4wME17XQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVn6tZ3NwscunXENtfRZCSzQmVNpxuVkDKSDgHhhyB7g6FFAFLTLOW3V5byZLi9lwJZUj8tcDOFVckhRknBJ5J55q7RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXOw+BvCcN493D4Y0NLt2LtMthEHJPU7tuea6KigCG1tbezi8q0gigjyTsiQKMnvgVNRRQAVwfxF+Fnh/x5LJcam+o2l9Jaiya6sbpo2eASeYI2U5Rl3c8qe3oMd5RQB8+yfsq+DTtEWseIlXcCwaaE5H/AH6GD155r17wl4I0Hwo0s2kWWL2ZQk17cSNPcSgAABpXJYj5R8ucDAwK6SigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiorq4htLaW5u5o4LeFDJJLKwVUUDJJJ4AA71hf8ACc+E/wDoaNC/8GEP/wAVQB0VFc7/AMJz4T/6GjQv/BhD/wDFUf8ACc+E/wDoaNC/8GEP/wAVQB0VFc7/AMJz4T/6GjQv/BhD/wDFUf8ACc+E/wDoaNC/8GEP/wAVQB0VFc7/AMJz4T/6GjQv/BhD/wDFUq+N/CjMAvifQiTwANQi/wDiqAOhooryzQrl9G8Ez6/qV2LXcGVLkXDSyyMZiFQrL8gJIUA9vUDNAHqdFZHhG4uLrw5ZT3t/a6hcupMlxalTEW3HKqV4O37ueM7c4HStegAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDmPij/AMk48Tf9g6f/ANANYvxF8eaf4NvLWzOlC9upo/NKhhGETJAOcHJyDxjtXivxL8Ya/wCJdU1nSdTnnsNPtruaybT7ZmiBCngyODmQspVuDtww4zk16F4H+FfhbXPBunai1jeadeXQMs7xXcjmVgxXcfNL4yADxjrXNOq5N06fxI9/CZdTw8KWNx6vRndWT1vra+3bozr9L+I/ga8sIZ7nXNC0+d1y9reXcMUsR9GVmB+h7jB71a/4T3wB/wBDX4W/8GNv/wDFVz6/De48IX13rHw61KS0nmCNdaXfsZrW82A4+b78TnJ+ZSR/s4rtvBevweKvCek67ap5cV/bJP5e7d5ZI+ZM8ZKnIz7V0RvZX3PErODqSdL4bu197dDJ/wCE98Af9DX4W/8ABjb/APxVH/Ce+AP+hr8Lf+DG3/8Aiq7CimZnH/8ACe+AP+hr8Lf+DG3/APiqdH468BSSKkfinwu7sQFVdRtyST2A3V11FAFTVtQt9K0u71C9cpbWsTTSMBkhVGTgdzx0rPt9U1WSKRpNAnjYx74lNzESTkDa3PynnPG4YB5JwDe1vTYdY0e9026LiC7haFyhwwDDGQexHUVkXOl+JJ9Mubb/AISG0iuHiEcVxFpxDIcjLkGUgttBAxtAJzg4xQBoeHtXXWLOaXyGt5YJ5LaWNmDbXRsHDDgj3/MA5FalZnhzTZNI0mKyke2cRZCG3haMYPPIZ3JYnJLE5JOTzWnQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVPV9StdI06a+v3ZLeLGSkbSMSSAFVVBZmJIAABJJAFAFyivO7P4q2d8X+weFvGVwqM6F10eRVDKxVlyxAyGBBHYginah8T10+zkurrwZ40W3jG53Gmq20epAfOPwoA9Coqtpt2l/YQXUaSxrKgby5V2uh7qw7MDkEdiDVmgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8x+GV7oXipvFtld2UFzqWn6/di9S4tw6hvNZImUkYP7qNF45+Tp0z6YirGioihVUYAAwAPSuM+F1ssEHiZntIrW9l169e5Eb7t53/ALtyP4SYvKOO+c/xYrtaVupTlJpRb0QV5r+zpazWvwi0ZZgRHI9xNACuD5LzuyHHupDD2IrofipdvZfDbxPNCXE39nTpEUOCHZCqnPbkjmt3RtPh0nR7HTrVQlvZwR28ajoFRQoH5CmSXKKKKACiiigAooooAKKKKACiiigAoorwDxp8WfEekfFXV/Dmmyaa/wBmvdOtbKwms5C139ojVpMzhwsZXJI3DnPQ7TQB7/RXlcvxLfT7/WLRLW71XUP7fXRrG0JjhXeYlf7+OEAyctk9vpkXXxU1vUPEHhZPD+iTTfaptVtbrSzNEGlktRGARK3CgFmPHX0NAHtdFeR+DvitqPizxroVlpuhgaJqWjHUmeSVRNCwn8pmzuwUByMbdxJB6ZFXPGPxCl8JfEDWI9Sd30DT/DSao0EUamRpjdNEMMeeRtGCcd6APUKK8ltfjKs2ny7/AA3erqp1C2061tRKDHcyzhmTExAAAEb7uOMDrmu08BeKh4ssNSmaxksZtP1CfTZoXkEn7yIgMQw4IyaAOmooooAKKKKACiiigAooooAKKKq3+o2enm2F9cw25uZlt4fMYL5kjAkIuepODx7UAWqKqPqdjHa3V1JdwJb2hYTys4CxFfvbj2x3qrJ4h0uO9itPtW+4ljjmVI42f5HJCMSoIAJVsE+hoA1aKKKACiiigAooooAK43xlqcUniHRtDt9QtoNWmElzbwtIvmMwUoGCH7wRWlkxjrCo4zXZVwnhSGHWPiR4s8QMsEpsTFoVpKpyVWNRLN24zJNtPPWLtigDtbK1isrWK3t12xRrtUdT9Se57k96lIDAhgCDwQe9LRQB5l4Ank8KeONZ8D3MV39hnebV9GneMLD5Lsplt0IPOySQkA84bnjbn02uH+LkM9r4ft/Etgge98N3A1QKMBpIFVluIwxHG6FpPxC+1drBLHPDHNC6yRSKHR1OQwPIIPpQA+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiob27t7G0lur2eK2tYVLyTTOERFHUsx4A9zQBwevahr/hLxLrWo2fhu51rQby3ju5Hs7mJZYJ40KPmN2UsDGkWNuTlehzx1Xg7XU8T+F9N1uG1uLSG/hE8cNxt3hG+6TgkcjBHPQiuO8TfEvT7+zn0n4ey2nifxLcoUgtrWQSQRA8GWaQfIqLnoTljhR1yNb4NaXq2i/C/wAOab4hDLqdtaiORGIJjUMdiHHHyptX8KANL4h6Rda94G1zTNOKC9ubV0g8w4UyYyoJ7AkAZrn/AAf8VNF1m9t9F1nzdB8VkKs2lX6NE3mdMRsRtkBIO0g5IwcV6DXPeOfB+k+NdEbTdZifaGWSG5hIWe2kBBDxOQdrcdR2yOlAHQ0V5HrVr4j+GMdprMPibUtf8LQypHqltq+2WeCF2Cm4jlRQx2ZyVII259Mj1sEMAVIIPII70ALRRRQAUUUUAFFFFABRRRQAVyWs/DnwrrU+sT6npKzzavJby3j+fKrO8ClYmUhhsKgkZTGcnOa62igDgPFnwy0zV9IubXSxDY3VzqCalLcziacmdU2BwRMjo2Mcq46d8mpPAnwz0jwtZ6QZWk1DVNNlupor1yyYe4I83CBiMEBR824jHXJNd3RQByWl/DrwvpU+jzadprW8ukRNBZsl1MCkbOXKN8/zruJOH3DNaGqeEtC1XU7vUNR06O5uruw/sydpGYq9vvL7Cudv3iTnGfet2igDzvXPhTo1z4bn0vRh9jeSaCZZryW5vPLMROzZmZXTG5sbHXGfwrY+GfgyLwN4el01LyS9mnupbyed1275JDzgEsQOB1JPqa6yigAooooAKKKKACiiigAooooAK5nxtoT6/LoMBjZ7WK9kkuHVwrRIbS4jDjPOQ8iYxyDz2zXTUUAeXJ4T8Sah4cvYtQltYLo3V1O9s8ImjvHKqIpBtkXaMgsFbOCVJGVFaH9iarAdHe2s7uPWUt7K3uL+G5VLbyo3JeN4jIdxCvKB8rcsMMO1zVPFmordzDSrTTJ7JWZFuHuZnbKMVcskULhFDq6AswyUb0roPDutQa1aPJEYhNE3lzJHKsiq3qrDqp6g4B7EKwKgA1aKKKACiiigAooooAq6rf2+laXeahevstbSF7iZsZ2oilmP5A1ifDfTrjS/BWmRagWOoTq97d7hgied2mlGPZ5GH0FHxBjlvNAXSoYTMNVuIrCZQcHyHYeeR7iISGuloAKKKKAGyIsiMkihkYEMrDIIPY1yXw2R9MsNQ8NzSq50O6Ntb/NlvsjASW+R1+VGEee5iPWuvrhPEME+ifEzQdct5ETT9WjOj6irHALgPJauB67jJHn/AKaqPoAd3RRRQAUUUUAFFFFABRRRQAUUUUAFFed/HXUPGWneBpZvh/bxSX28/aZmZA9vAEYs6ByATkAdyATgdx8/fC7Xn1+2jtNc+Ik019dujvI3ii+06e1VtqlEV4jDKy8kAHk8dKAO81TxF4t+HPx81B9Qstb1nwl4hZfs6WyPceW4QHMaDOGTa4KDBKDdzgV71oOs6d4g0i21TRbyK90+5XdFPEcqwzg/Qgggg8ggg81xtt8KtJS60u4vda8U6lNp06XMJvtZnlHmr0crnGcEjgDgkd6r6v4T8T6BrV7ffDOXRLeDU3M99Y6p5ogFxkZmjEYJy68MMqMqp9QQD0mivLV0H4sanc+df+M9D0JAu37Ppmmfa0Y4GW3TYYHqQOQM4561LN4A8YzSpO/xR1kXC90sLZY/+/YXB/GgD02qup6lY6VaPd6peW1lapy01xKsaL9WYgCvOF8F/EtXOPiwWj6AN4ctiR+Ibr/nFXdP+D3hFNQbU9cs5fEesSf6291mQ3LP7eWf3YA6ABRgcUAWNU+LHg+1khttN1aHXdTuCVt7DRmF3NM3XA2EqvGTliowDzWZofhDU/GUzav8VrC3JSctp/h8TCe1tEAwGlx8s0p+bk5UA8AZIHeaR4f0XRWLaPpGnaexUITa2yREqOg+UDj2qt4w8R23hjSob27XzBLd29mkYcKzNLKsfGeuAxbHopoA1NPsbTTrSO10+1gtbaMYSGCMIij2UcCrFFFABRRXO3Ws31t4/sNIljtv7LvtPmnikG7zRPFJGGU9tpSUEd8q1AGtrOnW+saRfabfJvtbyB7eVfVHUqR+Rrmvg7eTX3ws8LT3RBm/s+KNmDbtxRduc++3P411Gprdtpt2umvEl8YXFu0wJQSYO0tjnGcZ9q4n4GW02mfDmy0S9lhlvtGmn064aHOzfHI2NpIBI2lecCgDv6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5r4ha/N4e8NSzWCpJq13Iljp0T/dkupW2Rg8j5QTubn7qtXS1xMkza58VPsfkxy6doFos7y7wdl5NkKhUjqIvmznjevrQBueEfDlj4X0WPT9OhhQbjJNJHEsZmlONzsB3OAOcnAAzxWP4z0t9LkfxZ4esFfWbXD3kUEf7zUbZRh4iBjfIFG6MnJDKFBCuwPZUUAVdJ1G11fS7TUdOmE9ldwpPDKAQHRgCpweRwRweatVxHg2MeFdeu/CTALYTebqWjngAQs4M0GABjy5JAR/sSIP4DXb0AFFFFABRRRQBmXbLNr1jbkE+RHJdEj+FuI1z9Q8mP92tOsbRZxeavrc6srCGdLNSo7JGGOT3IeVx+FbNABRRRQAVieM9CTxH4cu9PLeXcECW1nDFTBcIQ8UgI5BV1U++McgkVt0UAY/hDXYPE3hjTdZtQFjvIRI0e4MYn6PGSO6sGU+6mtiuE8HRtoHj3xN4fa4LWd5t1ywibJKea7i5UH0EoD47ecK7ugAooooAKKKKACiiigAooooAr6jZW2pWFzY30KT2lzG0M0TjKujDDKfYgmvme++EeveFPi3Yaz4K8Jwp4etN20affxyXEgKnl/tjFVbd/dHC5wc4NfUFFAHm1x428cwmP/i12oMrHDEavaEj6AMf1xWjYeIPHF/fmMeBrbTrRcEy6jrUYZ/UKsKS/qRXcUUActql940i2Np2g6DcKM70k1eVGPoF/0fH51zi+M/iGpcT/AArm4bAMOvWrhh687T+lemUUAeejxf43K5/4VnfBvQ6xZ9P++6bb+K/iBc3nkr8NVtoT0nu9egVR9RGrn8ga9EooA81n8I+M/E53eK/Fz6PaE5/s7wyDCRhjt3XTjzGyMZAVBXNeMvhB4M8MaXF4j0XSpYtZsNQs7tbqS7mmZiLmMvkO5Ukjd26mvb6434wLK/w61ZYCglPk7S44/wBcnXkUAdlRRRQAVw3xIEVjrPgvXpcKlhq4t5GLYCx3MTwc/wDbR4jz6V3Ncz8TNFTxD4B17TGbY8tq7RPnGyVPnjf8HVT+FAHTVxnw6NudR8bG0Mvlf2/JnzP7/wBnt9+Pbfuq/wDDbXpfFHgHQNauF23F5ZxyTDZtHmYw5A9NwOPbFcV+zjr8fiLw74nvFREkbxDeyMASSQ5V1Jz6Bgo9loA9ZooooAKKK5jWZZ7zxdZaO15PZ2j2ct1+4fY87q6Lt3dQFDZIGCdw7DBAOnorlP7R1K213TdI0+4t9SiK77mWYEyxQgkF3ZcLkkbVG3JIY/wsRT8Uapqs0+gw2tpqdg1zeSRSQCWBZZFWB3BDBnUDIHcHj8wDt6K42+a7XXdHtNO1C/fUQYpbuCSRWjhtgDvMmFxuYghe5bkfKrY7KgAoqhrmrWmiaa9/qMjR2qPHGzKjOQXdUXhQT95hXLW/xY8DTOyHxFaQMvmZF0rwEbMbv9Yo9Rj17ZoA7iivPbv4qad9jtrvSNC8Sa1a3W37PLp9gW8zPIO1irhcc7ioGOcnIzdutR1/UMjSoL7eyYVhEtnDExPO9p0aRiAOCkWPUcjAB2tFefNpOvvd2dwujK2pQK7S3cviGWFJW6BSI4cSIeuGjUKei81Hc+EfEjRGXR9X/sXUXQKZpdQvNUWIn7zLHM6xMewynfPGKAPRaK8/g8GeLJLJYNT+JWsys6lJntdPs7csDwdh8pmQ++SRWro3gw6TZG0g8S+JJoDIZD9qvFmfkAbQ7IWCjGQARzmgDqJ5Y4IZJp5EjijUu7uwCqoGSST0Arno/HHhu4Rm03VYtW2Y3rpKtftHnOCywByoODgkAHBqk3w50G4hmh1ZtW1eCY5eDU9UuLmEnOR+6ZynBAx8vHapovhz4Mhj2QeFtFhXG0+VZohYejEAFvxzQBoReKNOeREdNSgDDd5lxptzDGoxnLO8YVf+BEUuieLPDmvXb2uh6/pGpXKIZGis72OZwgIBYqrE4yQM+4qK18H6HZtusbNrR8Bd1rPJCdoOQuUYHHt0rMuvhj4MlWI23h3TtOuYXEsN1psC2k8TjoyyRgNx6EkHuDQB2VFchHZ+K9D+23K6n/wk8BKeTYzwRWtwqjhtsq7UZjycMqgnAyo5rodI1OHU4XaNXhnibZPbS482B8A7XAJAOCCCCQQQQSCDQBeooooAR2VEZ3YKijJJOABXK/DUi88PSa4QwfXbl9Tyx5aJ8LBkdj5CQgj1Bp3xMLzeDrvToc+bqzx6WCv3lW4cRO491Rnf/gNdHZWsNlZwWtpEsVtBGsUUajARVGAB7ACgCaiiigDk/H+lxSJpuvRqF1HRJjPDOIfMZI3XZKuOuwqctjnC8c101lcJd2sc8eQrjO1sZU91OOhByCOxFSSRpLG8cqK8bgqysMhgeoIrl/DCy6JqFzo1z5ZgMu60dXJYqVyu8En5iEk5/iMbscFhkA6qiiigApssiRRPJIwWNAWZj0AHU06uS+K3nzeA9U0+ynEF5qaDToX8suczHYcAEc7SxznjGe1AF3wFHOnhLT5rzIurxWvplP8AA87mVk/4CX2/hXQUiKqIqIoVFGAAMACloAKKKKACiiigDhvihLNo58P+J7WHzW0u/SK6CruY2lxiKUDvwxif/tnzxXcKwZQykFSMgjkEVX1Kyh1HT7myuQTBcRtE+Dg4IxwexrmfhtqF3Ppd7puqQCC/0q7ktWXzN4eMMTHIM9FZeQOwGO1AHX0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXH/ABhtIr34WeKoppPKA06aVXzja6KXQ5/3lFdhXFfEUNqN94Y8PbkW21PUQ92GGd8ECNOUA/2nSNT/ALJb1oA63TWuH061a9VVumiQzKvQPgbgPxzViiigArgPjFqF0+jWfhbR5vJ1nxPMdPhl258iHaWuJsf7MYbHIOWWu+ZgqlmICgZJPAArzvTdS07xV8YfP0y8tNQtfD2ksjSQSLIsdxdSjgEfxBLcg/7/ANaAO60fTrbSNJstNsUMdpZwJbwoTnaiKFUZ+gFeX/s9eFoPDMXjVLKQvZPr9xDbgg5CRYXBPchty/8AAc967zx7r6+F/BmsayQrSWluzQocnzJj8sacd2cqv41F8N9Bbwz4H0fS5sm7igD3TFtxe4f55Wz3y7MaAOkooooAKqalplhqkSxanZWt5ErblS4iWQA+oBB5q3RQBlR+HNEjuormPRtNW5hCrHKtqgdAv3QDjIx2x0rQlt4ZZYZZYo3khJaN2UEoSCCVPY4JHHY1LRQBmzaDpE+pDUJtKsJL/crfaXt0MuV+6d2M5GBjnjFaVFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWTqvh3StTulvLmyt/7RRQsV8sS/aIcEkbJCMjBJOOnJyCCRWtRQBy2keI72PXZdF8S2Asbkvtsb2N91tqI2ljs7xyABiYmycKSpcAkdTWV4m8PaX4m0v+z9btvtFr5iTKBI0bo6MGVldCGVgR1BB6joTWO6+LtKsxYadFY60yxlYdQ1C7MDggfL5ypGdx6ZZMZ9F6kA1JXW/wDEsVuFfZpii5ZyMAyyK6KoPfCeYWHGN8fXJrZrD8IaE2g6W0d1eTX+pXUn2m+vJWP7+cqqsyqThFwqhUXAUAD1J3KACiiigArnvGFmzW8OoQ7w9ocymPBbySQWIB4JRlSQDBJ8vb/EQehooAoaJfNqFgkssfk3CnZNFkHa49ME8EYYHurA96v159DYan4c1+5e1mims4YBJBaR27GWe1V2LQj5zl4d2UIAyJNmOjDu7O6gvbdZ7WVZYm6Mp/MH0Pt2oAmrmddhTUvFWjWroHism+2P+8KlZCGERAAw33JQc9Mj1FdDdXEVpbS3Fw4SGJC7seygZJrG0OK8l1Ka8vhLGzKzrEdu2NXKhYzjneqxKTyRmVsZAFAG9RRRQAUUUUAFFFFABXAeKZ38KeOtM1+WSQaHqQ/s6/4Gy3mYp5M7scbVO0xnJwCy4GW57+sjxb4d07xX4fvNG1qAT2N0m11yRg9QwI7ggEe4oA16K43wD4gmupb/AEHWXK63pcgidXzmaPaCsik/fU569emec12VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxl9cWmrfFPTLGK5Q3Gh2ct7NGCM7p/3cY65+6spPHGU/vVv+KNXXQtAvdRMZmkhT9zADgzyk7Y4l/wBp3KqPdhXmepfDHSV+GGuzeLbCz1TxNd2s99faiYQ0ouShYCJ+qonCqBgYXpyRQB63dXMFpbvPdzRQQIMvJKwVVHqSeBXDXHxO0y/v20zwRA3ivVFAZxYSqLaAHo0twfkUHB4Xc3HC0yT4W/DzRdPmu28JaS0VpE0rGWASkqoyc785PHepvgfYw2nwu0KaC0tbRtQh/tGWO1iEab5iZOAOgAYKPQKB0AoAs2vhK61WZ7rxxfJqhYgx6ZCpSxgwcj5CczN6tJkeir0rD+FNnYQePPiVLpFpb21n/aNtbKLdFRN0dsm8ADgEMzZ46k9813fiTW7Pw7o1zqepM4ghAASNd0kjk4VEX+J2YhQO5Irlvgpo1/pPgZZtesRZa7qt5c6nqEWQT5s0rMCcdDs8sY7Yx1oAZ4vtJPFXjvQNGhkxpuizJrOpbTgtICRaxcHnLB5CD2jX+8K7+uE+DzjU/Dt74lkikjudfv571hKBuWNXMUK/QRRR/iT613dABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRVXVr+30rS7zUb1ylraQvcTMFJKoilmOByeAaoReI9PnSM2rTXDSWovEjihYu0Zbb0xwc8EHkd8YoA2aK5//hLLA26usN49w1w1r9kWEmYSKu9hjpwvOc45HOSBWxp15BqNhbXtnIJLa5iWaJ8EblYAg4PsaAMP4hXtzYeGvOspZ4pmvbKHdAFMhWS6iRwu7jJVmA+tYOpjX4/B2o3k11fwXdoZ5rVXnijlEIAKvNtG1ipDELkAggNzkjvri3huYxHcwxyoHWQLIoYBlYMrYPcMAQexANVdR0fTNTeJ9S06zvHiz5bXECyFM4zjIOOg6elAHNazNc3WraFDpWqXy3F+yXLqu0Rx20e1pHKlSRuyqAZ6yZ7GuzqIW0AujciGP7SUEZl2jeUBJC564ySce9S0AFFFFABRRRQBT1ax+32nlrK8E6MJIZ0+9E46Eeo6gjoQSDwTWfDHLcy3EsK/YdWiIEqtlophjAYqD8ykDhuGG3HYqdyquoWUV5CQ7yQyhSEnibbJHnHKn8Bwcg45BHFAGf8AZr+aNH1y4sFtoWWZ0hjZRlMMpLs3ADDPTsOcZFW9FjcWrzzDEtzI05ypUhSfkDA9GCBFPuDVSLRZ3eA6hq99eRwyCRYyI4g5HTfsUbueccLwOOK2qACiiigAooooAKKKKACiiigDlvGfhx9VkttQsCo1G0BAXd5fnJ12hxyjA8q3ODkEEMRXSWjSNawtOrJKUUurYyGxyDjjP04rmNelm1W7lji1qXRtI05h9ruoSitNIR/qxI4IRVypYgZJIGRhgeh0qTzdOt3+2RXuUH+kxABZP9oYJH5UAW6KKKACiiigAooooAKKKKACiiigAooooAKKKjup4rW2luLmRYoIkMkjscBVAySfYCgDzvUUPi/4uW9ixf8AsjwiiXk8f8M1/MuYQRjny48vx/E613ms6dBq+kX2m3e/7NeQSW8uxtrbHUqcHscE81yfwdiebwgdcuI3juvEN1LrEiOclFlP7pc+0SxD8K7igDyHxr4zPhPwfrGi+Pre8CNYyWttrMMDS2+oFoyqhioPlTNzlWwuQSGx09E8EWa6d4L0CyjUqltp9vCFJyQFjUYz+Fc18XbibU9Ji8F6VJENW8SB7Xc6bxbWuP387L3wp2qMjLuuO9W/hDqU174Jt7K+cPqWiyyaPeMMkNLbt5e/J67lCv8A8CoAwPjFcX8+v+GbCyuILeCxMmvTmWAy+d9mkhRIgNw6tPnPUFVIrvdd1+y0jQtQ1R5opY7SGeUokgy5iDF0H+0CpBHY15H+0xoU0UeheNob2Zk0K5gWTSo8qb5XuIjsVxyDlV4IPQHqOeC+FHw88S+IfiRaal8Sbe+ttNQ3Gu2Gm3MwZRNJMrMDGTlBuYMVIBJxkdRQB9FfDPT7jS/h54csr6MxXcVhCJ4yu0pIUBZSPYkiuloooAKKKKACiisfVdZe11KDTbG0a91CaJp9gcRpHGpALMx6ZLAAAEnnsCQAbFFc3q/iS60uyhurnRLrY5SMoJ4t3mO+xUA3fMSSMY9frTtK8SNqmp3EFlYNJaQXMlrLMJ496OjFWLR53BdwIB6ng4wc0AdFRWN4i11dGl0+IWz3Et7K0UarIiAFUZySWIHRTSxeIrD7ba2N1Ibe/uMBIGUkFtm/aHA2sdoJ4PY0AbFFI7KiM7sFRRkknAArEXxNZXLTRaWk+oXkQDPaQqI5QhOA+JSg2nnDZw2Dtzg0AblFZM2vWdtNZQXq3Ntc3jFIYXgdizgFioKgqSArHgngE9Bmor3UdTt7ee+Fggs4F3mAszXEig/MQqggEKCVQbi2QCUNAG3RXM2vjXTLq409YodQS1vpmt4ru4tHt4vOC7hGfMCtlhnawXaSCu7dxU2peM/Dml3M8OpazZ2ht5Fhmknk8uKORl3CNpD8gcr820nOOcYoA6Ciq2m6hZarYxXumXdve2coJjnt5FkjcA4OGUkHkEfhUF7q9nZ3a2sryPclPN8qCF5nVOfmIQEgEggE4yQQMmgDQorGk8TaTDEkt1cSWkTZw93BJAvHUEuoAPsarXniUyWTTeHtPn1hsNh43WGAEAkFpXIG3IwSgcj0oAt+MNMm1rwjrel2rRpcX1jPbRtISFDPGygsQCcZPYGsW28O6npfizU9U01rOWzmt8W9tNI0ZSVpN8oJCthScsDydztxjFX1m1H+yV1efVbOBTAJpIki+0WyJjcdrAq7nsHyAR/ACeOamuviLplneavqDeH7hBMscWnLvt0hti4zcSyneRIoJ3qu5AqEqSeoBcsPC+rac9ve2kenC4hvZp47A3EggiikiCFFl2Fs718z7mPnYccGun8L6Y2i+HNM015BLJa26RO6jAZgBkgdhnNWrK9S6Z4yjw3Maq0kEuN6BgcZwSCOCMgkZBGcg1aoAKKKwfFviW38OwWyeRNfapfSGGw0+3GZbmQAkgZ4VQBlnYhVHU8gEAl1/wAS6boSyG9ed5I0Erx20DzMiHIDOEB2KSrAM2ASp54NYOn/ABJ0u5vZrK70rxJp98nmMlvc6ROWnjRlVpI/LVg6guvQ5+YcVf0DwrDDf3Wta5BaXWv3rxyyyBTIltsXCRQluQq5PzAKWZmYgbsDf1Cxt9QgEV1HuCtuRlYq8bYI3KwwVOCeQQeTQA+0uYbyBZraQSRkkZHYg4II7EEEEHkEYNTV55qeg6p4RuTr/h251fWA9yJNW06ecSNdQ7dm6FSMCSNQpAXBkVNrFm2mpH+K/hW6uzY6Pq+n3N6Iw7+fcrbxQAjjzGfBzwQUUM6nhgvWgDv6K8y034hXRN/YKkOu3umuzz3mkwtJDcRbQwWOONpWSXLBNrnHyls4IB2G8VvrumsmhQanBPJwSkMf2mEjllMb5WN+CoE20ZBODjBAN/VPEuh6TO0Oq6zptlKq72S5ukjIXrk7iMCuct9a0rx9BdDR5otZ0q3uTbssXNtI6qCfOY/fTLDCrnOAfmVhia28Lz6totrZ6zNdxacPLaaxmMU0t5tIJ+1yYZX3bRuVML1XLLgDrbO1t7K1itrKCK3tohtSKJAiIPQAcAUAcg3h3XNK0+ODwzc2EEsMamPz5LgwZDZ8oQl2CRlflBU5XjAIAFV7vxtq2l3Ym1bwxfDQULJcahbq7yW7qMkm3VSzxZz+9Qkd8Ac13tFAFfTr621PT7a+sJkntLmNZoZUOVdGGQR9QasV57L4VuvA1kJ/hzAv2Y3CSXmkXM0kkUkZY+Y8JJJjlwc4GVO37pPXq/DfiCx8Q6fBd2JmTzYllMNxE0UsYORhlPcEMpxkZUjNAGvRRRQAUUUUAFcn4/8AGEPhiCxtIFjuNd1WQ2+m2jyBBI+OWdv4Y1BBY/gMkgVa8ZeIZNFhtLXTrdbzXNSkMFhas21WYDLO56rGg+ZiPYDJIBg8I+FH0pjqGvXqa34jkDJJqclusRWMsWEUSgny4xxwDyRk9sADNA8NSi00s65JbzGyQPHbQbmh8853TMzcyMSSQSAAWJxnBHVRRpFGscSKkajCqowAPpTqKACiiigAooooAKKKKACiiigAooooAKKKKACuD+NN7Ongz+xrHd9v8RXMeiwELnYJsiRz6BYhIc+oFd5Xn9+8OofHHTLK9m2/2To76hZQ5I82WaRoZH9DsRQMf9NjQB3Njaw2Nlb2lqgjt7eNYo0HRVUYA/IVPRXn/wASLm812/s/A+iSNFJqSGTVruJhusrEHDY9HlOY16/xnHy5ABD8MwviLxN4l8cedHcWd9IumaUwUHbaW7MGZW7rJKZG+iqfYS/DG4ji8U/EPSW2rc2+ti7ZAMfu57eJkY/Uq/5V2+ladaaRplrp+mwJb2VrGsUMSdEUDAFcmyDS/jCkuVWLXtI8vAU5M1rJkZPulw3X+5QB2NxBDcqqXEUcqq6yKJFDAMpBVhnuCAQexFcZbXU1x8bL+3GfstnoEBP/AF0luJP6Riu4rzvwZK83xk+I/mFT5MWlwoN2WC+VI/TsMu36+lAHolFFFABRRRQAViato9zNq9vqml3sdpexwtbOJoDNHJGzBuVDKcgrwQ3c5B7bdFAGJJos93f6Rc6lercDT/Ml8tIdiyTsNqyfeOAqlwF55YHORVCbwrLdeJLbVLy4sC1tcNPFJBYeVclcMBG0285XDYICjIA989VRQBzt14R0qSfS/s9nZW9pZ3D3DWsdqgSVmiaPJAwARkHOD90Clj0K8TxYdV+22jWaQi3t7U2jbrePA3BHEmAWYAk7OiqO2T0NFAGT4r0d9f8AD15pSX1xYC6URvcW6qXCbgWUBgR8ygryDw1NjjOizgBry4sZ35Lu87QOSTkk5bYenXCYHGCduxRQBki61K+kH2G2S0teD592p3v0PyxDBAwSMsVII+6RVV/Dc6gmz8Ra5ayvkyuJYpvMb+9tljdUxz8sYVeenTHQUUAcje+CmvLS5sJfE3iA6Tco8U1k8kEivG4IdDK8TTYOW58zIzhSAABLpnw78G6ZbJBZeFtFRFiEO5rKN3dcAYd2BZyccliSepzXU0UAcRd/C3wlJLJLp+mvosssYhlbRbiSwEiBs7XWFlVs5I+YE4PXpi3Y/Dzwxp8EiWOnyW00mA95DdzJdsAAApuA/mlcAfLuxx0rrKz9Y1rTdGRH1W8htUfO1pWwDjGf5j86AKEnh2S5njuLzWdTe6gG23khl8lY+25o1HlyOR1Lqw67VUEinyeHbe/Zm8QMurAn5YLiMfZ48EEERcgtxnc2WHOCAcVdh1jTpxZ+VewMbxmS3G8AylQxYKOpwFY/gabFrenS6odOju4jejd+66E7fvAHoSMjIHTvQBGvh7TEvftUVu0TmTzmjildInkyTvaIEIzZOdxBOQD1AxqOqujI6hkYYIIyCKWigDjdT8G3R1WHWdL1u/8A7Tshss4bp1NssJx5kDBVDMrhV+Zy7KyowzgqzdS8Tapoaz3XiSGwsraPcYkhLzC5AUEKsx2hJCeAjJ8xwFY5O3tKKAPPLj4hjUGli0vSNet9OOI/7auLEwRhmU4EUcoDu5YBF+TaXYA54B0fCPhrU4tYfxB4p1GS+1bypLS0iG1Y7S2Zw2CFAVpm2IZHAAyoVQFGT2VFABRRRQAUUUUAAGBgdKKKKACiiigAooooAK4nxtoWsQQXus+C7iKDWI4HZLWWMtFPJkMeARhmA2nruwvQqGHbUUAYWi+JINQFulxBPZzzorxCWNhHKGXcNrkbScdV4YYOR3O7XOSaU2nvfKtpFf6NeSmeWzZctC55copyHVmAYrwQdxG4kAZVtr1tpWoi00W0ur60mQFLCBPLmgkBO4hZmQbCCMgHKkE4O4kAHcVyOteMfsnmC0sJGtd5i/tW4nghso37lmaQOQp4O1TkggdDit4mTxVq1ulha3GnaGbqXYpCteSPEDl93CKnyAjA3csMMuMnWsfDMRuYrjWhZX8lqdtjGloIorNMYGxCzYfHBbPTgBRkEAyPhzorpcX3iO71LUNRl1NI1tXvnVjHbqOGRVVRH5h/eFQB/BnkV3FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5j4/wDD9rcfF34fazPd3lpIjXNrG9u6qJJAnmpG+QfkZEnBHfIwR39Orz/443H9leB18QpC00+g31rqSIvVgsoSQe2Y5JB+NAHoFeX/AARaa6vvHd/rEbR+IZddlhuo5OHihRFFunugQ5VhwdxOTXp6sGUMpBUjII5BFeelRofxzRlZUt/E2kNvQLy9zaOuGz/1ymI/4AKAPQ64T4uQXlno9n4q0iNJtQ8NSvqH2dzgXEHlsk8eexMbMQcH5lXg13dZ3iS3F34d1S3OAJrWWM56coRQBB4Q8R6d4t8N2GuaNK0ljeJvQsuGUgkMrDsQQQfcd6x2WKy+LSMUjjfVdHYBw2DI1vMMgjuQLgYPpn0ql8CtJ0zSPhR4cXRYpI4Lqzju5PMcszSyKGck/XjjA4qP4gwCL4ifDbUzn93f3VkSGxxNaSHHvzEp/CgD0GiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKw/Gtjc6l4ZvLSyj824k2bU3Bc4dSeTx0BrcpssiQxPJK6pGgLM7HAUDqSewoA5fxZa3UviLwvd2ekTXn2K9eae4jaFTHG1vPHj53Vj80iHAzwD3GKZEmp6h41WfUtJuodPsTIljIskJjYsuGmfEm/JGVVdvAYk9flZfv4q1eCHUdBubXTIIXaWKxu7fe1+m35RI+cwBieMKzLhS38UY6TS9Qh1G3aSEMkkbeXNA+PMgkwCUcAkAgEHgkEEEEggkAuUUUUAFFNkdY0Z5GCooJZmOAAO5rnvEfiyDRLZJhpesaiZJfJSKwtDJIzdyFJBKDqX+7yOeaAOjorjp9b8VXlu0uleG2syqF1i1KWPfN8uVX93IQhJyCTnHXB6F0fijXbXRPtus+DNSS5DHda6bcwXjKuM5yWQnnIwAT0oA6+iuH1H4jWtndw26eHfFV40kEUzNaaU8oi3kDY+PuuvVlPIwa0rfxJqsscrSeDNeiKLlQZrE+Z7L/pHX/exQB01FcUPGeqyXQWHwR4hW2Ubpp5zAmz5c4VRIzOc4XgYzznHNPt/FevX1olxYeB9XjUyqpTULm3t5NmcMwUO3I9DjPrQB2VFcbY+IPF1zcXJl8Ei2tI5tkbS6rEZpU/56BApUD2Lg+1S3HirUY7idD4Z1GCKJgge4BfzSe6C3WX5fdtuOcgUAdbRXM6Z4rmuRN/aHhrxBphjiEoE8EcvmDnIXyXk5GOhweRgGpNH8ZaTrBYafHqzhWKs0mk3UQBHUZeMDI9OtAHRUVzE3jjSYJ7KG4j1O3kuwWjNzp80CKACSXkkVUTp0ZgeRxyKitPiH4XurzU7SLVYRdaaQLuOT935eQSMM2FYYB5UkUAdZRXFaj8SdFtMfZ7XW9SBiSYnT9KnnCo2dpYhcLnB4OD3pbT4laBPbGeSPWreLaH3TaPdBSMA8MIypPOMZznjFAHaVS1jSrPWLI2uoRGSLcHUq7RujA5DK6kMrD1BBrj5/ibYmfybDw/4svWZgiSJodykZz3LOgwoPUkfgatS6n4gunlVVls4mwyvDprSNGO4LO43fhGKANvSdCj0+7+1S3t9fXKxGCOS7m3eXHuztAAAzwuWILNtGScVsV55/xUaIn/E916YAHLro0C7ue4IB3DscAeoNWJNR8XWyjyrO4vI4tpG6yiWSYBTkOftAUEnHKrwe2KAO7oJ/WuIn8TeLxYLLbeAbh7kqD5Euq26YPoWBb+VRWer/ABFkiMtz4T0KMysfLg/tlt0AA/5aMISGyem3p3oA7yiuGi1j4gfZpp5vCWjB02lLZNZJeUE/NhjCFBA9etdpaPLLawyXEPkTsitJFu3bGI5XI64PGaAJaKKKACiiigAooooAKKKKACiiigAooooAKwPiDpx1fwJ4j05SA11p1xCpIzgtGwBx9TW/SEBgQwBB4IPegDn/AIdXsmpfD7wxfTHMtzpdtM5zn5miUn9TXN+NBK3xl+Gwij3IsWqNI/8AcXyYh+rFa0vg2WHw00SFkKG1SS02Fi23ypHjxk+mzFV9Fjk1n4ta7qrPmz0S0j0e3AbKmaTbPOfYhfs6/gaAO7pGUMpU9CMGlqpq8jxaVeyR8SJA7L9QpxQBx3wIkaT4P+Ey/UWKIDgjIXIB59gKh+KKC58T/DmzQ5nbXvtAAbB2RW07Mfp0zWv8JYkg+FvhBI23L/ZFoQfXMSn+tZc8EWtfG22d9si+G9JMq4PKT3blfzEcDdez0Ad/RRRQAUUUUAFQS3ltE5SW4hRx1VnAIqeuT8Q6JbXnjDQLmTTIZ0/0j7RK1uGH+rAXece2BmgDq9wyRkZAyRnoKjtrmC6jMlrNFNGCV3RuGGR1GRXG6Wba18aeLHaw1A289tCzlrKdkmZPN8wKSuG4ZcKp5zxmmeDo7m8GralYQHR728aIi1u9NlVIYkUhQQfLDyEZLFSQPlXkAEgHdUU2MMEUSEM+BuKjAJ9hk4p1ABRTJ9/kyeTjzNp25GRnHHGRn8x9RWUurTwWN1cX1jMWgRnEdrHJK8gUEkBdg+Y44ALZ7E0AbFFcbb/EGxm0o3h0PxXFKDj7JJoN0JiecD7m3t13YHcitO612Jv3AuDaTk8oIXknAz0Ee3rjPPI/3hQBuySJGu6RlRRgZY4HPFYdx4v0OG9ms0vvtV3CCZILKGS6dMdQyxKxB9jzT49Ke5vBdT5iG3HJ3TNkYOW6IOTwmP8AexxWlptha6bZx2ljCsNumdqL6k5J9ySSST1JoA5H/hN9Tvre5k0DwT4huzEXVGvVi09ZGA+XAmcSBW9dnH6VsR6XfarbxHxFNGkZ2u+n2hPlZ6lJJD80qg47IrY5UgkVv0UAFYuq2U9rdTavpEImvzCI5bbcFF2qklRuP3XGW2knHzEN2K7VFAHJN8Q/DFuluupapFpt9Ngf2fe/urpW/umL7x+oyD2JHNSza3rlxqDxab4cuf7PETH7ZcTxws75wFSI5YDGTucDHHynnHUUUAc5pdhd3Ee+90uy02SVS8rxyrPP5m7PJMYX3zz6ADFb1vbQ2+7yYlQt95gOW9yepPualooAKKKKACiiigAooooAKKKKACiiigAqO4t4bhQtxFHKoOQHUMAfXn61JRQBFb28Nsmy3ijiTOdqKFGfoKloooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBHLBGKAMwHAJxk/WuN8Ha1qN1qEVrrtxNb6jJbNJJYT2BhAcFdxhlBKui7sEAseVOR0PZOodGRhlWGCPUVlaZ4e07TboXNulw86oYke4upZzGhIJVfMZtoOFyBjOB6CgCC78YeGrO5ltrvxFo0FxExSSKW+iVkYdQQWyDUX/Cc+E/8AoaNC/wDBhD/8VV258OaHczvNc6Nps00h3PJJaozMfUkjmo/+EV8Pf9AHSf8AwDj/AMKAKc/j7whBDJLL4p0MIilmxfRMcD0AbJ+gql4X8R+Jtd0y3vn8LW+nw3EayxC51QFmVhlThI2xxjg8jNN8beE9EbwhrCWumeHrKeS1kjjubu3jjihZhgOzbeME5rko/F/irxVfXOi/DubQJrO3tRHPrypK1tbTdPLiPKzOFIbjKjI3Z6EA5/SfGnj7RNN0ODTvCVtf2974i1G3u3t2ll8pftj7hkKAg3NIA5yMR5IFei/BvyZNA1q6idnkute1KWUt1yLl1Uf98KlcbqFr8RfAGk+BdI0JrfWtNW9ig1Se3sna4w0m5yxLMNjBnzJgEEA5Ga7L4ZL9h1fxxo7bd9rrkl0CueUuY0nHXvukcfhQB3lUPEHm/wBg6l9nYLP9mk8tj0DbTg/nV+ub+JeotpPw88S38UiRzQadcNEXOB5nlkIPxbA/GgCL4UgL8LvB4DK2NHsxlTkHECVhfCS3S41nx7rsjGS9vddmtGkwQPKtgIo1A6cfNyOufaut8FaXJofg3QdJnIMthYW9q5HdkjVT+orlvg9ZzacfG9pPGYyvie8lVSc/JKscqn8VkBoA9CooooAKKKKACuag1bWH8WzaS9tp4gigS5MomfcY2d1Axtxu+T1xzXS1RTTIU1uXVA0n2iW3S2K5G3arMwIGM5y57+lAHPnxXc/2Tqtw+nrDdWupRaZFC824M8rQojMQOBmYEgZ4FUr3xnd2kQiuYrO2livJbS5vJd5toiiK6k4GQXV1wCQBhuTgA6sXhCEW2qQT6nqNwL+4S7ZpPJDQzIUKum2MYIMaHnI+Xp1zND4ba3g22ms6pbzvNJPNcJ5Jednx98NGU4AUDCjAGPWgDU0e6a+0u2une1kMqB99rL5sTg9GRsDII5/GrlUtF0y30fTYbGz3eTFuOXOWZmYszH3JJPpzV2gAooooA4uXxlLF4qudLMFo0cWoxaeEW4P2lt8EcvmCPHKr5nPPAVj2xVr4f+Jp/FOlW9/ILFFmtopzFbys7xF13bWyoHHI49KtXz6L4Qi1nX9UultYLqdJ7iebGEby4oVVcDOD5acc8k/QaHh7T7fSdA03TrGR5bSztoreGR2DF0RAqkkAAkgDkCgDQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArhvjJ4rv/B/gmXUNKgV7uaeO0S5m/1FkZDgTzEA4RTjseSB3ruaKAPlq2ufhNBfrdfEP4gXvjLVUcSOJVuJbNXByNkcalMckYJKnJ47V6HN8XIrGG1tfB3w78W6lpq4WKW20p7e28vHBjyvT2IUV7FRQB5rpfxK1i5H+mfDbxdAxPyiOOBh+JaRMVteCdMv/wC3fEPiLVbNtNm1ZoEjsXkSR4o4UKhnZCV3sWbIBIAC85zXYUUAcz4s8YWmgahp+lRW1zqOu6kJDZafbgBpQgyzM7YRFHGST9AelZ1j4QutbSC7+Ic1vqd3FOLiCwtty2VqR93CnBmYdd0gP+yq854Lx7+z+3iS6sH03xlqen21lNPcW8E8K3H2eSaTzHMbhkYfNz8xY8DmtDwn8JPFeh6lFPc/FbxFd26xmF4PLBBXH8IleRVPA52k+hFAHdeN/F+g6DYXlrqPifTtG1F7dzCZZEeaMlSFkWHO58HkDHOMVy/wB0CXRdF1u5WfV5rDUtQNzavq6lbqYCNEeZweRvdWKhgDt2k9a6/wr4J8P+FkJ0jTolunLPLey/vbmZ2OWZ5Wy7Eknqe/GBXR0AFFFFABRRRQAUUVynjLxTJoGoWdtGunhZrO5u2kvbkwr+5MI2A7Ty3m/ht70AdXRXF6L4yk1TXLm0MdnZRQPGGjuZWWfa1tFOSVxtGPMIOT/Ca6vT7+01G3Fxp91BdQEkCSCQOuR1GRxQBZooooAKKKKAKN5Gk+p2CSLkw+ZcIQ2PmC7OncYkb8cUyRodJ+ZYWSyclnMakrE3UnaOgPJJHAPJ6k1bDK14Vw26OMHPYhif8A4n9amoAwo/F/h5jEsmsWVvLKu5IrmUQSMvqEfDEe+MVr2t3b3drHc2lxFPbyDcksbhkYeoI4NTVl3Xh3RLvUxqV1o+mz6iF2i6ktUaUD03kZx+NAFldSsW3bb22O0sGxKvBX7wPPbvWVL428Kw2y3E3ibQ47dhlZWv4gpGccHdjrxV/U9C0jVbT7Lqml2F7bbt/k3FukibvXawIzV+ONIo1SJFRFAVVUYAA6Ae1AGPZ+LPDt622z1/SbhuOIryNzz06HvVyLVrCZiLa5juSGCsLf97tP+1tzj8avUUAUTq1msbySSmKJCQ0kqMiqQcYLEAA5IHvUlnfR3ke+CK5Cbtp86B4SPwcA49wKtUUAZn9t2v2xbXytQ81t2G/s+fZ8vXL7No9uee2amh1KCW4EKx3YfOMtaSqv/fRXH61dooAy59ctYLyK1kh1HzZELgpp88iAD1dUKg+xOTST69ZwTmJ4dTLjGSmm3Drz/tCMj9a1aKAMxdZgebyYrfUHl2FwDZSoCPTeyhQfYkGmHWJHhMtppGp3Cg4xsSFifpK6H8enpWtRQBmxajdPGGbR7+M4ztZ4Mj24kIqEalqc0kkcGhXETKhZZLy4iSNj2XMbSMPrt/PpWxRQBlXFxrYlZbXTdPeMMAGlvnQsMDJwIm6HIx3xUU2qapBdwwN4fuZ0kAzcWtzC0cZzg7t7I2O+VU8ds8VtUUAY9/ceII7UNYaZpc9x3jm1GSJfwYQMf0qpHf8Aik2YWXQtNW/Mu07dTZrcR4zu3+SHLZ42+Xj/AGq6OigDm9TvfFipAul6Jo8spQmZrnVJI0Rs8BdsDFvqQtR3cnjSeyxa23h6xuxtOXuZrpG5+Zf9XGV46N83+7XUUUAc9a2XicabDHda3pbXoA3zR6Y4Vj/umbp/nimT2/i9YwtvqehM4bG6XT5fmXA5IE3Bzn2PtXSUUAZaadehWL61eGRgOkUIVT/sjZnHsSfrVSXR9XeNVj8TXkbBCrN9mtzls8MPk4+nNb9FAGBa+HZoZJ5ZvEOt3UsmQGlliUID2VEjVePUgn3qX/hHopIo0vNR1a4aPo/22SEn6+UUB/EVtUUAc5eeDtLvIBFcT6yyA5XGsXalfxEgNRN4NgF7b3FvrfiOBYTzCNTlkjkBGCGEhYn1yCCD0IrqKKAMWHQTEoT+19WeMAja84J6/wB7bu/WtLT7b7HZxwefPcbM/vZ33O2Tnk/jViigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArOutKtLjXrHUpiTdWtvNDEhxt2yNEzNjGcgxJgg8ZPqMaNcB8RdL1jUPEOkvo6SNHHp94LlVynnIZrRjAsvSN5AjAE9g2MfeAB1+l6fbWlzqV3bSNIdRuFupCWBUMIo4vlwOm2JT35J+g0K851UajLLdz6LDqtpZWmnafJp9rFC8KiTz5hIhjwMkIsYKHIAIOOhqi8ni77Tq72894uqgXqxW7WszQuvzeRsdv3AwBGQRgkkhuc4APVKK5LwB9t2X32q6vZoCY2jS6triJozg7sNP8zZwDgcA9OuB1tACOodGU5wwwcEg/mOlVLO3WwCQLPK8TEhPtExkcHrgM2WbueSSMenR+pahZ6XZSXmp3dvZ2keN89xII0XJAGWJAGSQPqafdcIsgi81o2BABwRngkfQE8d6AFWELdyTYG50RCfoWP/ALNUtQwMWkuAWyFkwPb5V4/PNTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFVv7Qs/wC0v7O+12/9oeT9o+y+Yvm+Vnbv2ZztzxnGM8UAWaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4X436NqHiD4X61pmj2zXV/P5HlxKQC22eNjySB0BP4Vn/8AC8vh1/0MP/klc/8AxuvSqKAPMbf42fDe3iEcXiFtoyfmtLpjycnJKZNSf8Ly+HX/AEMP/klc/wDxuvSqKAPNf+F5fDr/AKGH/wAkrn/43R/wvL4df9DD/wCSVz/8br0qigDzX/heXw6/6GH/AMkrn/43R/wvL4df9DD/AOSVz/8AG69KooA81/4Xl8Ov+hh/8krn/wCN0f8AC8vh1/0MP/klc/8AxuvSqKAPNf8AheXw6/6GH/ySuf8A43R/wvL4df8AQw/+SVz/APG69KooA81/4Xl8Ov8AoYf/ACSuf/jdH/C8vh1/0MP/AJJXP/xuvSqKAPNf+F5fDr/oYf8AySuf/jdH/C8vh1/0MP8A5JXP/wAbr0qigDzX/heXw6/6GH/ySuf/AI3R/wALy+HX/Qw/+SVz/wDG69KooA81/wCF5fDr/oYf/JK5/wDjdH/C8vh1/wBDD/5JXP8A8br0qigDzX/heXw6/wChh/8AJK5/+N0f8Ly+HX/Qw/8Aklc//G69KooA81/4Xl8Ov+hh/wDJK5/+N0f8Ly+HX/Qw/wDklc//ABuvSqKAPNf+F5fDr/oYf/JK5/8AjdH/AAvL4df9DD/5JXP/AMbr0qigDzX/AIXl8Ov+hh/8krn/AON0f8Ly+HX/AEMP/klc/wDxuvSqKAPNf+F5fDr/AKGH/wAkrn/43R/wvL4df9DD/wCSVz/8br0qigDzX/heXw6/6GH/AMkrn/43R/wvL4df9DD/AOSVz/8AG69KooA81/4Xl8Ov+hh/8krn/wCN0f8AC8vh1/0MP/klc/8AxuvSqKAPNf8AheXw6/6GH/ySuf8A43WT4Q8Q6b4w+Ocut+HJZbzSYvDhs3uvs8kaCYXQfZl1HO1ga9gooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4k+J7rwl4b/tKx0/+0JjPHCIdzDhjgt8qk8delWPAPiFvE/hyPUnNjl3ZMWU7SoMHoSyqQfUEVe8RaS2tWC2yalqOmsriQT2Eojk4zxkggjnoR6VB4P8M2PhTR/7P01p5FaV55ZriTfLNI5yzueMk/QUAbdFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcHefFHQrbVpdP+zavNNHdyWG+Cxd0a4Rd3lKw6sR0A+pwOapXvxNt59MbUNEMckTaJeapFDcQusheAlSrEHAAYEEdfQ1sRfD7So79btbi+8way+uYLpjz3j2Ffu/cwOnXPeqVr8K9EtrBbSO61IxLp15pgLSJnyrmRnkP3PvAscHpjqDQBkW3xMvHTVHuorK3S0i0l0fy3fLXa5YEA9jwPTvmugHxL0A6xqdiPthTTTMt3diHMMJiUs4bndxgjO3BOACcioX+GGivBexG61HbdrYK/7xMgWY/dY+Tv/F69sUy++FWgal4gutW1SS9vZZxOvlStGFQSqVYBlQOQFYgBmIXt0FABZ/Fjw1c2N9cl7yE2ixN5EkB82USnbH5agncWPGOo74qzffEbTbGOIXWm61HeOJZDZGzPnJHGAXkIzjYAw5BOegyQaq23ws0eLS59Plv9UngcR+UzyRq9uY2DIyMiKdwIHLbj+tT3/wAObW/WKS613Xn1BFliN958YmeKQANEcR7QnyjACgg5IOSTQBFqnxW8OaeGcDUbu3S2gvJJ7W0aSOOGX7kjHsPY8+3Wq3i34mQadfJY6Lay3s0d/a2dzcNEfs8XnMPl35GX2kHAyPX0q9N8MtCex1Wzie8t7bUdPg0144pFxHFCCE2EqTu55Jzmo774YaTd6k90NQ1a3iku4L6S0hljEMk8O0K5BQnJCjOCAfrQBoeHPHmk+ItauNO0qK9l8h5I2uPJxFuQ4YZzkc8cgZ7V1lcZovw70rSvFjeIhc311qO2RUacx4QOctkois/oN5bHauzoAKKKKACiiigAooooAKKKKACiiigDj/Hfi+58L6l4ct49Je5t9W1KDT2ujMqpC0jEfd5YnAJ6Y46iud8Z/E+60HWtfS20uC40rw79j/tKV5isp+0kbfKUAg4BBOTz04rqPG3guDxdNpj3eq6pZDTrhLuBLNogBMmdsh3xsSRk+3tVDXfhlo2t6pPe3t1qOLtYBf28cqrFfeScxmUbc5GP4StAGZa/Ei8m+I8/hqWwsLS3S7NtHPc3MiSXAAyTGvl7WPbG4V6ZXIT+A7K78TW+s6hqmsXv2W4N3bWVxchraCU9GVQoPGeAWIFdfQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Repeated electrical stimulation (S) of the median nerve of the arm or the posterior fibular nerve of the leg is followed by averaging of electrical signals measured between a pair of electrodes (FZ, C2, C3 are illustrated). The resulting display of the positive (P-downward) or negative (N-upward) deflections can be used to determine the speed of neural transmission.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14853=[""].join("\n");
var outline_f14_32_14853=null;
var title_f14_32_14854="Aminocaproic acid: Pediatric drug information";
var content_f14_32_14854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"20\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aminocaproic acid: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"    see \"Aminocaproic acid: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/17/30996?source=see_link\">",
"    see \"Aminocaproic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F133225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amicar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hemostatic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F15673263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO), high-bleeding risk patients:",
"     </b>",
"     Limited data available: I.V.: 100 mg/kg prior to or immediately after cannulation, followed by 25-30 mg/kg/hour for up to 72 hours; target activated clotting time (ACT) range during therapy of 180-200 seconds has been used (Downard, 2003; Horwitz, 1998; Wilson, 1993); variable results; patients requiring surgery just prior to or while on ECMO seem to benefit most; further studies needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of perioperative bleeding associated with cardiac surgery:",
"     </b>",
"     Limited data available: I.V.: 75 mg/kg administered at the beginning and end of cardiopulmonary bypass, along with 75 mg/100 mL added to the priming fluid for cardiopulmonary bypass (Martin, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"      see \"Aminocaproic acid: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Control of hemorrhage (oral, epistaxis, menorrhagia) in hemophilic patients, adjunct treatment:",
"     </b>",
"     Limited data available: Oral: 50-100 mg/kg/dose every 6 hours; maximum daily dose: 24",
"     <b>",
"      g/day",
"     </b>",
"     (Acharya, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Control of mucosal bleeding in thrombocytopenia/platelet dysfunction:",
"     </b>",
"     Limited data available: Oral, I.V.: 50-100 mg/kg/dose every 6 hours; maximum daily dose: 24",
"     <b>",
"      g/day",
"     </b>",
"     (Bussel, 2011; Lipton, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hematuria (gross; upper tract), refractory:",
"     </b>",
"     Limited data available: Children &ge;11 years and Adolescents: Oral: 100 mg/kg/dose every 6 hours; continue for 2 days beyond resolution of hematuria; dosing based on case series (n=4) which showed hematuria resolution within 2-7 days; risks and benefits must be weighed prior to use; further studies needed (Kaye, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prevention of bleeding associated with dental procedures in hemophilic patients:",
"     </b>",
"     Limited data available: Oral: 50-100 mg/kg/dose every 6 hours; maximum daily dose: 24",
"     <b>",
"      g/day",
"     </b>",
"     ; used in conjunction with DDAVP or factor replacement therapy; continue for up to 7 days or until mucosal healing is complete (Acharya, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO), high-bleeding risk patients:",
"     </b>",
"     Limited data available: I.V.: 100 mg/kg prior to or immediately after cannulation, followed by 25-30 mg/kg/hour for up to 72 hours; target activated clotting time (ACT) range during therapy of 180-200 seconds has been used (Downard, 2003; Horwitz, 1998; Wilson, 1993); variable results; patients requiring surgery just prior to or while on ECMO seem to benefit most; further studies needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prevention of perioperative bleeding associated with cardiac surgery:",
"     </b>",
"     Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &lt;2 years: Dosing regimens variable: I.V.: In the largest trial (n=120, all patients &lt;20 kg), a dose of 75 mg/kg was administered at the beginning and end of cardiopulmonary bypass (CPB), and 75 mg/100 mL was added to the CPB priming fluid (Martin, 2011a). Another study group in two separate trials (n=110, age range: 2 months to 14 years) used a 100 mg/kg dose after induction, during CPB pump priming, and when weaning CPB (over 3 hours) for a total of three doses (Chauhan, 2000; Chauhan, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;2 years and Adolescents: I.V.: 100 mg/kg after induction, during CPB pump priming, and when weaning CPB (over 3 hours) for a total of 3 doses; regimen used in two separate trials (n=110, age range: 2 months to 14 years) (Chauhan, 2000; Chauhan, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prevention of perioperative bleeding associated with spinal surgery (eg, idiopathic scoliosis):",
"     </b>",
"     Limited data available: Children &ge;11 years and Adolescents: I.V.: 100 mg/kg (maximum dose: 5",
"     <b>",
"      g",
"     </b>",
"     ) administered over 15-20 minutes after induction, followed by a continuous I.V. infusion of 10 mg/kg/hour for the remainder of the surgery; discontinued at time of wound closure (Florentino-Pineda, 2001; Florentino-Pineda, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Traumatic hyphema:",
"     </b>",
"     Oral: 50-100 mg/kg/dose every 4 hours for 5 days; maximum daily dose: 30",
"     <b>",
"      g/day",
"     </b>",
"     (Brandt, 2001; Crouch, 1999; Teboul, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Acute bleeding:",
"     </b>",
"     Oral, I.V.: Loading dose: 4-5",
"     <b>",
"      g",
"     </b>",
"     during the first hour, followed by 1",
"     <b>",
"      g",
"     </b>",
"     /hour for 8 hours (or 1.25",
"     <b>",
"      g",
"     </b>",
"     /hour using oral solution) or until bleeding controlled (maximum daily dose: 30",
"     <b>",
"      g",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustments are provided in the manufacturer&rsquo;s labeling, but aminocaproic acid may accumulate in patients with decreased renal function; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustments are provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 250 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 1.25 g/5 mL (237 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amicar&reg;: 1.25 g/5 mL (473 mL) [raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amicar&reg;: 500 mg, 1000 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer without regard to food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Further dilute in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS to a maximum concentration of 20 mg/mL and administer I.V. over 15-60 minutes (rate dependent upon use); or a continuous I.V. infusion may be used. Do not administer undiluted; rapid I.V. injection (IVP) of undiluted solution is not recommended due to possible hypotension, bradycardia, and arrhythmia.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F133268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, Ringer&rsquo;s injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible",
"     </b>",
"     with fenoldopam",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15673207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral (tablets and solution): Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); dispense in a tightly closed container; do not freeze solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Further dilution in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or LR is required before administration. Solutions diluted to 20 mg/mL or 100 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS are stable for 7 days at 4&deg;C or 23&deg;C; dilutions in D",
"     <sub>",
"      5",
"     </sub>",
"     W may develop a slight yellow color when stored at warmer temperatures [ie, 23&deg;C (73&deg;F)]; potency is not affected.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To enhance hemostasis when fibrinolysis contributes to bleeding (causes may include cardiac surgery, hematologic disorders, neoplastic disorders, abruptio placentae, hepatic cirrhosis, and urinary fibrinolysis) (FDA approved in adults); has also been used for traumatic hyphema, prevention of perioperative bleeding, refractory hematuria, and prevention of bleeding associated with ECMO in high-risk patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F133270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Amicar&reg; may be confused with amikacin, Amikin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amicar [U.S.] may be confused with Omacor brand name for Omega-3-Acid Ethyl Esters [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F133267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, edema, hypotension, intracranial hypertension, peripheral ischemia, syncope, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, delirium, dizziness, fatigue, hallucinations, headache, malaise, seizure, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, cramps, diarrhea, GI irritation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dry ejaculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, bleeding time increased, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site necrosis, injection site pain, injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased, myalgia, myositis, myopathy, rhabdomyolysis (rare), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Vision decreased, watery eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, intrarenal obstruction (glomerular capillary thrombosis), myoglobinuria (rare), renal failure (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion, pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylactoid reaction, anaphylaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Hepatic lesion, hyperkalemia, myocardial lesion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aminocaproic acid or any component; disseminated intravascular coagulation (without concomitant heparin); evidence of an intravascular clotting process",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in renal impairment; accumulation of aminocaproic acid may occur and dosage adjustment may be needed; may also increase serum potassium; monitor patients closely. Use with caution in hepatic impairment; monitor patients closely.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid rapid I.V. administration; may induce hypotension, bradycardia, or arrhythmia; rapid injection of undiluted solution is not recommended. Intrarenal obstruction may occur secondary to glomerular capillary thrombosis or clots in the renal pelvis and ureters; consider risks versus benefits when using for hematuria. Do not use unless hyperfibrinolysis has been confirmed with laboratory studies; inhibition of fibrinolysis may promote clotting or thrombosis; more likely due to the presence of DIC. Do not administer with factor IX complex concentrates or anti-inhibitor coagulant complexes; may increase risk for thrombosis. Skeletal muscle weakness ranging from mild myalgias and fatigue to severe myopathy with rhabdomyolysis and acute renal failure has been reported with prolonged use; monitor CPK; discontinue treatment with a rise in CPK.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Injection contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of injection in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-inhibitor Coagulant Complex: Antifibrinolytic Agents may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Factor IX (Human): Aminocaproic Acid may enhance the adverse/toxic effect of Factor IX (Human). Specifically, use of this combination may increase the risk of thrombosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Factor IX (Recombinant): Aminocaproic Acid may enhance the adverse/toxic effect of Factor IX (Recombinant). Specifically, use of this combination may increase the risk of thrombosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Factor IX Complex (Human): Aminocaproic Acid may enhance the adverse/toxic effect of Factor IX Complex (Human). Specifically, use of this combination may increase the risk of thrombosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibrinogen Concentrate (Human): Antifibrinolytic Agents may enhance the adverse/toxic effect of Fibrinogen Concentrate (Human). Specifically, the risk for thrombosis may be increased. Fibrinogen Concentrate (Human) may enhance the adverse/toxic effect of Antifibrinolytic Agents. Specifically, the risk for thrombosis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tretinoin (Systemic): May enhance the thrombogenic effect of Antifibrinolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fibrinogen, fibrin split products, serum creatinine kinase (long-term therapy); serum potassium, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1056456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic concentration: &gt;130 mcg/mL (concentration necessary for inhibition of fibrinolysis)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively inhibits activation of plasminogen thereby reducing fibrinolysin, without inhibiting lysis of clot",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Inhibition of fibrinolysis: Within 1-72 hours; onset shortened substantially with loading dose",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributes through intravascular and extravascular compartments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic metabolism is minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1.2 &plusmn; 0.45 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (65% as unchanged drug, 11% as metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Acharya S, \"Hemostatic Disorders,\"",
"      <i>",
"       Manual of Pediatric Hematology and Oncology",
"      </i>",
"      , 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 402-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brandt MT and Haug RH, \"Traumatic Hyphema: A Comprehensive Review,\"",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2001, 59(12):1462-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/11732035/pubmed\" id=\"11732035\" target=\"_blank\">",
"        11732035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bussel J and Renaud T, \"Disorders of Platelets,\"",
"      <i>",
"       Manual of Pediatric Hematology and Oncology",
"      </i>",
"      , 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 372.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chauhan S, Das SN, Bisoi A, et al, \"Comparison of Epsilon Aminocaproic Acid and Tranexamic Acid in Pediatric Cardiac Surgery,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 2004, 18(2):141-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/15073700/pubmed\" id=\"15073700\" target=\"_blank\">",
"        15073700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chauhan S, Kumar BA, Rao BH, et al, \"Efficacy of Aprotinin, Epsilon Aminocaproic Acid, or Combination in Cyanotic Heart Disease,\"",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2000, 70(4):1308-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/11081890/pubmed\" id=\"11081890\" target=\"_blank\">",
"        11081890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crouch ER Jr and Crouch ER, \"Management of Traumatic Hyphema: Therapeutic Options,\"",
"      <i>",
"       J Pediatr Ophthalmol Strabismus",
"      </i>",
"      , 1999, 36(5):238-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/10505828/pubmed\" id=\"10505828\" target=\"_blank\">",
"        10505828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Downard CD, Betit P, Chang RW, et al, \"Impact of AMICAR on Hemorrhagic Complications of ECMO: A Ten-Year Review,\"",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 2003, 38(8):1212-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/12891495/pubmed\" id=\"12891495\" target=\"_blank\">",
"        12891495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Florentino-Pineda I, Blakemore LC, Thompson GH, et al, \"The Effect of Epsilon-Aminocaproic Acid on Perioperative Blood Loss in Patients With Idiopathic Scoliosis Undergoing Posterior Spinal Fusion: A Preliminary Prospective Study,\"",
"      <i>",
"       Spine (Phila Pa 1976)",
"      </i>",
"      , 2001, 26(10):1147-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/11413428/pubmed\" id=\"11413428\" target=\"_blank\">",
"        11413428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Florentino-Pineda I, Thompson GH, Poe-Kochert C, et al, \"The Effect of Amicar on Perioperative Blood Loss in Idiopathic Scoliosis: The Results of a Prospective, Randomized Double-Blind Study,\"",
"      <i>",
"       Spine (Phila Pa 1976)",
"      </i>",
"      , 2004, 29(3):233-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/14752343/pubmed\" id=\"14752343\" target=\"_blank\">",
"        14752343",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horwitz JR, Cofer BR, Warner BW, et al, \"A Multicenter Trial of 6-Aminocaproic Acid (Amicar) in the Prevention of Bleeding in Infants on ECMO,\"",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 1998, 33(11):1610-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/9856877/pubmed\" id=\"9856877\" target=\"_blank\">",
"        9856877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaye JD, Smith EA, Kirsch AJ, et al, \"Preliminary Experience With Epsilon Aminocaproic Acid for Treatment of Intractable Upper Tract Hematuria in Children With Hematological Disorders,\"",
"      <i>",
"       J Urol",
"      </i>",
"      , 2010, 184(3):1152-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/20650477/pubmed\" id=\"20650477\" target=\"_blank\">",
"        20650477",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipton JM, \"Bone Marrow Failure,\"",
"      <i>",
"       Manual of Pediatric Hematology and Oncology",
"      </i>",
"      , 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 131.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin K, Breuer T, Gertler R, et al, \"Tranexamic Acid Versus &epsilon;-Aminocaproic Acid: Efficacy and Safety in Paediatric Cardiac Surgery,\"",
"      <i>",
"       Eur J Cardiothorac Surg",
"      </i>",
"      , 2011a, 39(6):892-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/21115357/pubmed\" id=\"21115357\" target=\"_blank\">",
"        21115357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin K, Gertler R, Liermann H, et al, \"Switch From Aprotinin to &epsilon;-Aminocaproic Acid: Impact on Blood Loss, Transfusion, and Clinical Outcome in Neonates Undergoing Cardiac Surgery,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 2011, 107(6):934-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/21857014/pubmed\" id=\"21857014\" target=\"_blank\">",
"        21857014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teboul BK, Jacob JL, Barsoum-Homsy M, et al, \"Clinical Evaluation of Aminocaproic Acid for Managing Traumatic Hyphema in Children,\"",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 1995, 102(11):1646-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/9098257/pubmed\" id=\"9098257\" target=\"_blank\">",
"        9098257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams GD, Bratton SL, Riley EC, et al, \"Efficacy of Epsilon-Aminocaproic Acid in Children Undergoing Cardiac Surgery,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 1999, 13(3):304-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/10392682/pubmed\" id=\"10392682\" target=\"_blank\">",
"        10392682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson JM, Bower LK, Fackler JC, et al, \"Aminocaproic Acid Decreases the Incidence of Intracranial Hemorrhage and Other Hemorrhagic Complications of ECMO,\"",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 1993, 28(4):536-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/32/14854/abstract-text/8483066/pubmed\" id=\"8483066\" target=\"_blank\">",
"        8483066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12564 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-9070587B58-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14854=[""].join("\n");
var outline_f14_32_14854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133225\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056453\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673263\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056447\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133202\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133186\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056458\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133268\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673207\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056457\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133270\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133267\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056462\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056446\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056445\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298735\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133195\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133198\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133211\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056452\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056456\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056444\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056460\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056461\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12564\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12564|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=related_link\">",
"      Aminocaproic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/17/30996?source=related_link\">",
"      Aminocaproic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_32_14855="Balantidium coli life cycle";
var content_f14_32_14855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Balantidium coli life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 578px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cysts are the parasite stage responsible for transmission of balantidiasis",
"    <strong>",
"     (1)",
"    </strong>",
"    . The host most often acquires the cyst through ingestion of contaminated food or water",
"    <strong>",
"     (2)",
"    </strong>",
"    . Following ingestion, excystation occurs in the small intestine, and the trophozoites colonize the large intestine",
"    <strong>",
"     (3)",
"    </strong>",
"    . The trophozoites reside in the lumen of the large intestine of humans and animals, where they replicate by binary fission, during which conjugation may occur",
"    <strong>",
"     (4)",
"    </strong>",
"    . Trophozoites undergo encystation to produce infective cysts",
"    <strong>",
"     (5)",
"    </strong>",
"    . Some trophozoites invade the wall of the colon and multiply. Some return to the lumen and disintegrate. Mature cysts are passed with feces",
"    <strong>",
"     (1)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Balantidiasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/Balantidiasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/HTML/Balantidiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14855=[""].join("\n");
var outline_f14_32_14855=null;
var title_f14_32_14856="Treatment of lipids (including hypercholesterolemia) in primary prevention";
var content_f14_32_14856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of lipids (including hypercholesterolemia) in primary prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/32/14856/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/32/14856/contributors\">",
"     Michael Pignone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/32/14856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/32/14856/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/32/14856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/32/14856/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/32/14856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have found a graded relationship between the total cholesterol concentration and coronary risk (",
"    <a class=\"graphic graphic_figure graphicRef60146 graphicRef50334 graphicRef78556 \" href=\"UTD.htm?22/37/23120\">",
"     figure 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with known coronary heart disease (CHD; including myocardial infarction, angina, and prior coronary revascularization) or coronary risk equivalents (",
"    <a class=\"graphic graphic_table graphicRef71255 \" href=\"UTD.htm?43/30/44523\">",
"     table 1",
"    </a>",
"    ), clearly benefit from treatment with a statin (over a wide range of initial lipid levels) and, perhaps, with certain other agents, such as niacin or fibrates that reduce LDL-C if a statin cannot be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients without known CHD are generally at much lower and more varied baseline risk of cardiovascular events. As such, the treatment approach will depend on a determination of global CHD risk, as the potential absolute risk reduction with treatment for hypercholesterolemia will usually be smaller than for patients with established CHD.",
"   </p>",
"   <p>",
"    This topic reviews the evidence for treating patients with increased CHD risk due to elevated LDL-C",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low HDL-C but no known CHD or CHD equivalents. The clinical trials are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with familial hypercholesterolemia and related disorders are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIFESTYLE MODIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is reasonable to recommend that all patients with high LDL-C undergo lifestyle modifications such as weight loss in overweight patients, aerobic exercise, and eating a prudent diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    .) The United Kingdom Lipid Clinics Programme study of 2508 subjects found that, with diet alone, 60 percent of subjects had a mean reduction in body weight of 1.8 percent, which was associated with 5 to 7 percent reductions in serum total and LDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/2\">",
"     2",
"    </a>",
"    ]. In occasional patients with poor baseline diets, marked dietary change can lower LDL-C by as much as 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"     \"Lipid lowering with diet or dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study randomly assigned 180 postmenopausal women and 197 men with low levels of HDL-C and moderately elevated levels of LDL-C to aerobic exercise, diet, diet plus exercise, or no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/4\">",
"     4",
"    </a>",
"    ]. Although there were no significant changes in HDL-C in any group, there were significant reductions in LDL-C in both men and women (14.5 and 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.38 and 0.52",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    respectively) in the diet plus exercise group compared with control or diet alone and, in men, in the diet plus exercise group compared with exercise alone.",
"   </p>",
"   <p>",
"    The benefits of LDL-C lowering may be evident within 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The individual response to a cholesterol-lowering diet depends upon many factors; some of the response is genetically determined, and increased body mass index is associated with less response to dietary change [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients who are referred to a dietitian may have greater success in the short term with lowering LDL-C compared with patients who receive dietary counseling by clinicians, although long-term compliance with dietary therapy is inadequate for both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these benefits on LDL-C, there is limited evidence that lifestyle modifications improve cardiovascular outcomes. In the Multiple Risk Factor Intervention Trial (MRFIT) in 12,866 high-risk men, an intervention that included dietary advice to reduce cholesterol levels did not significantly reduce CHD mortality (1.8 versus 1.9 percent) or all-cause mortality (4.1 versus 4.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the differences in achieved total cholesterol levels between the groups (generally 5 to 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.13 to 0.26",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    were probably too small to expect significant effects on mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have examined the effects of lipid-lowering pharmacologic therapy on CHD events. Most trials have compared a fixed dose of a single pharmacologic agent with placebo, with both groups receiving basic, limited lifestyle counseling. No trials to date that have evaluated effects on CHD events have tested any medication in combination with statins or treatment to specific LDL-C goals.",
"   </p>",
"   <p>",
"    As discussed below, when a pharmacologic agent is required for treatment in primary prevention, a statin is the preferred medication. If a statin is not tolerated or a particular LDL-C goal is not achieved on a statin alone, we suggest NOT administering or adding a nonstatin lipid-lowering medication.",
"   </p>",
"   <p>",
"    Patients with familial hypercholesterolemia and related disorders of LDL metabolism represent special cases and their management is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonstatin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early trials of lipid lowering therapy in primary prevention with medications other than statins, several trials found a disturbing increase in noncardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Particularly in primary prevention, where the absolute benefit of any therapy may be quite small, well-designed trials demonstrating greater benefit than harm are generally needed before a particular agent can be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'Effect of early trials on mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the results seen with nonstatin hypolipidemic agents, a number of studies have demonstrated a benefit from lowering the serum cholesterol with statins in patients without clinical evidence of CHD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The West of Scotland Coronary Prevention Study (WOSCOPS) showed that cholesterol lowering with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      reduced both the number of nonfatal myocardial infarctions and CHD mortality in middle-aged men with a serum LDL-C concentration above 155",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef59494 \" href=\"UTD.htm?21/5/21598\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/15\">",
"       15",
"      </a>",
"      ]. There was a borderline significant 22 percent reduction in all-cause mortality. Long-term follow-up after completion of the trial found that these benefits were sustained and the reduction in mortality increased over five to ten years, despite equivalent post-trial use of statins between groups [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'West of Scotland Coronary Prevention Study'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      These observations were extended in the Air",
"      <span class=\"nowrap\">",
"       Force/Texas",
"      </span>",
"      Coronary Atherosclerosis Prevention Study",
"      <span class=\"nowrap\">",
"       (AFCAPS/TexCAPS),",
"      </span>",
"      which showed that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      reduced the incidence of a first major coronary event (unstable angina pectoris, fatal and non-fatal myocardial infarction, and sudden cardiac death) in low-risk men and women without clinical evidence of cardiovascular disease (CVD) and LDL-C levels near the average for the general population (150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.9",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      range 130 to 190",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.4 to 4.9",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/17\">",
"       17",
"      </a>",
"      ]. These patients also had HDL-cholesterol levels that were below average for an age and sex matched cohort. For every 1000 men and women treated with lovastatin for five years, 19 major coronary events, 12 myocardial infarctions, and 17 coronary revascularizations could be prevented. No effect was seen on all-cause mortality.",
"     </li>",
"     <li>",
"      Similar results were seen in the ASCOT-LLA, which studied",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (10 mg) in men and women with relatively normal serum cholesterol levels but with hypertension and at least three additional cardiac risk factors, however there was a trend toward a reduction in all-cause mortality (hazard ratio 0.87, 95% CI 0.71-1.06) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'ASCOT-LLA trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The JUPITER trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      20 mg daily in healthy adult men and women with elevated C-reactive protein levels and LDL-C levels below 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      found a marked reduction in the primary endpoint of first major cardiovascular events and for all-cause mortality (hazard ratios 0.56 and 0.80, respectively). The absolute benefits for the primary endpoint was 0.59 events per 100 person-years and for all-cause mortality was 0.25 deaths per 100 person-years. This trial was stopped early for benefit which may exaggerate the true level of benefit, particularly for the primary endpoint [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'JUPITER trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these trials suggest that statin therapy for primary prevention is effective over a wide range of baseline LDL-C levels and lipid profiles and carries a similar relative risk reduction to statin therapy in secondary prevention. The absolute magnitude of benefit, however, is typically lower than in secondary prevention, but greater than the benefit of treating mild hypertension. Additionally, a meta-analysis that reanalyzed existing trials of statins, but carefully limited the inclusion of patients to only involve those with no prior cardiovascular disease, found a reduction in mortality that was not statistically significant (risk ratio 0.91, 95% CI 0.83-1.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link&amp;anchor=H1570848031#H1570848031\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'Meta-analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DECIDING WHOM TO TREAT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the evidence discussed above, it may be most appropriate to view lipid lowering therapy with statins as an intervention that can reduce relative cardiovascular risk by approximately 20 to 30 percent regardless of baseline LDL-C. Statins have not been well studied for such a benefit in patients with very low baseline LDL-C levels (eg, below 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.8",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    but very few such patients would be expected to have a high enough absolute risk to justify statin therapy. The absolute benefit of treatment will be proportional to the underlying absolute risk. Determining when the benefits of treatment outweigh its burdens (costs, adverse effects) requires determination of the patient's underlying CHD risk, rather than aiming to target a specific goal LDL-C.",
"   </p>",
"   <p>",
"    In this view, patients' cardiovascular risk should be calculated using appropriate risk models, such as the Framingham Risk Score for men and women (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?43/28/44482?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/63/10226?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .) Patients and their providers can then decide whether a 20 to 30 percent relative risk reduction translates into an absolute risk reduction large enough to be worth the cost, burdens, and potential side effects of daily statin therapy.",
"   </p>",
"   <p>",
"    As an example, a 45-year-old nonsmoking normotensive woman with a total cholesterol level of 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.21",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and an HDL-cholesterol of 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.03",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    has a ten-year risk of a myocardial infarction of approximately 1 percent. This could likely be reduced by 0.2 to 0.3 percentage points if she were treated with a statin daily for ten years. Conversely, a 60-year-old normotensive man with a total cholesterol level of 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and an HDL-cholesterol of 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    has a ten-year risk of a myocardial infarction of approximately 12 percent. Use of a statin would reduce this risk to 8 to 9 percent, a 3 to 4 percentage point reduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Choice of risk calculator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues around the choice of risk calculator include the applicability of the data to the particular population or ethnic group being modeled and the outcomes being predicted.",
"   </p>",
"   <p>",
"    The Framingham calculators discussed above for men and women (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?43/28/44482?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/63/10226?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) are based on a sample population from the northeastern United States. Earlier Framingham calculators did not include stroke as a predicted outcome, although the effects of statins on stroke reduction are similar to the effects on other major cardiovascular outcomes. The current versions of the calculators do include stroke, but also include outcomes such as heart failure, that are not proven to be reduced by statin therapy, and development of claudication, which may be of less importance to patients than the outcomes of CHD death, myocardial infarction, and stroke.",
"   </p>",
"   <p>",
"    A calculator that allows modeling of a choice of outcomes based on population data from the United Kingdom is",
"    <a class=\"external\" href=\"file://www.patient.co.uk/doctor/cardiovascular-risk-calculator\">",
"     available online",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Additionally, many risk calculators do not apply to patients with diabetes. Whether patients with diabetes should be considered to have a coronary risk equivalent or should be assessed with a diabetes-specific calculator is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H1033672373#H1033672373\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Diabetes mellitus as a CHD equivalent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cost-effectiveness modeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cost-effectiveness models can help assess the net benefit of lipid-lowering therapy at different levels of risk by assessing both the benefits of therapy as well as its burdens, including adverse effects and costs. One such analysis from the United States suggested that treatment was reasonably cost-effective for middle-aged men (cost per quality-adjusted life-year gained of $42,500) when the ten-year baseline risk of CHD events was over 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/21\">",
"     21",
"    </a>",
"    ]. One subsequent analysis reached similar conclusions and noted that the threshold for prescribing a statin is decreasing as statin cost decreases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/22\">",
"     22",
"    </a>",
"    ], however, a second such analysis from the Netherlands found that even with low-cost generic statins, treatment in primary prevention did not appear to be cost-effective in low-risk primary prevention populations (ten-year risk below 5 percent) once adherence to therapy was taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Specific populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Young patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data on the safety of statins over decades of therapy. It is also uncertain whether long-term treatment leads to better outcomes compared with postponing treatment until the patient's cardiovascular risk rises to an absolute level at which treatment becomes warranted. Notably, statins are contraindicated in pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link&amp;anchor=H19#H19\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Risks in pregnancy and breastfeeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the benefits of therapy may be both small and delayed in young patients, even a low rate of harmful side effects could outweigh potential benefits in such a low risk group. If statin therapy is being contemplated for primary prevention in adults in their 20s and 30s, clinicians should carefully discuss the lack of good evidence on long-term safety prior to initiating therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Older patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision whether to treat hypercholesterolemia in an elderly individual is highly individualized, based upon both chronologic and physiologic age. A patient with a limited life span from a serious concurrent illness is probably not a candidate for drug therapy. On the other hand, an otherwise healthy elderly individual should not be denied drug therapy simply on the basis of age alone. The treatment of dyslipidemias in the elderly is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10760?source=see_link\">",
"     \"Treatment of dyslipidemia in the older adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     USE OF STATINS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a decision is made to treat with statins to achieve the 20 to 30 percent reduction in CHD events seen in most clinical trials, it may make sense to treat with the doses of statins shown to be of benefit in clinical trials.",
"   </p>",
"   <p>",
"    In patients with significantly elevated baseline lipid levels, this approach will frequently lead to similar treatment compared with targeting a goal LDL-C; in patients with low baseline LDL-C levels who are felt to be appropriate candidates for therapy because of other risk factors, this will typically lead to higher doses of statins than would be recommended in guidelines based on lipid goals.",
"   </p>",
"   <p>",
"    Statin doses that have been used in clinical trials of primary prevention include low to moderate intensity (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40 mg;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    20 to 40 mg;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    10 mg) and high intensity (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    20 mg) therapy. No trials have directly compared the effects of low-to-moderate intensity with high intensity statin therapy for primary prevention.",
"   </p>",
"   <p>",
"    When the decision is made to treat, we suggest treatment with a moderate dose of a statin (eg, 40 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , or 5 to 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    ). This issue is discussed in more detail as it applies to secondary prevention separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H8#H8\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Dose-based strategy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Side effects and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin side effects and monitoring, which vary somewhat among the statins, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measuring LDL-C response can be helpful in determining whether patients are adherent to treatment. When determining adherence is desired, LDL-C can reasonably be measured six weeks after initiating statin therapy and every 6 to 12 months thereafter, or as the clinical situation dictates. When a decision is made to treat using the strategy recommended here (a dose-based strategy using a moderate dose of a statin), there is no particular need to measure lipid profiles to look for response to therapy other than to assess adherence, since we do not suggest intensifying the regimen for any particular level of LDL-C response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H28#H28\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Monitoring therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1938740108\">",
"    <span class=\"h2\">",
"     Statin intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are unable to take statin medications because of side effects &ndash; most commonly myalgias and other muscular symptoms. Options for managing such side effects are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link&amp;anchor=H21#H21\">",
"     \"Statin myopathy\", section on 'Prevention and management'",
"    </a>",
"    .) However, given that the absolute benefit of statin therapy in primary prevention is typically small, patients who are having side effects with statins may reasonably choose to discontinue treatment rather than attempt multiple interventions (eg, switching statins, dose reduction, alternative dosing schedules, Coenzyme Q10 supplementation) to control statin myopathy.",
"   </p>",
"   <p>",
"    While treatment with nonstatin lipid-lowering medications might seem to be an option, as discussed above several early trials of lipid lowering therapy in primary prevention with medications other than statins found a disturbing increase in noncardiovascular mortality. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Nonstatin therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, in patients who do not tolerate statins, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    administering a nonstatin lipid-lowering medication for primary prevention. That is, no lipid-lowering therapy should be administered in patients who are intolerant of statins. Potential interventions include lifestyle modification and, in higher risk patients, antiplatelet therapy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Lifestyle modification'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H22#H22\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Primary prevention of CVD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FAILURE TO ACHIEVE GOAL LDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, we do not suggest targeting a goal LDL-C (such as the goals suggested by ATP-III) when treating with a statin for primary prevention. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'General approach'",
"    </a>",
"    above.) Also as discussed above, several early trials of lipid lowering therapy in primary prevention with medications other than statins found a disturbing increase in noncardiovascular mortality. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Nonstatin therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, in patients who do not achieve a particular LDL-C goal on statin therapy alone, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    adding a nonstatin lipid-lowering medication for primary prevention. That is, the patient should be maintained on statin therapy as their only lipid-lowering medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the treatment of hypercholesterolemia for primary prevention from the United States National Cholesterol Education Program (NCEP) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the approach suggested here, the NCEP and some other groups suggest using a goal LDL-C in determining therapy for hypercholesterolemia and would treat with nonstatin medications in patients who do not tolerate a statin or do not achieve LDL-C goals with statin therapy alone.",
"   </p>",
"   <p>",
"    Guidelines for lipid management for primary prevention of CVD from the United Kingdom's National Institute for Health and Clinical Excellence (NICE) make similar recommendations to those presented here [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14856/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CVD risk should be calculated as the 10-year risk of CHD plus fatal and nonfatal stroke and transient ischemic attack (TIA)",
"     </li>",
"     <li>",
"      Patients should be informed about the absolute risks and benefits of 10 years of therapy",
"     </li>",
"     <li>",
"      Other CVD risk factors should be optimized if possible",
"     </li>",
"     <li>",
"      Patients with a 10-year risk of CVD of 20 percent or more should be treated with statin therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"       \"Patient information: High cholesterol treatment options (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that all patients, including those with hypercholesterolemia, be counseled to exercise, eat a prudent diet, and lose weight as appropriate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Lifestyle modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials of statins have demonstrated similar",
"      <strong>",
"       relative",
"      </strong>",
"      risk reductions for cardiovascular events and CHD (coronary heart disease) mortality across a wide range of baseline lipid levels in patients treated for primary and secondary prevention. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with known coronary heart disease (including myocardial infarction, angina, and prior coronary revascularization) or coronary risk equivalents (",
"      <a class=\"graphic graphic_table graphicRef71255 \" href=\"UTD.htm?43/30/44523\">",
"       table 1",
"      </a>",
"      ) is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients without CHD or CHD risk equivalents are generally at much lower cardiovascular risk than patients with CHD or its risk equivalents. As such, the",
"      <strong>",
"       absolute",
"      </strong>",
"      benefits of therapy are smaller. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials have not shown consistent benefits from nonstatin lipid lowering therapy in primary prevention and some studies have suggested that such therapies may increase noncardiovascular mortality. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonstatin therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rather than targeting a specific LDL-C in primary prevention, we suggest calculating a patient's baseline risk for cardiovascular events and treating with a statin in patients for whom a 20 to 30 percent reduction in events translates into an absolute reduction in events that would be worth the costs and burdens of daily statin therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"       \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In primary prevention when the decision is made to treat, we suggest treatment with a moderate dose of a statin (eg, 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , or 5 to 10 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measuring LDL-C response at 6 weeks after initiating therapy and every 6 to 12 months thereafter may be helpful in assessing medication adherence. When the strategy described here is employed, there is no need to monitor the LDL-C response to therapy other than to assess adherence, since we do not suggest intensifying the regimen for any particular level of LDL-C response. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Side effects and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In primary prevention patients who do not tolerate statins, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      administering a nonstatin lipid-lowering medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). That is, no lipid-lowering therapy should be administered. Potential interventions include lifestyle modification and, in higher-risk patients, antiplatelet therapy. (See",
"      <a class=\"local\" href=\"#H1938740108\">",
"       'Statin intolerance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In primary prevention patients who do not achieve a particular LDL-C goal on statin therapy alone, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      adding a nonstatin lipid-lowering medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). That is, the patient should be maintained on statin therapy as their only lipid-lowering medication. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Failure to achieve goal LDL'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with familial hypercholesterolemia and related disorders of LDL metabolism represent special cases and their management is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/1\">",
"      Wallis EJ, Ramsay LE, Ul Haq I, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000; 320:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/2\">",
"      Butowski PF, Winder AF. Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolaemia. Data from the U.K. Lipid Clinics Programme. Eur Heart J 1998; 19:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/3\">",
"      Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/4\">",
"      Stefanick ML, Mackey S, Sheehan M, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998; 339:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/5\">",
"      Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/6\">",
"      Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/7\">",
"      Denke MA, Adams-Huet B, Nguyen AT. Individual cholesterol variation in response to a margarine- or butter-based diet: A study in families. JAMA 2000; 284:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/8\">",
"      Henkin Y, Shai I, Zuk R, et al. Dietary treatment of hypercholesterolemia: do dietitians do it better? A randomized, controlled trial. Am J Med 2000; 109:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/9\">",
"      Hsia J, Rodabough R, Rosal MC, et al. Compliance with National Cholesterol Education Program dietary and lifestyle guidelines among older women with self-reported hypercholesterolemia. The Women's Health Initiative. Am J Med 2002; 113:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/10\">",
"      Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982; 248:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/11\">",
"      A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978; 40:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/12\">",
"      W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1980; 2:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/13\">",
"      The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/14\">",
"      Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/15\">",
"      Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/16\">",
"      Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/17\">",
"      Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/18\">",
"      Sever PS, Dahl&ouml;f B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/19\">",
"      Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/20\">",
"      Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010; 170:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/21\">",
"      Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006; 144:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/22\">",
"      Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med 2009; 150:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14856/abstract/23\">",
"      Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ 2011; 342:d1672.",
"     </a>",
"    </li>",
"    <li>",
"     NICE clinical guideline 67. Available at: www.nice.org.uk/nicemedia/pdf/CG67NICEguideline.pdf (Accessed on January 19, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4549 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14856=[""].join("\n");
var outline_f14_32_14856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIFESTYLE MODIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonstatin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DECIDING WHOM TO TREAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Choice of risk calculator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cost-effectiveness modeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Specific populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Young patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Older patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      USE OF STATINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Side effects and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1938740108\">",
"      Statin intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FAILURE TO ACHIEVE GOAL LDL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4549\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4549|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/19/317\" title=\"figure 1A\">",
"      Increasing plasma cholesterol and coronary risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/19/34109\" title=\"figure 1B\">",
"      Plasma cholesterol and cardiovascular mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/20/27982\" title=\"figure 1C\">",
"      Cholesterol level and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/5/21598\" title=\"figure 2\">",
"      Pravastatin prevents CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4549|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/30/44523\" title=\"table 1\">",
"      CHD risk equivalents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?43/28/44482?source=related_link\" title=\"calculator 1\">",
"      Calculator: Framingham 10 year risk of general cardiovascular disease in men (2008 paper)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/63/10226?source=related_link\" title=\"calculator 2\">",
"      Calculator: Framingham 10 year risk of general cardiovascular disease in women (2008 paper)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=related_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10760?source=related_link\">",
"      Treatment of dyslipidemia in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_32_14857="Juvenile plantar dermatosis";
var content_f14_32_14857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62551%7EDERM%2F76443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62551%7EDERM%2F76443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile plantar dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile plantar dermatosis 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14857=[""].join("\n");
var outline_f14_32_14857=null;
var title_f14_32_14858="Surgical management of sternal wound complications";
var content_f14_32_14858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical management of sternal wound complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/32/14858/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/32/14858/contributors\">",
"     Dennis P Orgill, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/32/14858/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/32/14858/contributors\">",
"     Charles E Butler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/32/14858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/32/14858/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/32/14858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H391486116\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sternal dehiscence is an infrequent but serious complication that is often a precursor to mediastinitis. Median sternotomy, which provides excellent access to the heart and surrounding structures, is the most commonly used incision for open cardiac surgery. Transverse sternotomy in association with bilateral thoracotomy (ie, clamshell incision) is used less often but may be needed to manage large tumors, chest trauma or to perform bilateral lung transplantation. Median sternotomy complications occur in 0.5 to 5 percent of patients with 0.2 to 3 percent of patients developing mediastinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/1\">",
"     1",
"    </a>",
"    ]. For transverse sternotomy, the rate of wound complications appears to be similar [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The risk of sternal wound complications may be greater in adults undergoing open heart surgery due multiple medical comorbidities compared with other populations (eg, trauma, children).",
"   </p>",
"   <p>",
"    The use of minimally invasive surgical methods (including robotic surgery), alternative surgical approaches and catheter-based techniques have reduced the incidence of sternal dehiscence and mediastinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/4\">",
"     4",
"    </a>",
"    ]. However, mortality remains high (up to 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/5-12\">",
"     5-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis, management, and measure to prevent sternal wound complications will be reviewed here. The diagnosis and medical management of mediastinitis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link\">",
"     \"Postoperative mediastinitis after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1319298\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR STERNAL WOUND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of sternal wound complications is multifactorial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. Any factor that contributes to poor wound or bone healing (eg, osteopenia, malnutrition), or increases the risk for surgical site infection (eg, diabetes, immunosuppression) may be clinically important, especially if two or more factors are present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/17\">",
"     17",
"    </a>",
"    ]. Although postoperative sternal wound infection is clearly associated with sternal dehiscence, whether the sternal wound infection has caused the sternal dehiscence or the sternal dehiscence has caused the sternal wound infection is usually not known. Thus, it is essential to follow measures that can help prevent surgical site infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H391486152\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sternal wound healing is impaired if the edges of the sternum are not aligned properly, the sternum is ischemic, or the bone is abnormal. Technical factors that contribute to poor sternal union include the creation of an asymmetric sternotomy incision that is difficult to realign, residual separation of the sternal edges after closure, and bone ischemia due to excessive use of electrocautery or possibly internal thoracic artery harvesting (particularly if bilateral). Perioperative factors that increase the risk for sternal dehiscence include prolonged operative time, the need for chest compressions, postoperative bleeding, transfusion and reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H704058\">",
"     'Sternal closure'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Certain patient populations have risk factors that increase the risk for surgical site infection or poor wound healing. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients undergoing cardiac surgery have multiple risk factors for infection, including cardiopulmonary bypass, which leads to a relatively immunosuppressed state [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/5\">",
"       5",
"      </a>",
"      ]; the presence of multiple drains and thoracostomy tubes, which are portals for the entry of bacteria; and a higher prevalence of other postoperative risk factors for wound infection (eg, respiratory infection) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/9,20\">",
"       9,20",
"      </a>",
"      ]. Patients with coronary artery disease are often older, have an increased incidence of diabetes, obesity and tobacco use, which, in addition to being risk factors for atherosclerosis, are risk factors for postoperative infection following cardiac surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"       \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H17#H17\">",
"       \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obese patients are at a particularly high risk for sternal dehiscence [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/1,22-25\">",
"       1,22-25",
"      </a>",
"      ]. The excess weight of the chest wall places high tensile stress on the sternal closure, which is exacerbated by upper body movement or coughing. Similarly, women with macromastia have a higher risk of sternal wound complications compared with women who have smaller breasts [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/26\">",
"       26",
"      </a>",
"      ]. Even small amounts of additional stress on the sternum can lead to sternal wire fracture or cutting of sternal wires through the sternum, resulting in sternal separation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/27\">",
"       27",
"      </a>",
"      ]. Prophylactic sternal reinforcement may decrease the incidence of sternal dehiscence in obese patients. (See",
"      <a class=\"local\" href=\"#H704065\">",
"       'Sternal wiring'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H391486152\">",
"       'Prevention'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with chronic pulmonary disease have multiple risk factors for sternal wound complications. Preoperative chest deformities such as barrel chest or pectus excavatum can increase the difficulty in maintaining proper alignment of the sternal edges during closure [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/28\">",
"       28",
"      </a>",
"      ]. These deformities also exert additional stress on the sternal closure and coughing exacerbates the stress. Continued smoking in patients with obstructive pulmonary disease also adversely affects wound healing. (See",
"      <a class=\"local\" href=\"#H391486152\">",
"       'Prevention'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with diabetes exhibit poor wound healing and have a higher incidence of surgical site infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/6\">",
"       6",
"      </a>",
"      ]. They may also be more susceptible to sternal ischemia with harvest of the internal thoracic artery, particularly if bilateral [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/9\">",
"       9",
"      </a>",
"      ]. Improved perioperative glycemic control decreases wound infection rates in patients with diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/6,29-31\">",
"       6,29-31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H391486152\">",
"       'Prevention'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1318322\">",
"       'Internal thoracic (mammary) artery harvest'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H704058\">",
"    <span class=\"h1\">",
"     STERNAL CLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;To access the mediastinum, the sternum is divided with a surgical saw longitudinally in the midline (eg, coronary artery bypass) or transversely (eg, clamshell incision for bilateral thoracotomy). At the completion of the procedure, the sternal edges are reapproximated, usually with sternal wires, although other permanent suture materials have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/32\">",
"     32",
"    </a>",
"    ]. Sternal closure in low-risk patients is generally accomplished with simple (transsternal or peristernal) closure; however, prophylactic sternal reinforcement techniques (wiring or rigid fixation) may decrease the risk for sternal dehiscence in patients with risk factors. The subcutaneous tissues are typically closed with absorbable sutures and the skin closed in a subcuticular fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1319298\">",
"     'Risk factors for sternal wound complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H704065\">",
"    <span class=\"h2\">",
"     Sternal wiring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common wiring technique passes stainless steel wires through the sternum (transsternal) about 2 to 3 cm from the sternal edge. The ends of the wires are twisted anteriorly to draw the sternal edges together. Various wire sizes, numbers and configurations (eg, simple, figure of eight) have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Comparative prospective trials have not been performed to determine the optimal closure methods for specific sternal wound types.",
"   </p>",
"   <p>",
"    A wire cerclage technique&nbsp;passes wires around the sternum (peristernal) instead of through it (transsternal) (",
"    <a class=\"graphic graphic_figure graphicRef56237 \" href=\"UTD.htm?35/50/36655\">",
"     figure 1",
"    </a>",
"    ). Several variations of wire cerclage have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/22,37-39\">",
"     22,37-39",
"    </a>",
"    ]. As an example, with the Robicsek technique, the wires are weaved through the intercostal spaces parasternally with cerclage wires that are placed lateral to the woven wire (",
"    <a class=\"graphic graphic_figure graphicRef70037 \" href=\"UTD.htm?3/14/3299\">",
"     figure 2",
"    </a>",
"    ). Based upon observational studies, cerclage techniques appear to increase the strength and stability of sternal closure, but a clear benefit for more complicated wiring schemes over simple wire cerclage has not been established in randomized trials. Nevertheless, high-risk patients may benefit from prophylactic sternal reinforcement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review comparing sternal dehiscence rates in obese (BMI &gt;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and nonobese heart surgery patients used routine wire closure, figure-of-eight wiring or the Robicsek technique [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/40\">",
"       40",
"      </a>",
"      ]. The rates of sternal dehiscence were 6.5 percent, 1.6 percent and 0 percent, respectively. &nbsp;",
"     </li>",
"     <li>",
"      In a prospective study of 200 patients, Robicsek closure significantly decreased the incidence of sternal dehiscence compared with standard wire closure (2.5 versus 12.5 percent) for patients with two or more risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial, 700 patients were assigned to transsternal wiring or cerclage wiring with a double criss-cross technique; the double criss-cross technique was associated with a small but significantly decreased incidence of superficial and deep sternal wound infection (superficial: 0 versus 2 percent; deep: 0 versus 1.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second trial randomly assigned 815 high-risk patients to Robicsek closure or conventional wiring; there was no significant difference in the incidence of sternal dehiscence (3.7 versus 2.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H704072\">",
"    <span class=\"h2\">",
"     Rigid sternal fixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigid sternal fixation can be accomplished with sternal bands or sternal plates. Steel bands are composed of thin, wide pieces of steel that are placed below the manubrium in the intercostal spaces. Small trials have found decreased postoperative pain and decreased length of stay, but sternal banding does not appear to alter the risk for sternal wound complications and sternal wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/17,41-44\">",
"     17,41-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, one to four rigid anterior plates can be attached with screws across the sternum (",
"    <a class=\"graphic graphic_figure graphicRef79865 \" href=\"UTD.htm?36/52/37711\">",
"     figure 3",
"    </a>",
"    ). Some systems will extend plates to the ribs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/45\">",
"     45",
"    </a>",
"    ]. In a cadaver model, sternal plating increased sternal stability compared with wire cerclage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/46\">",
"     46",
"    </a>",
"    ]. Small retrospective reviews comparing sternal plating with wire closure suggest that plating may decrease the incidence of wound complications and mediastinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. However, sternal plating systems are expensive and may be justified for primary closure only in high-risk patients following longitudinal sternotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For transverse sternotomy, the use of sternal plating for primary closure has been associated with decreased rates of dehiscence compared with historical controls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/2,50\">",
"     2,50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1319298\">",
"     'Risk factors for sternal wound complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318308\">",
"    <span class=\"h2\">",
"     Technical considerations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318315\">",
"    <span class=\"h3\">",
"     Hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding from sternal edges during surgery is controlled by a variety of hemostatic agents. Electrocautery is commonly used to control bleeding from the subcutaneous tissues and bone edges. Minimization of electrocautery during sternotomy may improve wound perfusion and decrease wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone wax is an inert substance that was commonly used in the past to control sternal bleeding. However, bone wax does not degrade over time, may inhibit bone growth, and excessive use has been speculated to contribute to sternal nonhealing. The only randomized trial evaluating bone wax found no increase in sternal infection rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/51\">",
"     51",
"    </a>",
"    ]. Nevertheless, the availability of alternative hemostatic agents (eg, thrombin) has diminished the use of bone wax [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17769?source=see_link\">",
"     \"Overview of topical hemostatic agents used in the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318322\">",
"    <span class=\"h3\">",
"     Internal thoracic (mammary) artery harvest",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal thoracic artery is a superior conduit for coronary artery bypass grafting because of a higher rate of graft patency compared with a saphenous vein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link&amp;anchor=H2#H2\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Choice of graft'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a primate model, harvesting the internal thoracic artery decreased sternal blood flow by 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/53\">",
"     53",
"    </a>",
"    ]. In the clinical setting, this degree of blood flow reduction is probably not sustained. Even so, parasternal ischemia from internal thoracic artery harvest (especially bilateral harvest) is felt to diminish wound healing, potentially contributing to sternal wound complications, particularly in high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/6,54-56\">",
"     6,54-56",
"    </a>",
"    ]. However, some clinicians feel that using &ldquo;skeletonized internal mammary arteries&rdquo; may decrease the risk for ischemia. In one retrospective review of 560 patients undergoing bilateral skeletonized mammary artery grafts, the incidence of postoperative sternal wound complication was low at 1.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review of 6504 patients found no difference in the risk of sternal wound complications (eg, mediastinitis) in patients without diabetes who underwent bilateral internal thoracic artery harvest compared with either unilateral harvest or no harvest (eg, valve surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/6\">",
"     6",
"    </a>",
"    ]. However, those with diabetes who underwent bilateral internal thoracic artery harvesting had a significantly increased risk (relative risk 5.0, 95% CI 2.4-10.5).",
"   </p>",
"   <p>",
"    The Arterial (ART) Revascularization trial that randomly assigned 3102 patients to bilateral or single internal mammary artery harvest (SIMA, BIMA) found a significantly increased overall risk (relative risk 3.24, 95% CI 1.54-6.83) in the need for sternal wound reconstruction for those undergoing bilateral harvest at six weeks from randomization. There were no differences in the incidence in the need for sternal reconstruction in patients with and without diabetes for each group. Of note, the percentage of patients who did not receive the allocated treatment was 3.4 percent in the SIMA group and 15.5 percent in the BIMA group. In the BIMA group, vessel unsuitability due to size or condition, patient status, surgeon preference (n &frac14; 54, 23 percent), unsuitable coronary anatomy or other reason were cited as reasons not to perform BIMA. Whether patient obesity or diabetes factored into these reasons is not given.",
"   </p>",
"   <p>",
"    Other retrospective studies have not identified bilateral internal thoracic harvesting as an independent risk factor for sternal wound complications in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/11,58,59\">",
"     11,58,59",
"    </a>",
"    ]. Nevertheless, bilateral internal thoracic harvesting is reserved for younger patients (&lt;55 years) without diabetes in many institutions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link&amp;anchor=H5#H5\">",
"     \"Postoperative mediastinitis after cardiac surgery\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318463\">",
"    <span class=\"h2\">",
"     Experimental techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic placement of antibiotic-impregnated collagen implants just prior to closure has not been found in randomized trials to significantly alter wound complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. However, prophylactic placement of a silver-impregnated surgical dressing was found in a retrospective study to be associated with a small but significant reduction in the incidence of deep sternal wound infection (ie, mediastinitis) (0 versus 1 percent in controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/63\">",
"     63",
"    </a>",
"    ]. Antibiotic-coated sutures have also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other techniques that have been studied include the use of specialized tape (ie, Mersilene&reg;), reinforcement of wire or band closure with specialized clips, and a post-sternotomy vest to decrease stress on the sternal closure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/17,65-68\">",
"     17,65-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104702659\">",
"    <span class=\"h1\">",
"     WOUND ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early detection and treatment of sternal wound breakdown or sternal instability may prevent subsequent complications, such as infection or nonunion. When a sternal wound complication is identified, plain chest radiographs of the sternum (eg, lateral view) should be obtained to evaluate the integrity of the sternal closure. Findings of sternal separation, fractured or malpositioned wires, sternal fracture, or pseudoarthrosis are indicative of sternal dehiscence. Wound cultures are obtained for most sternal wound complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link&amp;anchor=H3#H3\">",
"     \"Postoperative mediastinitis after cardiac surgery\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with any surgical site, sternal wound failure can be limited to the superficial tissues or extend deeply through all layers of the closure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Soft tissue dehiscence &ndash; Soft tissue dehiscence refers to separation of the superficial tissues (ie, skin, subcutaneous fat, muscle) and occurs in 6 to 8 percent of patients undergoing cardiac surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/69\">",
"       69",
"      </a>",
"      ]. The sternum is stable to palpation. Although soft tissue dehiscence is considered a minor complication, sternal wires can become exposed and proper management is important to prevent further complications. If significant wound drainage is present or the patient has systemic symptoms (eg, fever, chills), deep sternal wound infection must be presumed even in the absence of sternal instability [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sternal dehiscence &ndash; Sternal dehiscence refers to the separation of the edges of the sternum from one another and can occur in the absence of soft tissue dehiscence. Patients may complain of a painful chest motion and \"clicking\" [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/71\">",
"       71",
"      </a>",
"      ]. The diagnosis is made on physical examination by placing each hand on either side of the sternum and having the patient cough; this will cause a click, or &ldquo;rocking&rdquo; of the sternum. Sternal dehiscence is considered a surgical emergency, since affected patients have an increased risk of ventricular rupture due to sharp wires or bone fragments rubbing against the heart. When sternal dehiscence occurs in the early postoperative period, the patient is taken to the operating room for exploration. (See",
"      <a class=\"local\" href=\"#H391486145\">",
"       'Surgical management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Deep sternal wound infection &ndash; Deep sternal wound infection, also known as mediastinitis, is a surgical emergency and can result from of an overlying soft tissue dehiscence, or due to intraoperative contamination of the deeper tissues. The patient typically presents with fever and systemic symptoms within several weeks of the surgery with or without local symptoms or signs of superficial soft tissue dehiscence, sternal dehiscence or wound infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/72\">",
"       72",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If deep sternal wound infection is suspected but not clinically apparent, computed tomography (CT) of the chest may show changes in the configuration of the bone, or the presence of fluid or abscess which can be aspirated for culture [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/73\">",
"       73",
"      </a>",
"      ]. The microbiologic diagnosis of mediastinitis is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link&amp;anchor=H7#H7\">",
"       \"Postoperative mediastinitis after cardiac surgery\", section on 'Clinical features'",
"      </a>",
"      .) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H391486145\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most&nbsp;patients suspected of having deep sternal wound infection (DSWI, also known as mediastinitis) on the basis of wound separation, wound drainage, sternal instability, systemic toxicity, chest radiography, CT findings, or positive results from wound or percutaneous culture should be taken to the operating room urgently for debridement and initiated on broad-spectrum antibiotic therapy with subsequent coverage based upon the results of wound culture and sensitivity. Antibiotic management in the treatment of DSWI is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link&amp;anchor=H11#H11\">",
"     \"Postoperative mediastinitis after cardiac surgery\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical treatment of DSWI is individualized based upon basic wound care principles and sound surgical judgment. The variability in presentation and clinical course limits the ability to develop consensus guidelines for management. In our experience, debridement of all nonviable tissue is essential. The sternum can be re-wired or plated if adequate bone stock is present and infection is absent. Flap closure is reserved for patients who have an inadequate amount of bone after debridement or if there is uncertainty whether the infectious process is controlled. (See",
"    <a class=\"local\" href=\"#H104691668\">",
"     'Sternal flap closure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104697597\">",
"    <span class=\"h2\">",
"     Debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical debridement is the mainstay of therapy for postoperative sternal wound complications. The exploration of the sternal wound in suspected dehiscence should be performed in an operating room equipped for complex cardiac surgical procedures with the availability of blood transfusion, defibrillation, and cardiopulmonary bypass. Sternal debridement and closure are often performed as a collaborative effort between the cardiac and plastic surgery services.",
"   </p>",
"   <p>",
"    All devitalized tissue is thoroughly debrided and foreign materials should be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/5\">",
"     5",
"    </a>",
"    ]. Recurrent infection or a chronic draining sinus tract can develop in wounds with residual nonviable tissue, infected bone or cartilage, or foreign material. Sternal plates are not removed unless they can be palpated or are overtly exposed. Any sharp bone edges should be filed down to minimize the risk of damage to the heart. We use pulse lavage with antibiotics although there are no randomized trials evaluating its effectiveness in sternal debridement.",
"   </p>",
"   <p>",
"    In the past, some surgeons advocated total sternectomy for all patients. Although this procedure is effective in clearing the infection, it is associated with significant morbidity from chest wall instability. Sternectomy can usually be avoided by judicious debridement and management of the open sternal wound until subsequent closure can be performed. If the sternum requires complete resection, the chest defect can be managed with immediate or delayed flap closure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H104691668\">",
"     'Sternal flap closure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104699968\">",
"    <span class=\"h2\">",
"     Deep wound culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep wound gram stain and cultures should be taken, whenever possible, even if wound failure appears to be superficial. Staphylococcus aureus and coagulase negative staphylococcus are the most common bacteria isolated from deep surgical wound infections and antibiotic therapy is initially targeted to cover these organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/74\">",
"     74",
"    </a>",
"    ]. Subsequent treatment is based upon the results of the wound cultures and sensitivity testing. The microbiologic diagnosis and antibiotic treatment of postoperative mediastinitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link&amp;anchor=H3#H3\">",
"     \"Postoperative mediastinitis after cardiac surgery\", section on 'Microbiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link&amp;anchor=H11#H11\">",
"     \"Postoperative mediastinitis after cardiac surgery\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104700157\">",
"    <span class=\"h2\">",
"     Re-closure versus delayed closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following debridement, the sternum can be closed immediately, or following an interval of open wound management. The choice of immediate or delayed closure is a matter of surgical judgment that is influenced by the operative findings and available surgical expertise. For example, a thin patient with intact sternal edges that readily come together would be more amenable to sternal closure than an obese patient with a highly fragmented sternum. Patients who are not candidates for immediate closure because of high anesthetic risk are treated with sternal wound dressing changes. (See",
"    <a class=\"local\" href=\"#H280139\">",
"     'Sternal dressings'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sternal re-closure, whether immediate or delayed, is accomplished with wire cerclage or rigid fixation (described above) or with flap closure provided infection is not present. For malunion of the bony edges with an intact sternum, simple rewiring with a figure-of-eight or cerclage technique is usually sufficient (",
"    <a class=\"graphic graphic_figure graphicRef56237 \" href=\"UTD.htm?35/50/36655\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For sternal malunion with multiple wire fractures, additional stability can be achieved with the Robicsek technique (",
"    <a class=\"graphic graphic_figure graphicRef70037 \" href=\"UTD.htm?3/14/3299\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/40\">",
"     40",
"    </a>",
"    ]. Steel bands or titanium plates (",
"    <a class=\"graphic graphic_figure graphicRef79865 \" href=\"UTD.htm?36/52/37711\">",
"     figure 3",
"    </a>",
"    ) can be used to improve the strength and stability of the closure if the sternum is intact and the patient is high risk, multiple sternal fractures are present or if the transsternal wires ripped through the bone due to poor bone quality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/3,41,47,75\">",
"     3,41,47,75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H704058\">",
"     'Sternal closure'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H104691668\">",
"     'Sternal flap closure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104697611\">",
"    <span class=\"h2\">",
"     Management of the open sternum",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are not candidates for immediate primary sternal or flap closure due to the need for repeat debridement for ongoing infection, the open sternum can be managed with conventional gauze dressings with or without closed, antibiotic irrigation, or alternatively using negative pressure wound therapy, also known as vacuum assisted closure, while awaiting delayed closure. (See",
"    <a class=\"local\" href=\"#H104698238\">",
"     'Negative pressure wound therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who are medically unstable or unwilling to undergo additional surgery can continue with sternal dressings, but this approach leads to prolonged hospitalization and increases the risk for chronic infection and ventricular rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H280139\">",
"    <span class=\"h3\">",
"     Sternal dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sternum is dressed by placing moist saline-soaked gauze over a barrier dressing (eg, petrolatum gauze) that protects the beating heart. Soft suction drains may be placed into the wound in a position that minimizes contact with the heart. The entire wound is then covered with an elastic barrier dressing (eg, Steri-drape&reg;). For noninfected wounds, these dressing are changed in the operating room, usually every one to three days until delayed closure can be accomplished. Infected wounds require more frequent dressing changes (up to four times daily, depending upon the degree of purulence). When frequent dressing changes are needed, the dressing is often changed at the bedside.",
"   </p>",
"   <p>",
"    An alternative method uses closed continuous wound irrigation via large irrigation tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/76\">",
"     76",
"    </a>",
"    ]. To our knowledge, there is no proven efficacy for irrigation with antibiotics or disinfectant solution and these agents may be toxic to tissue leading to delayed wound healing. Also, with longer-term iodine irrigation, patients may develop other complications that include iodine toxicity seizures, metabolic acidosis, or renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104698238\">",
"    <span class=\"h3\">",
"     Negative pressure wound therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative pressure wound therapy (NPWT), also called vacuum-assisted wound closure, refers to a wound dressing system that continuously or intermittently applies subatmospheric pressure to the surface of a wound. NPWT stabilizes the chest wall, removes excess fluid and facilitates wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/8,78-80\">",
"     8,78-80",
"    </a>",
"    ]. The increased blood flow demonstrated for other wound models has been confirmed in a porcine sternotomy model [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/81\">",
"     81",
"    </a>",
"    ]. Respiratory mechanics are not impaired as a result of the application of subatmospheric pressure to mediastinal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. The general mechanism of action of NPWT and placement and management of the NPWT device are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although NPWT is associated with decreased times to delayed closure and may reduce overall patient mortality, a small number of deaths have been reported in association with this therapy, primarily due to cardiac rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/84\">",
"     84",
"    </a>",
"    ]. It is important to provide a barrier dressing between the gauze or foam and the heart to minimize the delivery of excessive negative pressure to the heart muscle.",
"   </p>",
"   <p>",
"    NPWT has become a popular treatment modality for the management of many acute and chronic wounds including sternal wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/85\">",
"     85",
"    </a>",
"    ]. In one questionnaire, nearly two-thirds of cardiac surgeons stated that they use NPWT to control the open sternal wound until primary closure or myocutaneous flap coverage can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/86\">",
"     86",
"    </a>",
"    ]. Following debridement, NPWT dressings are typically needed for 2 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/8,19,87\">",
"     8,19,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal frequency and duration of NPWT dressings has not been determined. As with gauze dressing, most clinicians use NPWT as a bridge to surgical closure, discontinuing the dressing when the wound is clean and has started to granulate. In patients who are not candidates for surgical closure, NPWT has been used to completely heal the sternal wound.",
"   </p>",
"   <p>",
"    There are no randomized trials comparing NPWT to standard therapy (eg, debridement with either immediate or delayed sternal closure over drains). The available evidence, consisting of retrospective reviews, suggests that NPWT is a reasonable option for managing open wounds following sternal debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/19,79,80,88-95\">",
"     19,79,80,88-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one of the largest series, NPWT was compared with standard therapy in 68 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/94\">",
"       94",
"      </a>",
"      ]. Patients in the NPWT group had a significantly shorter time to bacteriologic cure, reduced in-hospital stay, and reduced percentage of patients discharged with an open sternum. A reduced need for myocutaneous flap coverage has not been consistently demonstrated; however, the time interval between debridement and closure (either primary or flap coverage) appears to be shorter [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of NPWT may reduce overall mortality in patients with deep sternal wound infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/90,94\">",
"       90,94",
"      </a>",
"      ]. One retrospective analysis of 118 patients with post-sternotomy mediastinitis, found that mortality with NPWT was 6 percent, compared with 25 percent in patients treated with conventional therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/90\">",
"       90",
"      </a>",
"      ]. The groups were similar with respect to the type of their initial surgical procedure (ie, coronary artery bypass, valve placement) and risk factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104691668\">",
"    <span class=\"h2\">",
"     Sternal flap closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several options for sternal reconstruction are available for use following debridement, either for immediate or delayed closure. Flap closure is usually accomplished without bony re-approximation. For most patients, the resulting scar tissue leads to a stable anterior chest wall. Bone grafts are rarely needed, and because of the elasticity of the chest skin, skin grafts are also uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications associated with flap closure include hematoma, flap dehiscence, partial or complete flap necrosis, and recurrent wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/96\">",
"     96",
"    </a>",
"    ]. However, the incidence of recurrent wound infection is lower for flap closure compared with other wound management strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/8,96,97\">",
"     8,96,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pectoralis major muscle has become the preferred flap for the closure of anterior chest wall defects. A portion of the muscle, based upon the thoracoacromial artery, is detached from the sternum and advanced into the superior mediastinal defect. A larger portion of the muscle can be taken using perforators off the internal thoracic artery as a turnover flap. However, turnover flaps are unreliable in patients who have had the internal thoracic artery harvested as a bypass conduit.",
"   </p>",
"   <p>",
"    Bilateral pectoral flaps are frequently used for large defects (",
"    <a class=\"graphic graphic_figure graphicRef58711 \" href=\"UTD.htm?30/50/31522\">",
"     figure 4",
"    </a>",
"    ). In a series of 24 patients with sternal nonunion, the use of bilateral pectoralis flaps significantly improved patient symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Omental flaps are rich in blood supply and contour well to irregular defects [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. They can be harvested expeditiously with little morbidity. The omentum is pulled up through an opening in the central diaphragm and placed into the mediastinal defect (",
"    <a class=\"graphic graphic_figure graphicRef79083 \" href=\"UTD.htm?43/46/44770\">",
"     figure 5",
"    </a>",
"    ). Potential complications unique to this technique include injury to abdominal organs, and gastrointestinal obstruction due to diaphragmatic hernia, abdominal incisional hernia, or postoperative peritoneal adhesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=see_link\">",
"     \"Small bowel obstruction: Causes and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Omental and pectoralis flaps can be used together to fill larger defects (",
"    <a class=\"graphic graphic_figure graphicRef58711 \" href=\"UTD.htm?30/50/31522\">",
"     figure 4",
"    </a>",
"    ). Other muscles including the latissimus dorsi and rectus abdominis muscle have been used successfully as muscle or myocutaneous flaps when other flap options are not available. The rectus abdominis may be preferred when the defect is at the lower margin of the sternum [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1323136\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients requiring surgery for sternal wound infection will stay in the hospital until they can get up and move around and chest tubes are removed, which typically occurs three to five days after surgery. Antibiotics are continued for six to eight weeks if there is residual bone involvement. It is uncommon to have a recurrent infection with adequate management consisting of thorough debridement and antibiotics. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link&amp;anchor=H11#H11\">",
"     \"Postoperative mediastinitis after cardiac surgery\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients regain their baseline quality of life. In a small percentage of patients with flaps, chest wall instability can be uncomfortable, particularly in certain positions such as lying on the side. In young muscular men, significant disfigurement and loss of arm strength can result when pectoralis major turnover flaps are used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H391486152\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative measures that can reduce the incidence sternal wound dehiscence and infection include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/103\">",
"     103",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follow all recommendations for preventing surgical site infection. Prior to any cardiac or thoracic procedure, prophylactic antibiotics should be administered. Antibiotic choice and timing and other measures to prevent surgical site infection are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"       \"Overview of control measures to prevent surgical site infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assess the patient&rsquo;s risk factors (anatomic and medical) for sternal wound complications and choose an appropriate technique for primary sternal closure. For high-risk patients, prophylactic sternal reinforcement or minimally invasive surgical methods that avoid sternotomy should be used. Meticulous surgical technique is essential to minimize sternal asymmetry and provide adequate hemostasis without the excessive use of electrocautery. Avoid bilateral internal thoracic harvesting in high-risk patients, whenever possible. (See",
"      <a class=\"local\" href=\"#H704058\">",
"       'Sternal closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimize glycemic control. The risk of sternal wound infection can be significantly reduced by improving perioperative glycemic control in patients with diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/10,14,104,105\">",
"       10,14,104,105",
"      </a>",
"      ]. The management of glucose levels in patients with diabetes is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32502?source=see_link\">",
"       \"Susceptibility to infections in persons with diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=see_link\">",
"       \"Perioperative management of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Encourage smoking cessation prior to surgery, which may decrease the risk for wound complications [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/106\">",
"       106",
"      </a>",
"      ]. Smoking should be discontinued at least six weeks before the planned surgery to achieve significant benefit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5177?source=see_link\">",
"       \"Wound healing and risk factors for non-healing\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link&amp;anchor=H4#H4\">",
"       \"Strategies to reduce postoperative pulmonary complications\", section on 'Smoking cessation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Optimize nutritional status. Malnutrition is associated with an increased susceptibility to infection and poor wound healing [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/72\">",
"       72",
"      </a>",
"      ]. Preoperative hypoalbuminemia, which is often a reflection of impaired nutritional status, is associated with an increased risk for sternal wound complications [",
"      <a class=\"abstract\" href=\"UTD.htm?14/32/14858/abstract/14,72\">",
"       14,72",
"      </a>",
"      ]. The assessment of, and measures to improve, nutritional status in surgical patients are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=see_link\">",
"       \"Perioperative nutritional support\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H391486159\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sternal dehiscence is an infrequent but serious complication that is often a precursor to mediastinitis. Although the incidence of sternal wound complications has decreased, the mortality rate for deep sternal wound infection (ie, mediastinitis) remains high. (See",
"      <a class=\"local\" href=\"#H391486116\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of sternal wound complications is multifactorial. Any factor that contributes to poor wound or bone healing (eg, osteopenia, malnutrition) or increases the risk for surgical site infection (eg, poorly controlled diabetes, immunosuppression) may be clinically important. Other risk factors include the need for cardiopulmonary bypass, obesity, preoperative chest wall deformity and smoking. Technical factors that lead to poor sternal union or bone ischemia (eg, electrocautery, internal thoracic artery harvest) and perioperative factors such as prolonged operative time, the need for chest compressions, postoperative bleeding, transfusion and reoperation also increase the risk. (See",
"      <a class=\"local\" href=\"#H1319298\">",
"       'Risk factors for sternal wound complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with one or more risk factors for sternal dehiscence, we suggest a peristernal (cerclage) wiring technique over simple transsternal wiring for initial sternal closure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other surgical options for sternal closure in high-risk patients include prophylactic sternal reinforcement with specialized wiring or plating techniques. (See",
"      <a class=\"local\" href=\"#H1319298\">",
"       'Risk factors for sternal wound complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H704058\">",
"       'Sternal closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other surgical practices that decrease the risk for sternal wound complications include the appropriate administration of prophylactic antibiotics and other standard measures to control surgical site infection, and meticulous surgical technique with adequate hemostasis to minimize the need for transfusion or reoperation. Perioperative preventive measures that decrease wound complications include optimizing glycemic control in patients with diabetes, smoking cessation and optimizing nutritional status. (See",
"      <a class=\"local\" href=\"#H391486152\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sternal wound breakdown can be limited to the superficial tissues or extend deeply through all layers of the closure. Whenever sternal wound infection is suspected (eg, wound separation or drainage, sternal instability), broad-spectrum antibiotic therapy is initiated and the wound is explored. Deep wound gram stain and cultures should be taken, whenever possible, even if wound failure appears to be superficial. (See",
"      <a class=\"local\" href=\"#H104702659\">",
"       'Wound assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H391486145\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical debridement is the mainstay of therapy for postoperative sternal wound complications. Following debridement, the sternum can be closed immediately or following an interval of open wound management. The choice of immediate versus delayed closure depends on both patient and wound-related factors. The sternum can be re-wired or plated if adequate quality bone is present and infection is absent. (See",
"      <a class=\"local\" href=\"#H104700157\">",
"       'Re-closure versus delayed closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are not candidates for immediate sternal closure, traditional gauze dressings or negative pressure wound therapy systems can be used to manage the open sternal wound. Although negative pressure wound therapy is associated with decreased times to closure and may reduce overall patient mortality, a small number of deaths due to cardiac rupture have been reported as complications of this therapy. Clinicians should familiarize themselves with contraindications and proper use of negative pressure wound therapy systems prior to use in patients with sternal wounds. (See",
"      <a class=\"local\" href=\"#H104697611\">",
"       'Management of the open sternum'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"       \"Negative pressure wound therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Flap closure using omental or myocutaneous (pectoralis major, rectus, latissimus dorsi) flaps can be performed immediately following sternal debridement or after an interval of open wound management. Flap closure is reserved for patients who have an inadequate amount of bone after debridement or if there is uncertainty whether the infectious process is controlled. The muscle flap chosen depends upon the location and extent of the chest wall defect. (See",
"      <a class=\"local\" href=\"#H104691668\">",
"       'Sternal flap closure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/1\">",
"      Olbrecht VA, Barreiro CJ, Bonde PN, et al. Clinical outcomes of noninfectious sternal dehiscence after median sternotomy. Ann Thorac Surg 2006; 82:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/2\">",
"      Brown RP, Esmore DS, Lawson C. Improved sternal fixation in the transsternal bilateral thoracotomy incision. J Thorac Cardiovasc Surg 1996; 112:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/3\">",
"      Bertin KC, Rice RS, Doty DB, Jones KW. Repair of transverse sternal nonunions using metal plates and autogenous bone graft. Ann Thorac Surg 2002; 73:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/4\">",
"      McClure RS, Cohn LH, Wiegerinck E, et al. Early and late outcomes in minimally invasive mitral valve repair: an eleven-year experience in 707 patients. J Thorac Cardiovasc Surg 2009; 137:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/5\">",
"      El Oakley RM, Wright JE. Postoperative mediastinitis: classification and management. Ann Thorac Surg 1996; 61:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/6\">",
"      Loop FD, Lytle BW, Cosgrove DM, et al. J. Maxwell Chamberlain memorial paper. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. Ann Thorac Surg 1990; 49:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/7\">",
"      Trouillet JL, Vuagnat A, Combes A, et al. Acute poststernotomy mediastinitis managed with debridement and closed-drainage aspiration: factors associated with death in the intensive care unit. J Thorac Cardiovasc Surg 2005; 129:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/8\">",
"      Orgill, DP, Austen, WG, Butler, CE, et al. Guidelines for treatment of complex chest wounds with negative pressure wound therapy. Wounds 2004; .",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/9\">",
"      Mauermann WJ, Sampathkumar P, Thompson RL. Sternal wound infections. Best Pract Res Clin Anaesthesiol 2008; 22:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/10\">",
"      Matros E, Aranki SF, Bayer LR, et al. Reduction in incidence of deep sternal wound infections: random or real? J Thorac Cardiovasc Surg 2010; 139:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/11\">",
"      Wouters R, Wellens F, Vanermen H, et al. Sternitis and mediastinitis after coronary artery bypass grafting. Analysis of risk factors. Tex Heart Inst J 1994; 21:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/12\">",
"      Milano CA, Kesler K, Archibald N, et al. Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. Circulation 1995; 92:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/13\">",
"      Ottino G, De Paulis R, Pansini S, et al. Major sternal wound infection after open-heart surgery: a multivariate analysis of risk factors in 2,579 consecutive operative procedures. Ann Thorac Surg 1987; 44:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/14\">",
"      Nagachinta T, Stephens M, Reitz B, Polk BF. Risk factors for surgical-wound infection following cardiac surgery. J Infect Dis 1987; 156:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/15\">",
"      Gualis J, Fl&oacute;rez S, Tamayo E, et al. Risk factors for mediastinitis and endocarditis after cardiac surgery. Asian Cardiovasc Thorac Ann 2009; 17:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/16\">",
"      Liu JY, Birkmeyer NJ, Sanders JH, et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 2000; 102:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/17\">",
"      Okutan H, Tenekeci C, Kutsal A. The reinforced sternal closure system is reliable to use in elderly patients. J Card Surg 2005; 20:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/18\">",
"      Ko W, Lazenby WD, Zelano JA, et al. Effects of shaving methods and intraoperative irrigation on suppurative mediastinitis after bypass operations. Ann Thorac Surg 1992; 53:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/19\">",
"      Sj&ouml;gren J, Malmsj&ouml; M, Gustafsson R, Ingemansson R. Poststernotomy mediastinitis: a review of conventional surgical treatments, vacuum-assisted closure therapy and presentation of the Lund University Hospital mediastinitis algorithm. Eur J Cardiothorac Surg 2006; 30:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/20\">",
"      Losanoff JE, Richman BW, Jones JW. Disruption and infection of median sternotomy: a comprehensive review. Eur J Cardiothorac Surg 2002; 21:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/21\">",
"      Schimmer C, Sommer SP, Bensch M, et al. Sternal closure techniques and postoperative sternal wound complications in elderly patients. Eur J Cardiothorac Surg 2008; 34:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/22\">",
"      Schimmer C, Reents W, Berneder S, et al. Prevention of sternal dehiscence and infection in high-risk patients: a prospective randomized multicenter trial. Ann Thorac Surg 2008; 86:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/23\">",
"      Molina JE, Lew RS, Hyland KJ. Postoperative sternal dehiscence in obese patients: incidence and prevention. Ann Thorac Surg 2004; 78:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/24\">",
"      Lilienfeld DE, Vlahov D, Tenney JH, McLaughlin JS. Obesity and diabetes as risk factors for postoperative wound infections after cardiac surgery. Am J Infect Control 1988; 16:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/25\">",
"      Koshal A, Hendry P, Raman SV, Keon WJ. Should obese patients not undergo coronary artery surgery? Can J Surg 1985; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/26\">",
"      Copeland M, Senkowski C, Ulcickas M, et al. Breast size as a risk factor for sternal wound complications following cardiac surgery. Arch Surg 1994; 129:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/27\">",
"      McGregor WE, Trumble DR, Magovern JA. Mechanical analysis of midline sternotomy wound closure. J Thorac Cardiovasc Surg 1999; 117:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/28\">",
"      Nishida H, Grooters RK, Soltanzadeh H, et al. Discriminate use of electrocautery on the median sternotomy incision. A 0.16% wound infection rate. J Thorac Cardiovasc Surg 1991; 101:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/29\">",
"      Wilson SJ, Sexton DJ. Elevated preoperative fasting serum glucose levels increase the risk of postoperative mediastinitis in patients undergoing open heart surgery. Infect Control Hosp Epidemiol 2003; 24:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/30\">",
"      Zerr KJ, Furnary AP, Grunkemeier GL, et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997; 63:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/31\">",
"      Latham R, Lancaster AD, Covington JF, et al. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 2001; 22:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/32\">",
"      Luciani N, Anselmi A, Gandolfo F, et al. Polydioxanone sternal sutures for prevention of sternal dehiscence. J Card Surg 2006; 21:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/33\">",
"      Chughtai T, Chen LQ, Salasidis G, et al. Clips versus suture technique: is there a difference? Can J Cardiol 2000; 16:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/34\">",
"      Kiessling AH, Isgro F, Weisse U, et al. Advanced sternal closure to prevent dehiscence in obese patients. Ann Thorac Surg 2005; 80:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/35\">",
"      Ramzisham AR, Raflis AR, Khairulasri MG, et al. Figure-of-eight vs. interrupted sternal wire closure of median sternotomy. Asian Cardiovasc Thorac Ann 2009; 17:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/36\">",
"      Iriz E, Erer D, Koksal P, et al. Corpus sterni reinforcement improves the stability of primary sternal closure in high-risk patients. Surg Today 2007; 37:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/37\">",
"      Narang S, Banerjee A, Satsangi DK, Geelani MA. Sternal weave in high-risk patients to prevent noninfective sternal dehiscence. Asian Cardiovasc Thorac Ann 2009; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/38\">",
"      Bottio T, Rizzoli G, Vida V, et al. Double crisscross sternal wiring and chest wound infections: a prospective randomized study. J Thorac Cardiovasc Surg 2003; 126:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/39\">",
"      Sharma R, Puri D, Panigrahi BP, Virdi IS. A modified parasternal wire technique for prevention and treatment of sternal dehiscence. Ann Thorac Surg 2004; 77:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/40\">",
"      Robicsek F, Daugherty HK, Cook JW. The prevention and treatment of sternum separation following open-heart surgery. J Thorac Cardiovasc Surg 1977; 73:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/41\">",
"      Franco S, Herrera AM, Atehort&uacute;a M, et al. Use of steel bands in sternotomy closure: implications in high-risk cardiac surgical population. Interact Cardiovasc Thorac Surg 2009; 8:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/42\">",
"      Soroff HS, Hartman AR, Pak E, et al. Improved sternal closure using steel bands: early experience with three-year follow-up. Ann Thorac Surg 1996; 61:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/43\">",
"      Riess FC, Awwad N, Hoffmann B, et al. A steel band in addition to 8 wire cerclages reduces the risk of sternal dehiscence after median sternotomy. Heart Surg Forum 2004; 7:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/44\">",
"      Badellino M, Cavarocchi NC, Kolff J, et al. Sternotomy closure with Parham bands. J Card Surg 1988; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/45\">",
"      Raman J, Straus D, Song DH. Rigid plate fixation of the sternum. Ann Thorac Surg 2007; 84:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/46\">",
"      Fawzy H, Alhodaib N, Mazer CD, et al. Sternal plating for primary and secondary sternal closure; can it improve sternal stability? J Cardiothorac Surg 2009; 4:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/47\">",
"      Song DH, Lohman RF, Renucci JD, et al. Primary sternal plating in high-risk patients prevents mediastinitis. Eur J Cardiothorac Surg 2004; 26:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/48\">",
"      Snyder CW, Graham LA, Byers RE, Holman WL. Primary sternal plating to prevent sternal wound complications after cardiac surgery: early experience and patterns of failure. Interact Cardiovasc Thorac Surg 2009; 9:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/49\">",
"      L&oacute;pez Almod&oacute;var LF, Bustos G, Lima P, et al. Transverse plate fixation of sternum: a new sternal-sparing technique. Ann Thorac Surg 2008; 86:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/50\">",
"      Gandy KL, Moulton MJ. Sternal plating to prevent malunion of transverse sternotomy in lung transplantation. Ann Thorac Surg 2008; 86:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/51\">",
"      Prziborowski J, Hartrumpf M, Stock UA, et al. Is bonewax safe and does it help? Ann Thorac Surg 2008; 85:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/52\">",
"      Jackson MR. Fibrin sealants in surgical practice: An overview. Am J Surg 2001; 182:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/53\">",
"      Seyfer AE, Shriver CD, Miller TR, Graeber GM. Sternal blood flow after median sternotomy and mobilization of the internal mammary arteries. Surgery 1988; 104:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/54\">",
"      Grossi EA, Esposito R, Harris LJ, et al. Sternal wound infections and use of internal mammary artery grafts. J Thorac Cardiovasc Surg 1991; 102:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/55\">",
"      De Paulis R, de Notaris S, Scaffa R, et al. The effect of bilateral internal thoracic artery harvesting on superficial and deep sternal infection: The role of skeletonization. J Thorac Cardiovasc Surg 2005; 129:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/56\">",
"      Kouchoukos NT, Wareing TH, Murphy SF, et al. Risks of bilateral internal mammary artery bypass grafting. Ann Thorac Surg 1990; 49:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/57\">",
"      Bical O, Braunberger E, Fischer M, et al. Bilateral skeletonized mammary artery grafting: experience with 560 consecutive patients. Eur J Cardiothorac Surg 1996; 10:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/58\">",
"      Agrifoglio M, Trezzi M, Barili F, et al. Double vs single internal thoracic artery harvesting in diabetic patients: role in perioperative infection rate. J Cardiothorac Surg 2008; 3:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/59\">",
"      Walkes JC, Earle N, Reardon MJ, et al. Outcomes in single versus bilateral internal thoracic artery grafting in coronary artery bypass surgery. Curr Opin Cardiol 2002; 17:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/60\">",
"      Eklund AM. Prevention of sternal wound infections with locally administered gentamicin. APMIS 2007; 115:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/61\">",
"      Eklund AM, Valtonen M, Werkkala KA. Prophylaxis of sternal wound infections with gentamicin-collagen implant: randomized controlled study in cardiac surgery. J Hosp Infect 2005; 59:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/62\">",
"      Bennett-Guerrero E, Ferguson TB Jr, Lin M, et al. Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. JAMA 2010; 304:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/63\">",
"      Huckfeldt R, Redmond C, Mikkelson D, et al. A clinical trial to investigate the effect of silver nylon dressings on mediastinitis rates in postoperative cardiac sternotomy incisions. Ostomy Wound Manage 2008; 54:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/64\">",
"      Fleck T, Moidl R, Blacky A, et al. Triclosan-coated sutures for the reduction of sternal wound infections: economic considerations. Ann Thorac Surg 2007; 84:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/65\">",
"      Imagawa H, Nakano S, Kawachi K, et al. A prospective randomized study of sternal closure: comparison of Mersilene tape versus standard wire closure. Ann Thorac Cardiovasc Surg 2004; 10:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/66\">",
"      Sirivella S, Zikria EA, Ford WB, et al. Improved technique for closure of median sternotomy incision. Mersilene tapes versus standard wire closure. J Thorac Cardiovasc Surg 1987; 94:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/67\">",
"      Negri A, Manfredi J, Terrini A, et al. Prospective evaluation of a new sternal closure method with thermoreactive clips. Eur J Cardiothorac Surg 2002; 22:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/68\">",
"      Gorlitzer M, Folkmann S, Meinhart J, et al. A newly designed thorax support vest prevents sternum instability after median sternotomy. Eur J Cardiothorac Surg 2009; 36:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/69\">",
"      Zeitani J, Bertoldo F, Bassano C, et al. Superficial wound dehiscence after median sternotomy: surgical treatment versus secondary wound healing. Ann Thorac Surg 2004; 77:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/70\">",
"      Bor DH, Rose RM, Modlin JF, et al. Mediastinitis after cardiovascular surgery. Rev Infect Dis 1983; 5:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/71\">",
"      Chase CW, Franklin JD, Guest DP, Barker DE. Internal fixation of the sternum in median sternotomy dehiscence. Plast Reconstr Surg 1999; 103:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/72\">",
"      Gaynes R, Marosok R, Mowry-Hanley J, et al. Mediastinitis following coronary artery bypass surgery: a 3-year review. J Infect Dis 1991; 163:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/73\">",
"      Jolles H, Henry DA, Roberson JP, et al. Mediastinitis following median sternotomy: CT findings. Radiology 1996; 201:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/74\">",
"      Tom TS, Kruse MW, Reichman RT. Update: Methicillin-resistant Staphylococcus aureus screening and decolonization in cardiac surgery. Ann Thorac Surg 2009; 88:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/75\">",
"      Voss B, Bauernschmitt R, Will A, et al. Sternal reconstruction with titanium plates in complicated sternal dehiscence. Eur J Cardiothorac Surg 2008; 34:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/76\">",
"      Rand RP, Cochran RP, Aziz S, et al. Prospective trial of catheter irrigation and muscle flaps for sternal wound infection. Ann Thorac Surg 1998; 65:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/77\">",
"      Zec N, Donovan JW, Aufiero TX, et al. Seizures in a patient treated with continuous povidone-iodine mediastinal irrigation. N Engl J Med 1992; 326:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/78\">",
"      Bovill E, Banwell PE, Teot L, et al. Topical negative pressure wound therapy: a review of its role and guidelines for its use in the management of acute wounds. Int Wound J 2008; 5:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/79\">",
"      Song DH, Wu LC, Lohman RF, et al. Vacuum assisted closure for the treatment of sternal wounds: the bridge between d&eacute;bridement and definitive closure. Plast Reconstr Surg 2003; 111:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/80\">",
"      Sj&ouml;gren J, Gustafsson R, Nilsson J, et al. Clinical outcome after poststernotomy mediastinitis: vacuum-assisted closure versus conventional treatment. Ann Thorac Surg 2005; 79:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/81\">",
"      Wackenfors A, Gustafsson R, Sj&ouml;gren J, et al. Blood flow responses in the peristernal thoracic wall during vacuum-assisted closure therapy. Ann Thorac Surg 2005; 79:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/82\">",
"      Gustafsson R, Sj&ouml;gren J, Malmsj&ouml; M, et al. Vacuum-assisted closure of the sternotomy wound: respiratory mechanics and ventilation. Plast Reconstr Surg 2006; 117:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/83\">",
"      Conquest AM, Garofalo JH, Maziarz DM, et al. Hemodynamic effects of the vacuum-assisted closure device on open mediastinal wounds. J Surg Res 2003; 115:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/84\">",
"      Abu-Omar Y, Naik MJ, Catarino PA, Ratnatunga C. Right ventricular rupture during use of high-pressure suction drainage in the management of poststernotomy mediastinitis. Ann Thorac Surg 2003; 76:974; author reply 974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/85\">",
"      Harlan JW. Treatment of open sternal wounds with the vacuum-assisted closure system: a safe, reliable method. Plast Reconstr Surg 2002; 109:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/86\">",
"      Schimmer C, Sommer SP, Bensch M, et al. Management of poststernotomy mediastinitis: experience and results of different therapy modalities. Thorac Cardiovasc Surg 2008; 56:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/87\">",
"      Hersh RE, Jack JM, Dahman MI, et al. The vacuum-assisted closure device as a bridge to sternal wound closure. Ann Plast Surg 2001; 46:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/88\">",
"      Raja SG, Berg GA. Should vacuum-assisted closure therapy be routinely used for management of deep sternal wound infection after cardiac surgery? Interact Cardiovasc Thorac Surg 2007; 6:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/89\">",
"      Gustafsson RI, Sj&ouml;gren J, Ingemansson R. Deep sternal wound infection: a sternal-sparing technique with vacuum-assisted closure therapy. Ann Thorac Surg 2003; 76:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/90\">",
"      Petzina R, Hoffmann J, Navasardyan A, et al. Negative pressure wound therapy for post-sternotomy mediastinitis reduces mortality rate and sternal re-infection rate compared to conventional treatment. Eur J Cardiothorac Surg 2010; 38:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/91\">",
"      Fleck TM, Fleck M, Moidl R, et al. The vacuum-assisted closure system for the treatment of deep sternal wound infections after cardiac surgery. Ann Thorac Surg 2002; 74:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/92\">",
"      Agarwal JP, Ogilvie M, Wu LC, et al. Vacuum-assisted closure for sternal wounds: a first-line therapeutic management approach. Plast Reconstr Surg 2005; 116:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/93\">",
"      Luckraz H, Murphy F, Bryant S, et al. Vacuum-assisted closure as a treatment modality for infections after cardiac surgery. J Thorac Cardiovasc Surg 2003; 125:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/94\">",
"      Fuchs U, Zittermann A, Stuettgen B, et al. Clinical outcome of patients with deep sternal wound infection managed by vacuum-assisted closure compared to conventional therapy with open packing: a retrospective analysis. Ann Thorac Surg 2005; 79:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/95\">",
"      Catarino PA, Chamberlain MH, Wright NC, et al. High-pressure suction drainage via a polyurethane foam in the management of poststernotomy mediastinitis. Ann Thorac Surg 2000; 70:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/96\">",
"      Jones G, Jurkiewicz MJ, Bostwick J, et al. Management of the infected median sternotomy wound with muscle flaps. The Emory 20-year experience. Ann Surg 1997; 225:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/97\">",
"      Glower DD, Douglas JM Jr, Gaynor JW, et al. Candida mediastinitis after a cardiac operation. Ann Thorac Surg 1990; 49:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/98\">",
"      Cabbabe EB, Cabbabe SW. Surgical management of the symptomatic unstable sternum with pectoralis major muscle flaps. Plast Reconstr Surg 2009; 123:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/99\">",
"      Krabatsch T, Schmitt DV, Mohr FW, Hetzer R. Thoracic transposition of the greater omentum as an adjunct in the treatment of mediastinitis--pros and cons within the context of a randomised study. Eur J Surg Suppl 1999; :45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/100\">",
"      L&oacute;pez-Monjardin H, de-la-Pe&ntilde;a-Salcedo A, Mendoza-Mu&ntilde;oz M, et al. Omentum flap versus pectoralis major flap in the treatment of mediastinitis. Plast Reconstr Surg 1998; 101:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/101\">",
"      Stamatis G, Freitag L, Wencker M, Greschuchna D. Omentopexy and muscle transposition: two alternative methods in the treatment of pleural empyema and mediastinitis. Thorac Cardiovasc Surg 1994; 42:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/102\">",
"      Davison SP, Clemens MW, Armstrong D, et al. Sternotomy wounds: rectus flap versus modified pectoral reconstruction. Plast Reconstr Surg 2007; 120:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/103\">",
"      Trick WE, Scheckler WE, Tokars JI, et al. Modifiable risk factors associated with deep sternal site infection after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2000; 119:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/104\">",
"      Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/105\">",
"      Lazar HL, McDonnell M, Chipkin SR, et al. The Society of Thoracic Surgeons practice guideline series: Blood glucose management during adult cardiac surgery. Ann Thorac Surg 2009; 87:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/32/14858/abstract/106\">",
"      M&oslash;ller A, Villebro N. Interventions for preoperative smoking cessation. Cochrane Database Syst Rev 2005; :CD002294.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15123 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14858=[""].join("\n");
var outline_f14_32_14858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H391486159\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H391486116\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1319298\">",
"      RISK FACTORS FOR STERNAL WOUND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H704058\">",
"      STERNAL CLOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H704065\">",
"      Sternal wiring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H704072\">",
"      Rigid sternal fixation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1318308\">",
"      Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1318315\">",
"      - Hemostasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1318322\">",
"      - Internal thoracic (mammary) artery harvest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1318463\">",
"      Experimental techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104702659\">",
"      WOUND ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H391486145\">",
"      SURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104697597\">",
"      Debridement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104699968\">",
"      Deep wound culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104700157\">",
"      Re-closure versus delayed closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104697611\">",
"      Management of the open sternum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H280139\">",
"      - Sternal dressings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104698238\">",
"      - Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104691668\">",
"      Sternal flap closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1323136\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H391486152\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H391486159\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15123\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15123|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/50/36655\" title=\"figure 1\">",
"      Sternal wiring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/14/3299\" title=\"figure 2\">",
"      Robiscek sternal closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/52/37711\" title=\"figure 3\">",
"      Sternal plating",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/50/31522\" title=\"figure 4\">",
"      Bilateral pectoralis flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/46/44770\" title=\"figure 5\">",
"      Sternal space omental flap",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17769?source=related_link\">",
"      Overview of topical hemostatic agents used in the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=related_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=related_link\">",
"      Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32502?source=related_link\">",
"      Susceptibility to infections in persons with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5177?source=related_link\">",
"      Wound healing and risk factors for non-healing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_32_14859="Driving restrictions after an event";
var content_f14_32_14859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Driving restrictions after a medical event",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medical condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Wait time (months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Control of angina",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial infarction/coronary artery bypass graft",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmia with syncope",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient ischemic attack, single",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient ischemic attack, recurrent",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"       <td>",
"        6 to 12 months*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Laws vary from state to state.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Retchin, S, in Yoshikawa, Cobbs, Brummel-Smith, Practical Ambulatory Geriatrics, St. Louis, Mosby 1998, p 109.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14859=[""].join("\n");
var outline_f14_32_14859=null;
var title_f14_32_14860="Antivirals for influenza";
var content_f14_32_14860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended daily dosage of influenza antiviral medications for treatment and prophylaxis of adults - United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antiviral agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Zanamivir*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treatment, influenza A and B",
"       </td>",
"       <td>",
"        10 mg (2 inhalations) twice daily for five days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chemoprophylaxis, influenza A and B",
"       </td>",
"       <td>",
"        10 mg (2 inhalations) once daily",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Oseltamivir",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treatment, influenza A and B",
"       </td>",
"       <td>",
"        75 mg twice daily for five days",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chemoprophylaxis, influenza A and B",
"       </td>",
"       <td>",
"        75 mg once daily",
"        <sup>",
"         &Delta;&loz;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Zanamivir is administered through oral inhalation by using a plastic device included in the medication package. Patients will benefit from instruction and demonstration of the correct use of the device. Zanamivir is contraindicated in persons with asthma or chronic obstructive pulmonary disease.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Zanamivir should be used during outbreaks caused by oseltamivir-resistant influenza virus. It is important to assess the risk of oseltamivir-resistant influenza before choosing an antiviral drug for influenza prophylaxis. Clinicians should review local or state influenza surveillance data to determine which types of influenza (A or B) and subtypes (pandemic or seasonal H1N1; H3N2) of influenza A are circulating, as well as resistance patterns. This information, which is updated weekly, is available via the CDC through its website (www.cdc.gov/flu/weekly).",
"      <br>",
"       &Delta; Duration of prophylaxis depends upon several factors. (See \"Prevention of seasonal influenza in adults\").",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        A reduction in the dose of oseltamivir is recommended for persons with creatinine clearance &lt;30 mL/min.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Influenza Division, National Center, for Immunization, and Respiratory. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-28.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14860=[""].join("\n");
var outline_f14_32_14860=null;
var title_f14_32_14861="WHO brain tumor classification by histology and grade";
var content_f14_32_14861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO* classification of primary brain tumors according to histology and grade",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tumor classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tumor grade (WHO)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Astrocytic tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pilocytic astrocytoma",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diffuse astrocytoma",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic astrocytoma",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glioblastoma",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Oligodendroglial and oligoastrocytic tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oligodendroglioma",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic oligodendroglioma",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oligoastrocytoma",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic oligoastrocytoma",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glioblastoma with oligodendroglioma component",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Ependymal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subependymoma",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myxopapillary ependymoma",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ependymoma",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic ependymoma",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Choroid plexus tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choroid plexus papilloma",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choroid plexus carcinoma",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Neuronal and mixed neuronal-glial tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ganglioglioma",
"       </td>",
"       <td>",
"        I or II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Central neurocytoma",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Filum terminale paraganglioma",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysembryoplastic neuroepithelial tumor (DNET)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Pineal parenchymal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pineocytoma",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pineoblastoma",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Embryonal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medulloblastoma",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Supratentorial primitive neuroectodermal tumor (PNET)",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atypical teratoid/rhabdoid tumor",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Menigeal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Meningioma",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Atypical, clear cell, chordoid",
"       </td>",
"       <td class=\"sublist_other\">",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Rhabdoid, papillary, or anaplastic (malignant)",
"       </td>",
"       <td class=\"sublist_other\">",
"        III",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds.). World Health Organization Histological Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14861=[""].join("\n");
var outline_f14_32_14861=null;
var title_f14_32_14862="Tirofiban elevated troponin I";
var content_f14_32_14862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Tirofiban improves outcome in patients with a non-ST elevation ACS and a positive serum tropinin I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 376px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the PRISM trial, tirofiban significantly reduced the 30-day event rate in 629 patients with a non-ST elevation acute coronary syndrome (ACS) who had evidence of myocardial necrosis based upon a positive serum troponin I level (&ge;1 &micro;g/L) (4.9 versus 13 percent for heparin). The significant benefit of tirofiban was seen in patients managed medically (hazard ratio 0.30) and in those undergoing revascularization (hazard ratio 0.37).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Heeschen C, Hamm CW, Goldmann B, et al. Lancet 1999; 354:1757.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14862=[""].join("\n");
var outline_f14_32_14862=null;
var title_f14_32_14863="Airtraq device";
var content_f14_32_14863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Airtraq optical laryngoscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2XNGaSirEOzSg80ylzQA8Me9ODdqjzS5oAlDU7dz1qAk0u7nmiwFgNx7UbvyqFW5pwbmlYCYHNODY+lQbvSnA80WETBu1Lu/CogaXOKVgJQaUHFRA+9O3UAS5pwNQgnHtTlOaAJaBTM0uaAH5pfxpgNLmgB1A9aaKcOTQMcKXHSkFL1NMBaUUgp3Q4poApw60lKKoBad9KOR1p646nrQIQDr7UoHOOuacB144pVGP5UhiKPUU7HagDnr0pcUCADH4UuKB1p46ZxQA3FOA4zRjinqvHFFwEUfN7U5Rzg0oGD3pyj1NIAwOPWnAc8UoAI9qXFAwx+dFOA5opAcBSUvSiqEFFFFIYUtJR3oAWlzTaXNADs5wM0A03tRn8qBkganKSPWogaXNAiYNwacGqEH8qXP+TRYCXI9acDxxUQPf9acPrQBKDSg8mogfzp2cCkImDcYpQahB4p2aAJQc08e9RA8c0oNAyQU4VGDTs5oAeDTxUQI6U8HJoAfS5+lMB5pwOTmmA/t0pwximAjpTgfSmA8dyaeMk4HFM7Zp/bNADwOv0zS4OM0gORnFPx0oEAHNKOtAHP1pw96QBjpSgZpR0zSqMketAAo496eBgdKT+LtTwMnGKQCAYFPAoAHWnAUDClFAFKM9MUAAFFOA9aKVwPPcZopRSVQhKWg0UAHeiiigApaSigApaSloGFLSUo6UwFpc5pKKBj6UEUzNOB4pAPBNLmmdqUdKBD804H9Kb0oFAEgNOB4qIeg604GgCUN75pwbJqHNOBx0PNAiYHFOU1EDTgaBkoP60oNRg9qcp9KAJAxp+aZErO2F7d/SpGQIcGRM+lF7DsOHAzTwc9O1RYI6jj8809WxTETKeOetSA8+3pUCnOKlVs8AUASDr0zTgc0wHqPalBpCHgAn2py4OTk800dfenZ/SgB6+36U8DoaYuTjpT1B/CkMdSgUgpwpALjFLQKcOtAwA5opaKQHndBpKXFWSJ0pTzSYpaAEpce9FHegAHNFFLQAgo/nS0GgBKWjFLQAUUUUwFFAopfrQO47NKDTPxp1IB/ej0pBS0ALS9O9J2pRQA7NL0po9O1KDQA8GnKeKjpwPSgRIDTwahU1Ytlydx6L0+tD0GtSxFmMqO/U0roUcgjg8irunwLseaYZTGAD+pqvJIW4PzL6GoRZABz8vH0qVoWWJHOAGzjFJGi71JOEzySOlWpWSUt2A6D+tO4rFRTzipA2BTJRtYe/NIrVa1JehZBpymoFbAqRWzQBOp54+tOByDmogacCKLCJgfWngn04qFTzTwRmpAlXkDrinr9ajU8cYx/Kng9KQyQe1KKYD607PNIY6iiigDzukoNB4qyQpRRjiigQCloo60AFAopaAEFLRRTAKKXFFIBMUtFApgFKKABxS0AHtS0lLSGOH504dKYKdQAvSgfQ0UCgBe9KKQnpRQA7NSQIZZVjHGTUQ6VJDjzo933dwzihjRea2GDtAIHP0qW2h3skaU0gqzdia0bFRb2zTP8Aeb7orM02HXzqkYhTgKKoU52LMSTkk5oQUwsPDCOPHHNV48F8knYOTz2pZW3HFRTtsQIOC3J+nYUJXB6BJKZJC2MDsB2HpShsmoc9KUGtDMnDGpA9VgaeGpgWQ/FPD+tVQ3vT1bJ68UAWw/509WzxVVXzwakD8UWAuK1PVgR1qoGqRXwBk/nUtAWs04H0qurkVKr54pWAmBopqkZoqRnn34Uv40GirIEx60uKXtRQAmKWiigAopcUUAFFKBR9KADFGKXFKBTAQA0YxS4peaAG4pRS4oxQAlApaKAAUopBxS0gHUUgo7UALSikFGaAHUp6GmA0uQAScAdyegoA1V4CFhuXAz71cu7nzdoRcRqOBVW1VjaK7YIA9ccf400tzxwPSszYkU5NPY7VqNGAHTmkc570DG5ABZ+g5NVixZizE5PNSXTfIoB+XOT7mq9XFGcmSA0A1HnmlziqESg0oqLdTlagCYNTw3FQg/nTh70wJlbtTw1QKQaep5pgWFcZ4NSq3HWqgPNPD/XFAFsN0qRW44NU1fmpValYC4kg70VArZ6mipsBxxoNKOe1GO1AhKBTgKAKAEoxThRigQCjFOoxQAmKfHGznCKSevA6ClijMkqIMbmIFfK3xT+IupeK9TvbG1uJLfw5FK0UNrESouArY8yUjli2MhT8qjAxnJKlLlKjG57h4l+Kfg7w+Wim1X7fdKcGDTVE5B9C+Qg+m7NcNfftB2omYaX4Vnli/he7vljY/wDAVRsf99V4Gy7WIK7SONuMY/CkJ7isnUZfIj3yw/aCjadRqPhV0gJ+Z7S/Duo9ldAD+Yr0rwn498MeKgiaTqiLdt/y5Xf7icH0Ck4f/gBavjoSEZwM4pxkBHKhvrQqjDkR92MpRirggjsabjFfMnwu+LOoeG5007X5J9Q0A8Lk757T3jJ+8vqh/DHQ/Sum31nqmnW+oaXdRXlhcDdFPEcq3qPUEdCpwQeCBWsZKRm4tE3pQadSVQhBRS0E4FAB9aAc0n86AeOtAC0tNFLSAUH0pJYWkEQVS5LZ2DqRTlGWANaen4gSa+cA+X+7iX1Y9f8AD86lsqK6jEmWKxXLB5pXLtz90dh/WpIX81CQpAHXNZ2XeQ/xMxJOe5PWrhnEFuEeNxk8kDdk/hSsUmThQeVOPpSqjAjI3DOay2mmaYHDRRqMKDwSe5q1DeyJjdhx78U7MOZE12Cynau3+L6e1Uc1Yubnzhwm0d+c1VzVJWJk7vQWlzTCfzozj0qiSQNTgaizSg0BcnBp4JxUANPBpDJgfSnKelQhqeDTGSg04NUQNOBpgTKaercVBn1p4agCyj5FFQq3OaKAOeAopSKDUCEApfxoxS4oAMc0uPwoHWlxQAfzpaKXFAiS0BN3Bj++v86+HdXltn1/VJLd2js2ubgwNEgb5S7bMAkcEYGewOQDjFfU/wAYPGcXg3wlP5MuNb1GN4LCNT8yZGGmPoqAnHq20euPk2SE28KqykAqAmeBjjLfl+prKo7s1guojI2zzHfKouzzCxcMQMBFPcD16AfhmteTrbRjIBmYZVP7o9W/oPx6U67uPsqAsN0wH7tGOQgPOSP1A/E1iTMz5d2YsTkknJJ9SahIpsv6fqalhbX5XyHbInEYLwk9+OWX1U/hg1fuInt5fLk25YB0dWykinOGU9146+xBwQRXMN79K1NH1cWqfZb+JrnTmYtsDYeFj1eJudp9QflYAZBwpFOPYlPuaAHPBrqvAnjfWfBl8Z9JmVoZP+PiynyYbgf7QHRvR1wR7jIPPXFp5Nsl5bTJd6dIwRLlFxtYjISReTHJwflOQcEqzDmqqjkHIzUrQo+yfAPjrRfHFoW0t2g1KJN9zp0zDzYh0LL2kTP8Q6ZG4KTiuoIr4XtLq5sbqC6sriW2u4G3xTwuUeNh3DDoa+q/g98QP+E40SaLUfKTX7AL9qVAFWdDwsyr2yeGA4DYxgMANYzvozOUbHe0mPzpxFIa0IENMzTyKQjvQAgpR1zSUdBQBHKZmeNbY4lDAj654FXtRuQJxaW5/c2n7vIOcv1P5ZH60liBCkt5KBth+WMf3pD/AID+tUByepySSTnuTk/zqFq7mmysaVjksrsPmP3Qandw8jO/3Iv1aqKyy+XgbASMA4wQKHmLRomAqr6HOT6mnYlsVnLsWPekpuaXNUSPzTSaTNITTAXNApKKAHClzyKZS5oAkBpwNRA5pwP0pgTK1PBqAGnhqQXJgacDUINPBzQMlBFPFQg08HFMZKD0opinNFAGRiihaUdagBMUtFLQIAKbLJHBBLPcSxwwRIZJJZWCJGo6szHgAepp3evCf2mvEsqtp/he1kZYvLF9eqv8ZJIiU+oGGbHqVPYVMnZDSud9N8W/AMLsjeIVfacZhs53B+hCYP1rkfFHx706CNovCWmTXdychbrUR5UK+4jBLv8AQlfx6V8/zRD96EMJt0YsJ40JJVRzgnBI5BYY+X9DDMrQyeXtZZCB1HUHoV9Qazc2y+RGlrOr32q6pNqes3kl9q1xhnllIOwdgAOB14UDao7dqyL26FqWA+a7PJ3c7D6n1b27d/So7q7+ykpE2bjoz5z5fsP9r37fXpjk9O386lIbY5mZ2JYliTkknJJ71FKc+y1bsbVruQ8hIkG6V2bCqPUnt6ep7AmoNQeCS5xaBhCoC5bjcf72O30/matCKzHOPQUz61OkTyShI1LueijtUZT5jyDz+dMRa0rU7rS7lprOQKzqY5EdQ6SoSCUdWyrLkA4IPIB6gV09sbTWiDpS/Z7043aa7lt5/wCnd2OX9BGx39ADITxxh7Yp8ZJIXBbPGAOTScbjTsdU0bAHeCpHBVhgj2I7V1/wf1iTQ/iVoU6sRBPOLOdQcBo5iEOfoSrfVRXISTXE21rt3kuNoDyMdxJHqe5xgZ9q1vCSPc+JtHhjA8x763CgcY/erWa0K3Pth12MwPUHFMIqa45nk/3jUR9K6jAbRS4pKAEPeq9y7+fbwQDdNNIEQe+Ccn2Ayas9BnsKr6JzJe6y5DAZtLT06/Ow+rDH0SlJ6FRWpZ1N1R47SE5htxtz3Z/4if8APrVeJMsAenem4yck5PXNSqPkC936n0FCVgb6ils/N68L9KFNITluOnalzjimSKKXNNznp2pAfSgCTNNNNySeaTOKYDuwz2pQaYDznNLnk0wHg8UoNR56Z5FOzxjp9aAHUopoIpfbvQA7NPB6VHnigHmgCYGnK3rUAPang9KLAWFNOU1XDVKrUAmTA/jRUYPNFAzPFKKbmnCsxi0Yo70o6igBcV8m/G6R5vin4kd8/JMsS/7qxooH5AV9axJvkRM43EDPpXyH8Sr1fEGu33iK3jCW93dSxFAT8jR4Ck+7RhG+pbHSs6nQqBxKttO5Qu8DCkjJQ/3h7+9QX97IoJDYlkLHK/KsYPXYOiknk4/D2mcc1Bc263MW0/K4+6/b6H2rNFmOSO3p2qxaWoldjPIsMKDe7t12+w6knsO/sOaqzJJDIUkG1h1B/wA9KjO6RyepPrWhJc1C+89Ft7aMw2aHKx9S7dN7nu36DoPesNsKnK7pjxg9E/8Ar/y+vRNyxxgIcyngkjhfYe/v/wDrqeW4M8UcSQxwxgD5Ixyx9STye9GwiCDepwpYFhggHr7UyRsHb3HH0p7yBRsjPJ6sP5D/ABqKONpJFSNSzMcAAdaYAiliFVSzE4AFblhZC1+d8NOe4OQn0Pr7/lTrOwFny2GlIyXU5AB9P8f8myBgVEpX2KSDvwa6LwbcPpct7r64MmkQGeA4BH2hiEhGDwcO27HohrniuVJGcVseIz/Z+i2uhIQJ3db69Axw5UiJP+AozH6ye1Sij7B8HeIbfxZ4W07XLRdiXkW54858uQEh1/Bgw/CtivEP2XdSb/hF9VsZWPl2+oAgk9BLGD/6En/jxr3EjB6V0Rd0YNWY3FIRTqMc1QjG8RzTrbw2dg229vZBBCe4Zs/N/wABG5v+A1oTCK3ZNMshtsdOjW3Tj7zgfMc55wMA8dSap6OftXiO+1Z+bbS4jbW/o08mC5/4CgUf8CarfJ5Y5J5Jqd2VshFGWAP1P0qTPUnqfX0pijOff+VSe/aqRLEwAPag+tKaPbimAzoKCaD+NJQAfSkzSHNFMBaXNNFAoAcDS5/KmZopgPz1z0p2fwqLNKDQBKDSg9eKjB70uaYiSlzUWc04GgCUH3p4b1NQZ96dmkBYVqKhV6KLAQ06gUtZFXAU4U2nA0DJI2KSKw7EGvmXxzoK+B/FN9b6nZyXfhPVGyfI4dFJJRoyfuzRktgHhhkHg8fS4xWb4j0Wz8QaVJY38SSRsCAJBlTnqD3x7jkEAjkVM48yKi7Hxx4m0G50O4g8ySO6sLtDNY38I/dXkQONy+jDoyH5lPB7E4pBPFeqeIdHuvh9NdaTrlpcar4G1CYM8asBNazY+WaJ+iTgdD9yVQVYf3eF8Q6K+kTQNFcxX+mXamSx1GFSsd0gPPB5SRcgPGeVPqCCcbGhhXFulxDsl6j7rjqv+I9qzRpk++XzTHFFEu55i2VwRwF9SfQc+vetjAzjmkuIkuImjmUlRypHVT6imnYTRzaL3IpHk+XamQD1Pr/hUt/BJbSCNxlTyGHRx/ntUVtBJczCOFcsfwAHqT2FaeZA2GF55RHEpZz0AroLK1WzQgENKRhn/oPap7S0itItkZ3MfvyEfe9h6D2/yHEflUSlcpKw+Fkxsm3+UT95OWT3A7+47+oPNNnheFwDtdWBKSJkrIPUd/qDgjoQKaAQeOtaNpbQ21mb7VyyWTfNFBj5rhu2PQep7j25qSiTT2j0y1XVL1Fc5xaQN/y1fszd9o/z2zgT3Uk00s9xIZZ5WLySN1dj1JpuralNqV208wVBjCRr0jXso/z/AEAfo2ntqNw4YslrCN9xKP4V7Af7THgD8egJqrE3Pe/2d7Y2/g3U7tuPtd8Ng/2UTH82Ne66ZdfabfDHMseA3uOxryLwHJFZ6PFYxFQquWVR0CnGB+X8q7+yuXt5FljI3LwQehHpWkHoTNanUnrxWd4gv103Rbq6dd21CFUdWY8AD69Pxq7BMlxCJI87e4PVT6Vz2rSrqHjPR9IzmC0zqV36YTGxT9XKH6KatuyISu7Gta2B0zR9N053YzxA3F0QeJJ3yWz6gFjj8PQVI3QAdScU8y/aHabcH8w7sg5Bph+Z/YcD+tKKG2OQcZH4fSn4oFFWyBDSZpSKRqBjTxSGg0mfSmAlJS0lAg7UUfWjtTAM0maOtIeAaAHA0A0zNJn0pgS5ozTM0bqAJM0ufyqLdS7qAJQ3vS7ux5qHdQG5pgWAc0VEGopATgUUopccViMaKBTse1KRQFxBSk8UyjvQM57xzo13rekLDZw2t4EJ+0afcIAL6IjBiEhP7tgfmU8DcACV6185a/okvhG0nntY59Y8FX0uy4t58xTWsykqA+RmK4Q5VZMYPKupBKn6v6Vzfijw419JcahpccMl9NH5d5ZXGDBqMYGNrg8CQKAA3QgBW6KyxKPVFxl0Z8k6rpX2SGC+tLj7dpNyzLbXgTYSwALRSJk+XMuRlCemGUspBqh35/EV3nifQH8Jm51nw/A994Tu3WLUtLuy260cHiObB3LtJ+SYfMpbBPzAvyj2+nXnzaVfrGTybPUWWKaM+gk4jlAz975Sf7orI0Mx445I9k6B0PO0/wAxTYI4YEKQRrGp5OOSfqTzWidJvlPNrLn1GCPzHFKumXKk+agiGOrsABSuBR6H5eKSKKSeZUt0Z5G4CKMmrMv9n2rBLi5a4lxxHbjj8XPH5ZqOfWpRCYbJVt4j1jiPJ/336/gMUwLNyLPRVBvQl3fnlLRTlEPrIe+P7o4+tc9qV/c6jdPc3khkduAegUegHYU0RSSyZk5Ld6t6XpMt+7sXEFpEQJ7h1JWLPQADlnOOFHXGTgAkNaEvUg0fTZdTmdVdYraEBri4cHZEvYn1J6BRyT0rrLYRmJbWxR4bKPJCucvIx48xyOrH06KOB3JYUTbFa28RisISWjjJyWJ/5aOcfM5HfoOgwKuwRiPAxigNjutD1L7HPbzq2IxgMMdMDFer2dwtxAroRyM8V4BYXSqxhlOYpOK7nwTr5trn+zbqTJGPLbP3h2pp2BanrWm3bW86MMsmcOvqO/4+lUPDCNqN5r2qv8v264NtGSM/uYyQcfVi/wClZWp6k1vo13dWxCyrC2zj+M8D9cV1eh2J0uxs9Nj2eXZ2yRM38TSdWPt6/jWl72RNuW5pxgRxADsMUsY/Oo5j8pQEh2GVOODjqPY4qeMYGPQVojNjsUjcU7tTTQAhxTCeacaYaYCEkCm0ppDTASkp1J1piEopcUYzQAlHrS4zTW4pgNNFGabmgVxc+9JmmEjrTC3enYLk26jdVfdijf3p2C5YDZpQc1XDcU9Xp2C5YBoqNTzRSHc0KUUClHHSucYYpetFFACEA03GKfSHp70AhuKcOtJ1zQKYzlfGmiNI/wDa+nRxfa9nlXiSDdHcw4IxKmDvHJBOMgMThhuRvm/4geBIrZbvVPDkLiztwHvtNc7pdP3DIYcnzICMkOCcAHkgEj68BIPHWvOvGGiXejalJr1lPmxyWkmZNzaepOSrhcGS0J5JHzxH5gcZIynHqjSMr6M+Q1TYBsYhTz8p4p4OTyK9b8V+ArDVVuNS8PJ/Zc6SbbqxdQ0MTnkEFM7FYfMpAKMDwI8FR5xcaLfWrlZYQ2O8bhx+hrO5VjPAHB704KSemBVuKwuSQPKYH34rUsdHXIa6bcP7id/qf8KAKGnaeLnfO7tDZx8SSgZZj/cjHdj69AOT6HU8szLFGkQgt48+XCvITOMnP8THHLHk49MAa5XeqoEVUQYVQMKo9AO1KqIv3hk+tAmyrbwBQAR9M0+Ube3SpmI6ion5GP8AJpiK7nHIPTvV6FnnQSwsfPi5x3P0qi2M4pltdtZ3KyKeh5HqKAPW/A2rf8JA2l2chG/7Wgl44IQb/wCaqPxr1vSZhdC4nBBDSH+f+GK8i+F1tBCk2pWxOzypZlz2Z2Cgf+Q/1r1bwrbC00iKIZ3MfMY+pP8A9YCtYLS5M5dDSk5mQZGB1Ge/XpVtQdoJrPi+a8kYdhj+n+NaWOAK06GY00w+1PPNRmhDGsTTOhpWph61QAaaTQTSZp2ELRmkzSZp2C44mkJ/Cm5ozRYVxSTmgn3pp6k0madguDGmMaVj1phNVYQ0tTCaVjUTMM800gFZs0gJqMvye9Jk8807ATA09WqBW/KnqeaLAWUbpRUKmilYDdApe9IOlLXKWFLSfzpTQISkpaQ0DENFFJ/OgY6nxu0bBkJDDoRTBzS0AeZ+NvC1xokcmseE1SCKJCJIBHvFtGTudQnO+2PdMExE74+BtHB+Iba11bR21TSovKljIF5ZlgzQEgEEEEhkOQVcEggjk5BP0SjMjBlJVgcgjqK8u8b+DpdIvn8S+F4kMUcbC904JkLESWdogP4MlmaLpksygEkHKULao0TvozxRQvT+Yp2ABnjit7xFpMZ0621zSopF0y8G5A38PP8AL0Nc6pBFQIk3Age1NY88UwnrjpSEkigBrNUbHng09xxUDnimBFK2Pmqpe42hh061PK2Oveq88iwxMpIaUgkD+6Pf39vzpoex7n8OLT7P4GtgGKNKkIZsZK/L5hGD7mvUtMKraRmNy6bchj1PavO/BimLwHo+4ks0LysT/soFH866Xwrf7bR7a4cDCgrnse4rqpRvFo56krSTOk035ju7s5/StI1naVgeWO5Rm6e4H9a0D7dKUtxoRulRNT2qJjxQihjGmGlPNNNUhCMfem59aDSVSRIUZopaqwXEpD0paAKdhXG0Yp+00yeSO3TfM4Re2ep+gp2vog23ExUM0scbbZHRWPYnBrPudSkmJW1UxJ/fP3j/AIVSSMljxuJPJPU12UsG5K83Y5amKUfh1Nl29D16VA7e/FOt0zFtBOfSopQVbn8/WoqUHB+RdHERq+ohNIDnmmZ55/AUD24rKxuSg81KrYFVwaepqWguWAaKjVvWipsB0g4FLSDj6Uvb1rkLFpKKKACkNHakoGIaKOtHrQAope9JSdTQMWlVipBUkEcgjtTTQKYzmPFuhG4sLk2cKvE6kywBeh/vKP6Dp2r531ixfT714+sZOVPtX1gCQeDg1wfj/wCHcHiRjd6ZcJY6jyXRx+4n9zjlG9xwe4zzWco9UNM+fsmjFdBq3gzxFpKsdR0m6jVefNSMyxkeu9MqPxNYTwyLjKOR2wDWQyKTpg1VlwBubAA5Jq06sFJPGPevQfAmg6Raw6drk/l60rfO0MseIoGzgjYfvOpz97jI6dDWlOm5uyInNQV2eU3k3lZVQfP7gj7nH86y92Mg17D8bPCCwhfEml7pbWQASkc/L2J75Ud+69eV58ckGDmtJ0/ZuwoTU1c+jPDUzD4d+HXU/M1m/Tucj/CrVjJ8qHPcZrG8ETi4+GPhk56RTxH6rKyn+lT6PcBklAyNrDrW9N2Mqiud7qOtHRLLTbxo98crpFIvfYVJbHuMA108E8VzBHPbyLJDINyuO4rzvxFNEdG0p7yRUi3BFZuAM8DJ7ZJxz7VpeG5hothNPcz+VYFwPLk6KxOPl9/b/wCvXS6KnTVtznVZwqO+x2RNRseaXcrruRgw9QetNauLY7BhqNzTycCmHr6iqQMaaKWitESwFAGacADT1WrRIwLTm2xoXkYIi9WY4Aqnr+sab4c0ebVNcu0s7CIgNI3JZjnCIo5Zjg4A9CeACa5HQfEGo+LbWTUbnSX0vTXcHTIpZMzSw4/1si4wpJ5GDyDxwAzOC55cqJlLkjzHSXmrgZSzXJ/56MP5D/Gs0q80hknZnY92PNTxW2DlhzUwj7Ac16NKnGn6nBVrORWWP+FRVuKIKPfualWIIvv601jjpW3M5bHHKRG7FCCO1BulnglyvIwoYd2zk/kM/nTHAuA3JWIHDMOrH+6vv6nt+lIQAAFAVVGAo6AVNaSUeXqb4Wk5S53sRDP+NLzTgh7cU9YSa4Wj1LjFqRAT2qVID3FTpBUNDuQIpoq4sR9KKmwXNeikorgNRaKSgDNACn0pDQf0o/CgYn8qUUUUAFIaXNIT6UDDPNFJ3pwpgFLilpQBQFwRmjOUZlPscV5d8TPh1Lqtw+q+HIla6kObizDBS5/vx5wM+q59xnpXqPakIPrUtXBM+arb4e+Lrr7nh69UZ6zGOEf+PsK7LwR4B8WaPJcC6XS49PuRultjd75A4GAy7VK5PQjdyMegz7AaM04pxd0wklJWZxukbHtbjStQg32zgqUcfeU/yIP9D6V87fEvwbN4N177PlpNMug0llPj7yg8of8AaXI/DFfVWp2H2l1ng2rcqep/i/8Ar/zrH8QaJp/inQbjSNYjP2eQ5DL9+2lHR1PYjP4gkHrW7aqxs9zCzpu62PGfhTqHmeB5bNmBbT9UbIPaOeMEH6b0aty23W11IDnax/rXF+GtOv8AwZ8Qb/wvrQCnULfy4ZBxHOykvBKhPUNtdPYsQeRXZ7zImf8AlovB9x601FuCfYHJc1u50Ov2v9p+BJUXloGyRjORzx+eOK4fTvF1/p0ETKlldxBQYri5jMrQggbWGGAZSOm4HH0wK7/wrOJfOtHcoJl4Yfwtjg/gQD+FeSapatoXim70OaMC2kZprAfw7G5aD8CTt/LuK6ITtFMwqQuz6L8JR3sfh+0OpXa3c8i+YHUdFbkAnoTz1AA7dq1jXl3wg8UAoPDd/NukiBaxkZsl4+vln/aUZI9Vz/d59QauesmpXfU6KMk42XQYaYaeajaskzRiUo9qYTzSqelaRkS0SqOaxvGfivS/BukLf6xIxeUlbW0iI866YdQo7KOMueB7kgHG+InxB0/wbby26BL3XyP3djuO2HI4ecj7o7hB8zcfdHzD5k1/WNQ13U5tR1i7ku72bhpX4+UdFUDhVHZRgClUqqOi3KhDm1PQ9C8W6d45+IcNz4+kXy4wE0myz/oEDlvuuD94nC/M3DMPm4CqPeiCHcvu8wsd27rnvmvi90DRncAVPBBFe1fBnxtqeosdA1FJbv7NDvhveWMcY4Ecp/RW68YOeCNMHWV+R9TDF0G1zJ7HsDvk7V61IgCD3PWoYUIXeepqOafZnd0FexGN9EePOVieWUAZJ496jhha5Akk3JARlQDhpPp6L79+3qL1jpMkgEt6nPVYGHT3cf8Asv5+laosyxJbJJ5Jz1qZVow0ia0cM5e9MxTEzYAVVUDCgDAA9B6UqWhPat9bL25qUWmO1czqRPQSMKOz9qmW19QK2Ps3HSnGDHaodRFWMoW3txTxAB2rSMWO1NMftUc6Y7FEQ45oq2V9sUUroZXzRmmilrzzcWiilHSgAFLigUuKAAegoPNGMGg0CGkUhp+KQigY0U4UAUuKAFHNOApBThQIQijHFONJQBCwwaYTipnGahbimMaTzVe4hEh3rgSYwT/eHof8amamk0XsPc5Txp4ZtPFukJZXUhtdQtX87T79R89pMCCD67SQMj2B6ivONRW5t5pBeQC2vojsuYVPEb4BO31U5yp7qRXtVzFvG5P9YO2cbv8A69c34o0OPxBYgIyxalCpWCZ+Aw6mKT2yTg/wk56Eg9dGom7M5atNrVHmmka3HHOkrSbJYzhk/rUvxL0uPxNo0WpaeytcW5BDoeY37Z9AensQDUum/De81C9WfW2l021XIkiUgzS+wIyFH+1yfT1rtr+807wzp1vpmnW0UMcwKrbjnMYPzM5OSSTxk5JOT2NaciimnsRzuTVtz5y0rVp2lQyySpfwvvSQHa5KnPJHR1PINfSvgHxnB4h0KSa8cR3tmga62LkMn/PUAduuQPukHtivGfif4P8AKP8AwkGgqzW0nzyxxjBXH8QHqOhHpj3rO+F3jKz0HxAkurxobK5jNvPJj7gYj96p6qQQNw6EcjkAHLpyT+TLtrzw+aPqSFo7mIS20kc8R/jiYOv5il8mRz8qM30UmuM1PQZoh9s0l2nR1Dq9u+2QqRkEFcbxjnj8BXC6zLfXAkS5vry4iB+ZGuHbafdSf0xxXLJOO50Ralseo6/4j0XQFb+19Tt4JB0gQ+bMeOnlrkj8cD3ryfxf8VtQvle18Lwy6ZbNkNeSEfamH+xjIi+oJb0YVzUllGhcKiIOoYDr9ayri3KsdwrNzfQtRXUwpIiSxJLOSWZmOSxPUk9yT3NUpYsHgZ9q6COzlvrpLawgmurtukUCl2PvgdB7niu/8LfCrcyXXixx5fUadbyZ3f8AXWQf+gof+BdqKdOVR2iVOpGCuzz/AMF+C9R8W3BaAm10qNtst865UHusY/jf9B3PQH3zw/ouneHNMSw0iAw24O5mY7pJn/vyN/E36DoABxWltihgjht40igiUJHHGoVEUdAoHAA9BTYIpLmYJEM+56CvZwuHjS957nmV60qmi2NSzlEiKqgsx4CgZJPoK6vR/DyRt9pvObocxxj5hH7+7fy7c1D4bsLaxgWcESXDfKXHUH+6o/ma3ZZvKgL4KkcnnpWGIxbbcaeiLoYRL35ka2mOeo9R3qRbYAVialqz2iFo9zXUhzHGnc/T0/nXRQu7QRNMgSRkBdP7rEcj86wnzxipPqaxcZSaXQi8genFHkjsKsZ9KTNZc7L5Ss0YB6VGYwO1Wm9qiaqUgKzJ6VGy9qsNxmo3HWqUgK5FFPI4oq+YVjLopaXFcpqN7+1OHNGKUdKAFo9qKXvQIUeoHSjGKO/Sl680AJjjP40lPx+dBHNAEeKKdikx2oAdS0lKKBC0Yo/nRQMRhmoJBU5NRSUDKz8GoZDxippOtQSAZNADdwqGePzDvXAfp7MPQ/405hg0qmgCjNkKxcSEqCSAMsQBnAHc15VrdxLfXkl5OAskmDHtOVVB91QfQD9cnvXsMiZwRww6MO1cH4605bK1uNSjtZJbVQZLyGBdzRjvOi9wOrKOgyw4zXUp+1jyvc53H2cuZbHP6Jq5hL212vm20nDp3How9xXnPxB8NrYazc3GmopspiHTyx8oJHIwPunOeO/b0HQnXNMEDTW9wJ2/g8vqff8A/XiuZXWLqKeeaVgySf6yN+UI9DmspTsuWRqo3fNE1fh/4617wE8OnahZy3ugSESrAzY8tW58y3lPygHOdh+U5/gJJr3WzuPDvjqwa6smivtmFk6xXNufR8YYfjkHsTXGaFbWc3h3TopAbW5W3HyPnjOSAc9cAgc9hipp/BJivINQ0WV4JDEJ45bafDxsVBKDoSc5A7YxmtYWSs3dGcotu8dzSuPAVi8reXf30S5+46Rvj2zgH86bB8OdDUhryS+vf9l5REn5IAT+dbGjarqdwYob6CO7bGJCYjbTRnPBIPyOp9VIIP8AD3rYd0WVY2huldjgDYGB+jD+tWqVK+xm5VUUdP0yx0u2MGmWdvZwnkrDGF3e5PUn65p0gPbkn0q8o3IWKOgHJ84hMfX0pjyW8MReW4URY5MXyr+Ln+laqUY6IhQk9WVFsZXw0qlELbeQTzWoLePT4o3aWYb/AJGjiTkntyfu5wTzn9arWk896oTT4nhgUf60Dbx7M3P5AfWodcuUt54rZJkmkHWOPkggdCcnJOf096V5VHyjly01zG5BeRwW7XDERx/cWNXyzMuMjPpnk/8A6qdHcXlyy/IXkk/1UA4VR/ePoPc1i6PBcXcgZsAg8s4+WEegHdvb867SyjigiKw5OeWZjlnPqTWU4qi9dX/X9d2XCUqytsv6/ryHaXp8dkxmkYTXrj55iOnso7CtDdVffQH4rllJyd5HVGMYq0SzuoLVX3Ub+1SDJS1Rs3rTS/oajZqtEDnbPWoyeaRmppbmqQgYjoaKjJPQ0VQiiKWm9KcKwNQxxS+xpOxpwoEIB+dO60naloABx0paQfypR1FAC/zoH1pO3FLmgBKKCeaKYBS5puTS5pALmg03NJupgKTUTmlJ4qGRqBjHPNV2NSO1QOaQDCaTOOe9BpMiiwDtxxTHfkHcQy8gjqD601nxxVOabA4P601dbCepxmr/AA38H3t4002kvazOSTJYXDQq3/AB8o/AU+x+GnhS2aOS2hvRNGdyPcXTTpuHTdGflYZ7cVsXszEcE5+tVLfV3gfbcIWT++nUfUd/wrphOEtJownTmtYMr32kul0YZpUSdgGDb8qwPG8E846++Rg1KILpNWiawEhhjKKisD+8VfYeuD9Ota7Pp+sW4SdUmC/ddG2yJ+PX8Dx7Uyz0+6sWb7Hc/aoW6oxWOUfQkFT+lbSpJq6IjWs7SLUT6x5TRwRzQxZJ3PKvmMT/ABN1/LsOKe0erjYWvrqFG/j3IVP4Y61XvtZltyC1nq0b/wDTS18wAf7JVtv4kn6Vkf2rczz/AOhaTd3Mx6PeE4H4ABR+JqYUZvoXKtHudQLZpkXzJvOwc+ZKAxJ9QvTPviqt5Pp1lIJbqePzE6s58yT8P7v4VkTWetXan+0dQt7ODvHBk8fhj9TTLWy021cNBE17ODnzZsFQfUDp/Oto0VHWbMnWctII0JNTudSjb+zo3toG4a6m4yPRV6mn2FrBbjEe7B4aRvvt/gPpSKJZ2DSncew7CrsEJGKbrKK5YaCVFyfNPVmhBLsVQgCqowFHQVftr1kYY/KsuNW9DUqqaxk09zRKx01vdLMgI61Y3VzMMjxkMp59607e9VwA5wRXLOnbY2jPuaYb3o3VWEoJ4anbhWdirkpeml6jznpSZNUK48mmk00tSbuBz0qkIdmioy2aKYFWnZptKKxNB3NKDTRSg0CHj2pcGk70v1oEAoozSjrQAdqQ9OlJnjFBODTACefekJpM80maBjs00mmls00n1oAcWpCaaW/KmFqBj3aoHNKzVG5oAY5qFjnNPYnpUZ60gEzUbkg080xqYiGXuO9U5gce1XXFQsAe1WkMyp4N2etU3si3Uda3jEPSmiJeuKaQzn/7M+bcBhh0I4I/GrcUd3GMLOzY7MM//XrWEa9hT1jzjitItx2M5RUtylFNfL911X35H9akd7+ZcNcMB6Af41fSHPWrEcIHaqdZkeyj2MD+yzI2ZWeU9t5J/TpV+CxCgZFayxDjipBF7VDqNlKKWxTitgB0qwsQAPFThMDgZp20YoUgaIVQYHenbRgjFSAUY4HvVcxPKR7aOnSnn1oPPXrRzDsIGYfdJFSJcyKB8xIqMim0r3CxdW8z96pkuFbv+dZlGSKmyGa24EcEUcVmLIyng1MlyehpWAuZoqBJlNFOwDsUCnYpMAVgWJTsUYopgLSiminDFIA/lS0UGmIQnmmmlPFNNAxO1NPBoppNAxGNMJpx6Uw0AGeaSiigBppjU89eKYenFMCI1G1SMKjPWkBGeneo2NSsOtM24poCM8jnFRlT6VY20gX0qhlfZ2pwj/OpwnSn7R6U7iIEizipkjFSBealRP1pNiGqmakVD6U5V9O1P20rhYaBTgMClHFGKBhTu1IKKdxNBjpRil/GkzTuKwntSEU7+dHXvTuIZQQRTj70UXAjxRj0qQjjpRii4EWKQjHSpSOpFJtGaLgM5op+OeaKLjNCjGaKWsRiUEc0e1L3pgIPzpR1pOaUd6QCikoFB6UANpp5pT3pppgNPpTSaVjzTT1oGNNIaU+9J9aAEFBoFFADT1pCKfikxTAhZaZt9qsEUhUEUAVStIVqwy45phWkBDilC1IVpQtO4DAlOC+1PC4/wpyrxRcBAvpUgFApRQACloo/DigAopaO9ABSY5pe3elp3AT+VFFGOlAhKXHHXmgDNAHSi4APWkx+FLQKLgJRj2pxGaD+VFwE/CkxTscY70YouA3FFLiigC5S8Z5ooqBBRiiigYZoFFFMApD0oooEIaYetFFIYw9KYaKKYxvakoooAUUUUUAGKAMiiigAxSEYoooAaaYRRRQMAO9LiiigBQPyp1FFAhaO/NFFAC0flRRTAKKKKQBRRRTAKKKKAFHFBoooAO1Lx0FFFACe9HUUUUAKPSlxiiigQdaKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Optical laryngoscopes use lenses to provide a high quality view of the anterior glottis. The devices are an inexpensive, durable, and portable tool for difficult airway management.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Prodol Meditec S.A. Copyright &copy;2008 Prodol Meditec S.A.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_32_14863=[""].join("\n");
var outline_f14_32_14863=null;
